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ABSTRACT 
 Diagnostic errors are relatively common in medicine and can cause significant 
patient harm.  We adapted the National Academy of Medicine’s model of the diagnostic 
process to examine diagnostic errors in schwannomatosis, a rare, genetic syndrome in 
which patients commonly develop multiple nerve sheath tumors and chronic pain.  We 
specifically assessed how well the schwannomatosis diagnostic process currently 
functions; identified specific failures in the diagnostic process and assessed their 
contribution to diagnostic error; and explored the impact of diagnostic errors on patients’ 
lives. 
In study one, we reviewed the medical records of 97 schwannomatosis patients 
seen in two tertiary care clinics to assess the extent of diagnostic error in this population.  
It took a median of 7.9 years from patients’ first sign/symptom for a diagnosis of 
schwannomatosis to be established and communicated to patients.  One-fifth of patients 
had a clear missed opportunity for appropriate workup that could have led to an earlier 
diagnosis.  About one-third of patients experienced a misdiagnosis of their pain etiology, 
tumor pathology, or underlying genetic diagnosis. 
  x 
In study two, we created narrative summaries detailing patients’ diagnostic 
journeys using the medical record data of 52 schwannomatosis patients included in study 
one.  Directed content analysis of these summaries identified the specific diagnostic 
process failures patients experience.  Almost all patients experienced at least one failure, 
which most commonly reflected deficiencies in diagnostic testing, the clinical 
history/interview, or follow-up.  Two-thirds of failures significantly impacted patient 
outcomes, most often by delaying needed diagnostic workup and communication of a 
final diagnosis to the patient. 
In study three, we interviewed 18 people with schwannomatosis from across the 
United States and used thematic analysis to explore patients’ symptom appraisal and the 
personal impact of diagnostic errors.  Participants and their healthcare providers often 
ascribed schwannomatosis symptoms to more common conditions, which could delay 
care-seeking and initial workup.  Diagnostic delay and misdiagnosis could result in 
unnecessary surgery, delayed receipt of effective pain management, psychological 
distress, and stigmatization. 
Collectively, these studies give unique insight into the prevalence, causes and 
ramifications of diagnostic error in schwannomatosis, and highlight opportunities to 
improve the diagnostic process across rare, genetic diseases.  
  xi 
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GLOSSARY 
delayed diagnosis – a non-timely explanation of the patient’s health problem, with 
timeliness determined by the specific disease context 
diagnostic error – the failure to a) establish an accurate and timely explanation of the 
patient’s health problem(s) or b) communicate the explanation to the patient 
(National Academy of Medicine, 2015) 
diagnostic interval – the time period between a specified diagnostic starting point (usually 
time of first symptom) and a specified diagnostic ending point (usually the time a 
diagnosis is established or communicated) 
diagnostic process failure – any problem in the diagnostic workup or missed opportunity 
to make the correct diagnosis earlier (Newman-Toker, 2014; Singh, 2014) 
inaccurate diagnosis – a diagnosis that is not a precise and complete reflection of the 
patient’s true health condition 
inadequately communicated diagnosis – a diagnosis that is not communicated to the 
patient, or is partially or inadequately explained such that the patient does not 
fully understand the nature of their health problem 
incomplete diagnosis – a subcategory of inaccurate diagnosis, which is defined as a 
diagnosis that does not capture an underlying cause linking a patient’s multiple 
health problems 
misdiagnosis – a subcategory of inaccurate diagnosis, which is defined as a diagnosis that 
is wrong as judged from the eventual appreciation of more definitive information 
(Graber, Franklin, and Gordon, 2005)  
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CHAPTER 1: INTRODUCTION 
 Current literature suggests that diagnostic errors are relatively common in 
medicine and may cause significant patient harm.  Rare, genetic diseases may be prone to 
diagnostic error because of several inherent difficulties in their diagnostic process.  In this 
dissertation, we will take a model of the diagnostic process recently proposed by the 
National Academy of Medicine (NAM) in their 2015 report “Improving Diagnosis in 
Health Care”, and operationalize it to look at the diagnostic process in a rare, genetic 
condition.  Specifically, we will look at schwannomatosis, a tumor predisposition 
syndrome in which patients commonly develop multiple nerve sheath tumors and chronic 
pain.  Previous research (Merker et al., 2012) has shown that schwannomatosis patients 
experience lengthy delays between first symptom and diagnosis, but the prevalence, 
causes and ramifications of diagnostic error in this disease are unknown. 
The three studies presented in this dissertation address these gaps by specifically 
assessing how well the diagnostic process currently functions for patients with 
schwannomatosis; identifying specific failures in the diagnostic process and factors 
contributing to poor diagnostic performance; and exploring the impact of diagnostic 
activities and outcomes on patients’ lives.  Using a mixed methods approach, we 
ultimately aimed to identify facilitators and barriers to early, accurate diagnosis of 
schwannomatosis so that we may prioritize potential interventions to improve patients’ 
diagnostic experiences.  We also hoped to illuminate diagnostic problems common to 
other rare and genetic diseases, and offer comments on the utility of the NAM’s 
conceptual framework in guiding empirical research.   
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The following introduction chapter begins with a literature review regarding 
diagnostic errors in medicine; difficulties in diagnosing rare, genetic diseases; and the 
specific rare, genetic disease of schwannomatosis.  We then present a conceptual 
framework of the diagnostic process and discuss our modifications of this model to adapt 
it to the context of rare, genetic diseases.  We conclude with a summary of our research 
questions and methodological approach for the three empirical studies which comprise 
this dissertation, and discuss the value of a mixed methods approach to investigating the 
diagnostic process.  
Literature Review   
The Scope of Diagnostic Errors in Medicine 
Reducing medical errors has been a longstanding goal of clinicians, 
administrators, and researchers.  The scope of medical errors in the U.S. healthcare 
system was strikingly highlighted with the 1999 release of the landmark report “To Err is 
Human” from the Institute of Medicine (IOM, now renamed the National Academy of 
Medicine) (IOM, 2000).  However, after the publication of this report, the subset of 
medical errors that occurred during the diagnostic process was initially understudied 
(Wachter, 2010).  This may be because diagnostic errors (especially errors of omission) 
are difficult to reliably identify, and given that most errors are identified retrospectively, 
there is often insufficiently detailed documentation about the error to assess causation 
(Graber, 2005; Gandhi et al., 2006).  Recently, however, diagnostic error was recognized 
as an important target for patient safety and quality improvement efforts.  The need to 
study and improve diagnosis reached national prominence with the November 2015 
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release of the National Academy of Medicine report “Improving Diagnosis in Health 
Care.” 
Current evidence suggests that diagnostic errors are relatively common in 
medicine.  Researchers have estimated that each year, 5% of adults in the U.S. who seek 
outpatient medical care experience a diagnostic error (Singh, Meyer and Thomas, 2014).  
In a review of prior studies on diagnostic error, Berner and Graber (2008) concluded that 
the rate of diagnostic errors in radiology and pathology ranges from 2-5%, and is as high 
as 15% in other clinical specialties.  The high frequency of diagnostic error has been 
corroborated through other research methods, such as surveys and the use of standardized 
patients.  For example, in a large survey of U.S. pediatricians, 54% self-reported making 
a diagnostic error at least once or twice per month (Singh et al., 2010).  In a study using 
standardized patients trained to act out specific conditions during appointments at general 
internal medicine clinics, physicians made the wrong diagnosis in 13% of cases (Peabody 
et al., 2004). 
While diagnostic errors do not necessarily lead to patient harm, many do.  
Diagnostic errors may result in delay or non-receipt of needed treatment; the receipt of 
unnecessary procedures or treatments; psychological distress; and increased costs to 
patients and the healthcare system.  Reviews of medical records suggest that diagnostic 
errors account for 6-17% of adverse events in hospitals (Zwaan et al., 2010; Leape et al., 
1991).  After analyzing 53 published autopsy series, Shojania et al. (2003) estimated that 
4.1% to 6.7% of cases have a missed clinical diagnosis (i.e. physical evidence of a 
disease which was not diagnosed during the patient’s lifetime) that was likely to have 
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affected patient outcomes.  Research in a variety of diseases has shown that longer times 
to diagnosis can be correlated with decreased health status, poorer quality of life, and 
reduced confidence in medical professionals even after diagnosis (Risberg et al., 1996; 
Merelle et al., 2003; van der Kloot et al., 2010; Martindale and Goodacre, 2014). 
Defining Diagnostic Error 
While it is clear that diagnostic error is a major problem in health care, efforts to 
improve diagnostic error has been hampered by disagreement among clinicians and 
researchers as to what actually constitutes a diagnostic error (Newman-Toker, 2014; 
NAM, 2015).  Definitions of diagnostic error vary in part because ‘diagnosis’ can refer 
both to the process of determining what a patient’s health problem is and the specific 
label given to the patient’s health problem (Hautz, 2018).   For this reason, some 
researchers have argued that the term ‘diagnostic error’ should be used to refer to errors 
in the process of determining a diagnosis, and the term ‘diagnosis error’ should be used 
for times when a patient is given the wrong or no diagnosis label (Schiff et al., 2005; 
Berenson et al., 2014).  There has also been disagreement over whether diagnostic errors 
always imply that someone or something was at fault in the diagnostic process, or if 
diagnostic errors also includes problems that are unavoidable or could not reasonably 
have been expected (NAM, 2015).  
After reviewing previous, disparate definitions of diagnostic errors, the NAM 
committee proposed a new definition that takes a patient-centered viewpoint and focuses 
on the outcome, rather than the process, of diagnosis (NAM, 2015).  They defined 
diagnostic error as “the failure to a) establish an accurate and timely explanation of the 
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patient’s health problem(s) or b) communicate the explanation to the patient”, and it is 
this definition we use throughout the dissertation.  According to this definition, a 
diagnosis is accurate if it is a precise and complete reflection of the patient’s true health 
condition.  The concept of timeliness is context-dependent, and will vary based on the 
specific medical problem and the urgency with which that problem requires treatment.  
Finally, this definition newly highlights that adequate communication of the diagnosis to 
the patient is a necessary component of a good diagnosis.  Adequate communication must 
accommodate patients’ prior knowledge and health literacy, so that the patient truly 
understands their diagnosis and its implication for their health.  Following the NAM 
definition of diagnostic error, we establish three categories of diagnostic error for 
consideration in the proposed dissertation – inaccurate diagnoses, delayed diagnoses, and 
inadequately communicated diagnoses.   
Inaccurate Diagnoses 
 Inaccurate diagnoses – diagnoses that are not a precise and complete reflection of 
patients’ true health conditions - encompass both misdiagnoses and incomplete 
diagnoses.  We define misdiagnosis based on work from Graber, Franklin and Gordon 
(2005) as ‘a diagnosis that is wrong as judged from the eventual appreciation of more 
definitive information (i.e. another diagnosis was made before the correct one)’.  
Inaccurate diagnoses also include incomplete diagnoses, which represent failures to 
determine an underlying cause that links multiple health problems.   For instance, if a 
patient is separately diagnosed with migraines and seizures, but both are caused by 
undiagnosed brain tumor, this patient has not been given an explanation that is a 
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complete reflection of their true condition and should be considered to have an 
incomplete diagnosis.  Of note, if a diagnosis is under active consideration as part of a 
differential diagnosis or as a working diagnosis, it should not be considered inaccurate 
even if it does not correctly explain the health problem.  We recognize that many clinical 
situations are uncertain, and require time to investigate.  As long as working diagnoses 
are communicated as such (i.e. not given as the final label of a health problem), they 
should not be considered as misdiagnoses. 
Delayed Diagnoses 
Delayed diagnoses are failures to establish a timely explanation of the patient’s 
health problem. Given the highly contextual nature of ‘timeliness’, the definition of 
delayed diagnosis must be operationalized in the context of the specific disease under 
study.  For instance, an acute illness like stroke requires a much shorter time interval for 
timely diagnosis than a chronic disease such as low back pain.  A meaningful delay is 
often defined in terms of a specific unit of time (for example, not recognizing an ST-
segment elevated myocardial infarction within a specified door-to-balloon time goal or 
taking more than 30 days to follow up an abnormal screening test with further diagnostic 
work-up), but also be defined based on the consequences of a delay (for example, if 
otherwise preventable physiologic damage has already occurred by the time of 
diagnosis). 
It’s important to note that the difference between our definition of delayed 
diagnosis and previous uses of the term ‘diagnostic delay’ in the literature.  Some authors 
use the term ‘diagnostic delay’ to refer to the total time period between a specified 
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starting point (usually time of first symptom) and the date of diagnosis (see for example 
the conceptual model proposed by Olesen, Hansen, and Vedsted, 2009).  With this 
terminology, ‘delay’ may or may not imply fault with the diagnostic process; it simply 
describes the length of time required to make a diagnosis.  Recently, researchers have 
advocated for a change in terminology, wherein the time period from a specified starting 
point (usually time of first symptom) to the time of diagnosis is referred to as the 
‘diagnostic interval’, and ‘diagnostic delay’ is reserved for specific processes or errors 
that slow the time to diagnosis (Dobson, Russell, and Rubin, 2014).  Throughout the 
dissertation, we will adopt the latter terminology, using the term ‘diagnostic interval’ as a 
neutral description of the time period in which a patient is diagnosed and using the term 
‘diagnostic delay’ for occasions when this time period represents a meaningful delay (i.e. 
a non-timely explanation of the patient’s health problem). 
Inadequately Communicated Diagnoses 
 Finally, there are inadequately communicated diagnoses, in which the patient does 
not know or does not fully understand their diagnosis.  This may occur when medical 
professionals ascertain the diagnosis but the information is not given to the patient (for 
example, pathologic analysis of a tumor sample reveals that a patient has cancer, but no 
one follows-up with the patient to inform them).  Inadequately communicated diagnoses 
may also occur when a diagnosis is only partially explained to the patient or explained in 
such a way that the patient does not understand what is being said.  Patients’ cognitive 
limitations and health literacy, language or cultural barriers between patients and 
  
8 
providers, and providers’ communication techniques could all contribute to potential 
misunderstandings regarding diagnosis. 
Diagnostic Process Failures 
Importantly, given that the NAM definition of diagnostic error is focused on the 
outcome (rather than the process) of diagnosis, it does not assume that all diagnostic 
errors are preventable given current scientific knowledge and clinical practice.  And just 
as not all diagnostic errors are caused by mistakes in the process of diagnosis, not all 
mistakes or failures in the diagnostic process lead to diagnostic errors.   We use the term 
‘diagnostic process failure’ broadly to signify any problem in the diagnostic workup 
(Newman-Toker, 2014) or missed opportunity to make the correct diagnosis earlier 
(Singh, 2014).  Diagnostic process failures that do not lead to diagnostic error in a 
particular patient are considered ‘near misses’ (NAM, 2015).  Diagnostic process failures 
may be acts of commission (i.e. something was done that should not have been or 
something was done wrong) or acts of omission (something was not done that should 
have been) (Newman-Toker, 2014).  Diagnostic process failures may occur for any 
number of reasons, including patient-, physician-, or systems-level factors (for reviews of 
each, see Buetow et al., 2009; Croskerry, 2003; and Graber, Franklin and Gordon, 2005, 
respectively). 
Challenges in Diagnosing Rare, Genetic Diseases 
Rare diseases were defined in the United States (U.S.) as any condition affecting 
less than 200,000 American via the U.S. Orphan Drug Act of 1983; rare diseases were 
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defined in Europe as any condition with a prevalence of less than 1 in 2,000 people by the 
European Union Orphan Drugs Regulation of 1999 (EURORDIS, 2009).  There are more 
than 6,800 recognized rare diseases, which cumulatively affect an estimated 25 to 30 
million Americans (Genetic and Rare Diseases Information Center, 2017).  The majority 
of rare diseases (perhaps as high as 80%) result from genetic defects (IOM, 2010).   
The diagnosis of rare genetic disorders presents several unique challenges 
compared to more common and non-genetic diseases.  Given the vast number of rare 
diseases, it is unreasonable to expect that clinicians would be familiar with each and 
every rare disorder.  For this reason, clinicians may not ever consider the correct rare 
disease diagnosis when evaluating a patient.  Healthcare providers with access to clinical 
decision support tools or sufficient reference resources may be able to identify a rare 
disorder as a possibility, but many clinicians do not have access to or the time needed to 
use such resources.  Additionally, many rare, genetic diseases are multi-system disorders; 
that is, the underlying genetic defect affects multiple bodily processes in different organ 
systems.  These different manifestations may be diagnosed and treated separately, 
without any clinician considering the underlying genetic diagnosis that more precisely 
describes the patient’s health problem (a situation of incomplete diagnosis).   
Even when a clinician is aware of a rare disease, they would likely give common 
diagnoses more weight than rare diagnoses when establishing a differential diagnosis for 
a particular set of sign(s) and/or symptoms(s), as per the common adage “when you hear 
hoofbeats, think horses not zebras”.  Especially when a rare disease has non-specific 
symptoms, this may delay reaching an accurate diagnosis, as healthcare providers 
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sequentially move through ruling out more common, alternate diagnoses.  Finally, even 
when a clinician suspects the correct rare disease diagnosis, they may not be sufficiently 
experienced with the proper diagnostic testing and evaluation methods to distinguish 
between disorders with similar phenotypes.  
 Given all these challenges to making timely and accurate diagnoses of rare and 
genetic diseases, it is unsurprising that diagnostic error is common in rare disease.  
In a 2004 survey of approximately 6,000 European patients or caregivers with eight 
different rare diseases (the EURORDISCARE2 survey), 41% of respondents reported 
being misdiagnosed and 25% reported a diagnostic interval of five or more years 
(EURORDIS, 2009).  While no single definition has been established for what constitutes 
a delayed diagnosis across all rare diseases, it is clear that diagnostic intervals are 
unacceptably long for a significant number of patients.  In a 2013 survey of 887 rare 
disease patients and caregivers in the United States and United Kingdom, patients 
reported an average time to diagnosis of 7.6 years in the US and 5.6 years in the UK 
(Shire Human Genetic Therapies, 2013). 
 Even when a patient is correctly diagnosed, rare genetic diseases present an 
additional layer of complexity as healthcare providers communicate the diagnosis to a 
patient.  Beyond describing the actual diagnosed condition, clinicians must explain the 
genetic origin of the disease and the implications of such for patients’ health and that of 
their families.  This is a non-trivial task, as evidenced by EURORDISCARE2 survey 
results.  One-third of patients reported that they were unsatisfied with how their diagnosis 
was initially communicated, and 25% reported that the genetic nature of their disease was 
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not adequately discussed with them at the time of diagnosis (EURORDIS, 2009).  In a 
similar survey of Australian adults with rare diseases, 72% of respondents reported that 
they did not receive enough information about their condition upon diagnosis and 50% of 
respondents who received information reported not understanding all of it (Molster et al., 
2016).   According to our classification of diagnostic error in the preceding section, this 
lack of clarification about the genetic nature of the disease would be considered an 
inadequately communicated diagnosis. 
Adding to burden of diagnostic error in rare, genetic diseases is the unique impact 
errors have on patients’ current and future family members.  Patients with undiagnosed 
genetic diseases cannot receive appropriate genetic counseling, which inhibits the 
identification of family members who may also have the disorder and need medical 
attention.  It also prevents patients from considering the risk of transmitting their disease 
to offspring and accessing family planning resources that can reduce this risk, such as 
pre-implantation genetic diagnosis during in-vitro fertilization. 
Schwannomatosis: An Example of a Rare, Genetic Disease with a Challenging 
Diagnostic Process 
Schwannomatosis is a rare, genetic syndrome that predisposes affected 
individuals to develop multiple nerve sheath tumors, called schwannomas, throughout 
their body.  Patients with schwannomatosis often experience severe chronic pain, and 
may suffer from neurological deficits such as weakness, numbness, or difficulty walking 
because of their tumors (Lu-Emerson and Plotkin, 2009b).  Schwannomatosis is a rare 
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disease, with an estimated prevalence of 1 in 126,315 people (Evans et al., 2018) and an 
estimated U.S. population of 2,540 individuals (Merker et al., 2018).     
Schwannomatosis was only relatively recently recognized as a distinct disease 
entity from the other forms of neurofibromatoses (NF), which include neurofibromatosis 
type 1 (NF1) and neurofibromatosis type 2 (NF2) (Purcell and Dixon, 1989; Macollin et 
al., 1996).  While all forms of NF predispose patients to develop multiple nerve sheath 
tumors (neurofibromas in NF1 and schwannomas in NF2 and schwannomatosis), they are 
three distinct disorders caused by mutations in different genes (NF1 for NF1, NF2 for 
NF2, and SMARCB1, LZTR1, and additional, as-yet-undiscovered gene(s) for 
schwannomatosis) (Hulsebos et al., 2007; Piotrowski et al., 2014; Hutter et al., 2014.)   
While there is some clinical overlap between the three forms of NF, the vast 
majority of patients with non-mosaic NF1 and NF2 have additional clinical features that 
distinguish them from schwannomatosis patients. By late adolescence, virtually all 
patients with NF1 display characteristic skin findings — six or more café au lait macules 
and axillary and/or inguinal freckling — and patients may exhibit a wide variety of other 
ophthalmologic, cognitive, and orthopedic issues (DeBella, Szudek and Friedman, 2000; 
Lu-Emerson and Plotkin, 2009a).  Patients with NF2 typically develop bilateral vestibular 
schwannomas, which can lead to deafness, tinnitus, and balance problems; they may also 
develop peripheral schwannomas, meningiomas, ependymomas, and juvenile posterior 
subcapsular cataracts (Lu-Emerson and Plotkin, 2009b).  While a small subset of 
schwannomatosis patients develop unilateral vestibular schwannomas or intracranial 
meningiomas (Smith et al., 2012; Smith, 2015), schwannomatosis patients are not known 
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to be predisposed to any of the other clinical characteristics of NF1 or NF2 (Kehrer-
Sawatzki et al., 2017).  Accurate diagnosis that correctly distinguishes between NF1, 
NF2, and schwannomatosis is key in ensuring that patients are aware of the disease-
specific risks that they face (for example, the larger lifetime risk of malignant peripheral 
nerve sheath tumor for patients with NF1 or deafness for patients with NF2).    
  Diagnosis of schwannomatosis may be difficult for a number of disease-specific 
reasons, including its’ rarity, relatively recent discovery, phenotypic overlap with other 
disorders, and a still evolving scientific understanding of the disorder’s associated clinical 
features and genetic causes.  There is good reason to think that this has negatively 
impacted patients with schwannomatosis, resulting in significant delays in diagnosis.  
Most schwannomatosis patients in the U.S. are either undiagnosed or not connected to 
specialty care at dedicated NF clinics (Merker et al., 2018).  Even patients who are seen 
at specialty NF clinics have often experienced lengthy diagnostic journeys to get there.  
In a cohort of 87 schwannomatosis patients seen at Massachusetts General Hospital, the 
median time from first symptom to diagnosis of schwannomatosis was 7 years, ranging 
up to a high of 39 years (Merker et al., 2012).  Schwannomatosis patients may also face 
other diagnostic errors, such as the misdiagnosis of benign schwannomas as malignant 
peripheral nerve sheath tumors (Merker et al., 2012). 
Diagnostic errors and associated delays in referring schwannomatosis patients to 
specialty NF clinics has the potential to harm schwannomatosis patients, particularly 
regarding their surgical management and genetic counseling.  Standard treatment for 
symptomatic schwannomas is medical pain management or surgical resection.  However, 
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without a schwannomatosis diagnosis and the knowledge that they are predisposed to 
develop multiple tumors over their lifetime, patients with a schwannoma can’t weigh the 
cumulative risks of multiple future surgeries or be referred to surgeons experienced with 
the unique features of schwannomatosis-related schwannomas.  In the case series from 
Massachusetts General Hospital, patients often had multiple surgeries before being 
diagnosed or referred to a specialty NF center (Merker et al., 2012).  At the time of the 
medical record review, patients had undergone a median of two schwannoma surgeries 
(range 1-9), and many patients had persistent post-operative deficits (45% of patients 
with spinal surgeries and 27% of patients with peripheral schwannoma surgeries.)  It is 
possible that if patients had been correctly diagnosed and seen at dedicated NF clinics 
earlier, they would not have chosen to undergo as many surgeries (opting for medical 
management instead) or would have chosen surgeons more experienced in 
schwannomatosis, potentially reducing the post-operative complication rate. 
Regarding genetic counseling, the recent discoveries that that germline mutations 
in the SMARCB1 and LZTR1 genes cause schwannomatosis has expanded genetic testing 
options for schwannomatosis and increased clinical knowledge about the disease’s 
inheritance pattern (which is autosomal dominant with incomplete penetrance) (Kehrer-
Sawatzki et al., 2017).  However, patients who are not yet diagnosed with 
schwannomatosis are deprived of the opportunity to understand the risk of 
schwannomatosis in their family members and learn about available reproductive 
technologies, such as pre-implantation genetic diagnosis, that can allow the patient to 
have children unaffected by the disorder.   Given that diagnostic errors appear to be 
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prevalent in schwannomatosis and may cause significant patient harm through effects on 
treatment and reproductive decision-making, a rigorous study of the schwannomatosis 
diagnostic process is necessary to inform efforts to improve patient outcomes. 
Conceptual Framework 
Many prior studies of diagnostic error have been limited by a lack of a conceptual 
framework (Weller, 2012).  A robust conceptual framework of the diagnostic process is 
needed to select relevant variables for study and to explore what contributors to 
diagnostic error are common across diseases.  However, current models of the diagnostic 
process and diagnostic error were largely developed from studies of cancer and common 
chronic conditions.   It is unknown if these general conceptual frameworks are applicable 
to the unique characteristics of patients with rare, genetic conditions.  In the proposed 
dissertation, we will adapt current models of diagnosis to encompass situations common 
to people with rare, genetic conditions, and then apply this model to a specific genetic 
condition (schwannomatosis).  By investigating the incidence, causes, and ramifications 
of diagnostic error in schwannomatosis, we can begin the process of examining 
diagnostic problems that may be common to other rare, genetic disorders.  In this way, 
we can magnify the impact of our work in a relatively small patient population to inform 
research in other disease contexts.  
National Academy of Medicine Diagnostic Process Framework 
In developing the conceptual framework for the proposed dissertation, we 
primarily drew on the diagnostic process framework from the U.S. National Academy of 
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Medicine (NAM, 2015).  This model begins when a patient experiences a health problem 
and chooses to engage with the healthcare system to address this problem (Figure 1.1).  
Figure 1.1 The Diagnostic Process (National Academy of Medicine, 2015) 
 
Once a patient engages in the healthcare system, healthcare providers engage in 
an iterative process of gathering, integrating, and interpreting information to determine 
the reason for a patient’s health problem.  Healthcare providers elicit information by 
taking a detailed clinical history, performing a physical exam, ordering diagnostic testing, 
and/or referring to additional clinicians as needed.  Diagnostic testing includes but is not 
limited to medical imaging, laboratory tests, pathology, and functional assessments like 
vision or neuro-cognitive testing.  Information may also come from monitoring a 
patient’s response to treatment, which in some cases will be initiated before the 
determination of a final diagnosis. 
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The process of gathering, integrating, and interpreting information help providers 
to generate a working diagnosis.  This working diagnosis may be either a single possible 
diagnosis or a full differential diagnosis which is refined over time.  Once a leading 
diagnosis has been selected, it should be checked for its adequacy and coherency in 
explaining the patient’s health problem.  Throughout this process of diagnostic 
refinement and verification, diagnostic team members assess whether sufficient 
information has been collected to adequately explain the patient’s health problem.  The 
term ‘sufficient’ information reflects the idea that “the goal of information gathering in 
the diagnostic process is to reduce diagnostic uncertainty enough to make optimal 
decisions for subsequent care” (NAM 2015, pg. 36).  This idea recognizes that it may not 
always be preferable or possible to obtain definitive proof that a particular diagnosis is 
correct.  The diagnostic cycle of information gathering/integrating/interpreting ends when 
all members of the diagnostic team are satisfied with the proposed diagnosis and the 
evidence offered to support it. 
 Unique to this conceptual framework is the importance given to not only to 
determining the diagnosis, but also communicating it adequately to the patient.  In 
defining diagnostic error, the NAM committee (2015, pg. 4) argued that “from a patient’s 
perspective, an accurate and timely explanation of the health problem is meaningless 
unless this information reaches the patient so that a patient and healthcare professionals 
can act on the explanation.”  Communication should take place throughout the diagnostic 
process, as providers explain working diagnoses and the degree of uncertainty associated 
with them, and eventually discuss the health implications of the final diagnosis. 
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The diagnostic process is inherently a collaborative activity, in that it involves at a 
minimum two parties — the patient and a healthcare professional — and likely involves a 
number of other healthcare professionals as well.  In today’s complex and distributed 
medical landscape, diagnosis has become more likely to involve multiple healthcare 
professionals at different levels of practice (e.g. MD, NP, RN, etc.) and across different 
specialties.  The patient, clinicians, and other healthcare professionals who support the 
diagnostic process can be considered ‘the diagnostic team’.  Importantly, diagnostic 
teams are more fluid then many other teams in health care.  As the NAM (2015, pg. 151) 
noted, “teamwork in the diagnostic process rarely involves static, fixed diagnostic teams; 
instead participation in diagnosis is often dynamic and fluctuates over time, depending on 
what areas of expertise are needed to diagnose a specific patient and where the patient 
engages in the diagnostic process.”  This description highlights that while teamwork and 
collaboration are necessary to obtain and process diagnostic information, the actual 
participants in the process may or may not regularly work together, be co-located, or 
exhibit other classic characteristics of a team.  
The NAM committee provided an example of a diagnostic team (Figure 1.2).  
Patients and their family members represent a key part of the team, in recognition of the 
unique knowledge patients hold about their own health state (such as their symptoms, 
exposures to health risk factors, and responses to prior treatment.)  Patients are assumed 
to have the most significant relationship with a primary care practice, and to primarily 
seek care from their primary care providers.  The primary care team is then assumed to 
collaborate with other healthcare professionals in order to reach a diagnosis.  However, 
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the committee acknowledged that this kind of partnership and coordinated provision of 
care does not occur for all patients, a concept we explore further in the case of rare, 
genetic diseases. 
Figure 1.2 Diagnostic Team Members (National Academy of Medicine, 2015) 
 
Model of Pathways to Treatment 
While the NAM model of the diagnostic process includes patients’ recognition of 
their health problem and decision to engage in health care for that problem, the 
underlying cognitive processes and activities that patients undertake to accomplish these 
stages received relatively little attention compared to the diagnostic activities of 
healthcare professionals.  To better understand the processes and contributing factors at 
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play during patients’ symptom appraisal and help-seeking periods, we turned to the 
Model of Pathways to Treatment (Figure 1.3, Walter et al., 2012.)   
Figure 1.3 The Model of Pathways to Treatment (Walter et al., 2012) 
 
The Model of Pathways to Treatment was developed after a systematic review of 
studies that applied the Model of Total Patient Delay (Andersen, Cacioppo and Roberts, 
1995) to delays in cancer diagnosis.  As brief background, the Model of Total Patient 
Delay was developed to describe patients’ cognitive processes that lead up to seeking 
health care.  In this model, patients: 1. detect a sign or symptom that they can’t explain as 
part of their normal bodily experience; 2. interpret that sign or symptom as an indicator 
that they have an illness; 3. decide to seek treatment for the illness; and 4. act on that 
decision by making an appointment with the appropriate healthcare professional.   
In their review of the literature on diagnostic delay in cancer, Walter et al. (2012) 
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found that it was difficult to separate patients’ belief that they have an illness from the 
decision to seek health care in empirical studies (the appraisal and illness delay intervals), 
and that there was little evidence to suggest any meaningful delays exist between 
deciding to seek medical attention and acting on that decision (the behavioral delay 
interval).  For this reason, they collapsed the four listed stages of the Model of Total 
Patient Delay into two intervals: appraisal and help-seeking, which we describe further 
below.   
The Appraisal Interval begins when a person detects a bodily change.  The term 
‘bodily change’ is used rather than ‘unexplained sign/symptom’ to note that a patient’s 
assessment of whether or not a change is explainable is in and of itself an important 
process.  Bodily changes may be interpreted not as an abnormal symptom, but as a 
fluctuation in normal bodily processes or a normal response to changes in the 
environment.   Additionally, the model recognizes that patients may have alternative 
responses to bodily change that do not involve seeking medical care.  For instance, 
patients may ignore the bodily change, hope the change improves on its own, self-
medicate, change their lifestyle, or seek advice from non-medical professionals.  
 Once patients perceive there is a reason to seek medical care, they enter the Help-
Seeking Interval.  Patients may have a range of different reasons to seek care, and by 
focusing on these reasons, we may identify specific triggers to seeking care.  Reasons to 
seek care may be related to a patients’ symptom appraisal and self-management (e.g. 
symptoms persist or get worse, the patient is anxious about a symptom, etc.) or may be 
external (e.g. a family member suggests visiting a healthcare professional).  Barriers to 
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seeking care may also hinder patients from seeking or receiving health care.  While a 
person may perceive a need to seek medical care, they may be unable to do so because of 
a variety of personal factors (such as competing needs for their time or distrust in the 
medical system) or larger system-level factors (such as lack of access to an appropriate 
healthcare provider or financial barriers.)     
Once patients have their first consultation with a health-care professional for a 
new sign/symptom, they then enter the diagnostic interval.  As in the NAM (2015) 
conceptual framework, during the diagnostic interval medical providers assess the 
patient’s health problem and attempts to determine the cause through clinical reasoning, 
ordering of additional diagnostic tests, and/or referral to other providers.   
Importantly, Walter et al. (2012) also recognized that care pathways are rarely 
linear, and people may pass back and forth through different stages or skip some stages 
altogether.  Thus, while the authors present time intervals in the order in which most 
situations are expected to unfold, they acknowledge that patients may repeat or skip steps 
(as depicted by the circular shape and arrows of each process category in Figure 1.3).  For 
example, arranging and attending appointments for additional diagnostic testing and 
consultations is dependent on both providers’ recommendations and patients’ willingness 
and ability to pursue care, emphasizing the repeated importance of help-seeking 
behaviors throughout the diagnostic process. 
 The Model of Pathways to Treatment also includes contributing factors, which are 
“features of the patient, HCP [healthcare professional], healthcare system, and disease 
that influence processes and, in turn, the timing of events and duration of intervals” 
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(Walter et al., 2013).  Disease factors are biomedical features of the health problem such 
as where in the body a symptom is felt or how fast a symptom worsens.  Patient factors 
include patient-level demographic, medical, and psychological characteristics (such as 
gender, pre-existing comorbidities, and trust in medical providers, respectively) as well as 
the social and cultural context a patient lives within.  Healthcare provider and system 
factors are “aspects of the healthcare services that can impact both patient and 
professional decision and behavior” (Walter et al., 2013).  This includes access to care, 
organizational characteristics of healthcare facilities, and healthcare policy. 
 Many of the contributing factors conceptualized by the Model of Pathways to 
Treatment are related to the factors in Andersen’s behavioral model of the utilization of 
health services (Andersen, 1995).  Walter et al.’s (2013) ‘patient factors’ overlap with 
Andersen’s ‘predisposing characteristics’ (which include demographics, social structure, 
and health beliefs) and ‘personal/family level enabling resources’.  Similarly, Walter et 
al.’s (2013) ‘provider/system factors’ overlap with Andersen’s ‘community level 
enabling resources’ and ‘environment’.  By recognizing overlap between these models, 
we seek to highlight the opportunity for researchers to draw on the deep literature based 
on the Andersen model of healthcare utilization when selecting which contributing 
factors to study during diagnosis. 
Combined Conceptual Framework of Dissertation 
As shown below, our conceptual framework is based primarily on the NAM 
diagnostic process framework, but is supplemented with insights from the Model of 
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Pathways to Treatment and Andersen’s behavioral model of the utilization of health 
services (Figure 1.4).   
Figure 1.4 Modified conceptual model of the diagnostic process 
 
 
We base our understanding of the NAM time periods of ‘patient experiences a health 
problem’ and ‘patient engages with healthcare system’ on the Appraisal and Help-
Seeking intervals of the Model of Pathways to Treatment, respectively.   We also add to 
the NAM diagnostic process framework the contributing factors from the Model of 
Pathways to Treatment, in order to provide a basis from which to explore factors that 
modify the length and quality of the diagnostic process. 
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Our model, like its two progenitors, embraces the non-linearity of the diagnostic 
process.  As the cycle of information gathering/integration/interpretation progresses, 
patients can move between primary care, secondary care, and tertiary care settings, and 
see any number of healthcare professionals.  Patients’ experiences of a health problem 
and engagement with the healthcare system are continuous inputs, as patients monitor 
their symptoms and attend (or don’t attend) additional appointments throughout their 
diagnostic journey.  Similarly, communication of the diagnosis and treatment are 
continuously changing outputs, with communication changing as working diagnoses are 
refined and treatment response is monitored. 
We conceptualize the diagnostic process as an ongoing and collaborative process 
which unfolds through time with the contributions of multiple medical professionals and 
the patient.  As such, we have adapted the NAM depiction of the diagnostic team to better 
reflect the people and places involved in the diagnosis of rare, genetic diseases (Figure 
1.5).   In line with the patient-centered principles of the NAM definition of diagnostic 
error, we have framed the patient as the center of the diagnostic team.  We separate the 
healthcare and non-healthcare environment in recognition that a patient has 
responsibilities and desires unrelated to their disease diagnosis which can affect their 
willingness and ability to engage in the healthcare system.  Family members and other 
associates (friends, co-workers, spiritual advisors, etc.) are recognized as important 
resources for patients during the diagnostic process.   These associates may encourage or 
deter a patient from seeking care, and may provide emotional or material support that 
enables a person to receive care. 
  
26 
Figure 1.5 Modified representation of the diagnostic team for rare, genetic disorders 
  
 
Our conception of the diagnostic team de-privileges the patient-primary care 
partnership, which assumed that primary care providers would take the lead in 
coordinating diagnostic evaluation.  Patients with rare, genetic diseases almost always 
require secondary or tertiary care providers to provide appropriate disease-specific 
knowledge and care.  As patients see increasingly specialized providers, they may utilize 
primary care less and look directly to specialists to coordinate their care and confirm their 
diagnosis.   Finally, our conception of the diagnostic team adds professionals at genetic 
testing laboratories.  While pathologists, radiologists, and genetic lab 
directors/technicians do not interface directly with patient, they have a valuable role in 
interpreting diagnostic tests.  These professionals can also contribute to diagnosis by 
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assisting front-line clinicians with ordering appropriate tests and refining differential 
diagnoses in light of diagnostic test results. 
Research Questions 
Globally, this dissertation attempts to answer the question: What is the diagnostic 
process like in a rare, genetic disease like schwannomatosis?  We ask this question with 
the aim of identifying strengths and weaknesses in the current diagnostic process for 
schwannomatosis, so that we may identify potential interventions to improve this process 
in the future.  We also ask this question with an eye towards understanding the challenges 
of diagnosing rare, genetic diseases and determining how our conceptual model can be 
applied empirically in studies across diagnoses. 
In this dissertation, we assessed the diagnostic process for patients with 
schwannomatosis using two complementary data sources – medical records and patient 
interviews.  We employed a concurrent, convergent mixed methods research design 
wherein quantitative and qualitative analyses of medical records (studies one and two, 
respectively) were conducted in parallel with qualitative analysis of patient interviews 
(study three) (Table 1.1).   Given the complex nature of diagnostic processes, a mixed 
methods research approach can most comprehensively uncover barriers to timely and 
accurate diagnosis.  No single data source or mode of analysis alone would be sufficient 
to capture the necessary detail of patients’ experiences, provider behavior, and 
organizational contributors to diagnostic error.  By combining insights from medical 
records and patient interviews throughout data collection and data analysis, we could 
triangulate our findings and increase study validity (Creswell and Miller, 2000). 
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Table 1.1 Overview of Dissertation Chapters 
Chapter 2: Assessing the Accuracy and Timeliness of the Schwannomatosis 
Diagnostic Process 
Research Question: How well does the diagnostic process function for patients with 
probable or confirmed schwannomatosis eventually seen at specialized 
neurofibromatosis clinics? 
Data Source: Medical records at Massachusetts General Hospital and Johns Hopkins 
Hospital 
Methods: Retrospective chart review with descriptive and quantitative analyses 
Main Conceptual Framework Domains: Working Diagnosis, Communication of 
Diagnosis, Diagnostic Outcomes 
Chapter 3: Identifying Failures in the Schwannomatosis Diagnostic Process 
Research Question: What failures occur during the schwannomatosis diagnostic 
process and what affect do they have on diagnostic outcomes? 
Data Source: Narrative summaries of the diagnostic journey generated from the 
medical records at Massachusetts General Hospital and Johns Hopkins Hospital 
Methods: Directed content analysis 
Main Conceptual Framework Domains: Information Gathering, Information 
Interpretation and Integration, Diagnostic Outcomes 
Chapter 4: Understanding the Patient Experience of the Schwannomatosis 
Diagnostic Process 
Research Question: What is the schwannomatosis diagnostic process like from 
patients’ perspective? 
Data Source: Semi-structured interviews with U.S. patients recruited from the 
International Schwannomatosis Database 
Methods: Grounded thematic analysis 
Main Conceptual Framework Domains:  Patient Experiences a Health Problem, Patient 
Engages with Healthcare System, Communication of Diagnosis, Diagnostic Outcomes 
 
 In chapter 2, we present our first study, in which we conducted a comprehensive 
medical record review of schwannomatosis patients seen at two large specialty clinics in 
order to assess the accuracy and timeliness of the diagnostic process for schwannomatosis 
patients.  In this study, we also examined the impact of various disease- and patient-level 
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factors on diagnostic timeliness, and identified why patients with probable 
schwannomatosis failed to receive diagnostic confirmation.  
In chapter 3, we present our second study, in which we further explored the 
specific diagnostic process failures that occur in schwannomatosis.  To do this, we 
created narrative summaries of patients’ diagnostic journeys based on medical record 
data for a subset of the patients in study one.  We then performed a directed content 
analysis of these case summaries to identify failures in the diagnostic process, explore 
their impact on diagnostic outcomes, and record factors that contributed to the occurrence 
of diagnostic process failures. 
  In chapter 4, we present our third study, in which we sought to better understand 
the diagnostic process from the patients’ perspective.  To do this, we conducted in-depth, 
semi-structured interviews with schwannomatosis patients recruited from the 
International Schwannomatosis Database, which includes patients who are and are not 
seen at specialized NF clinics.  In these interviews, we explored issues that were not well 
documented in the clinical data used in studies one and two, including patients’ ability to 
access care, the quality of diagnostic communication, and the impact of a 
schwannomatosis diagnosis and diagnostic errors on patients’ lives.  
 Finally, this dissertation concludes with a summary of our main research findings 
and a discussion of the implications of these findings on efforts to improve 
schwannomatosis diagnosis; on our understanding of the diagnostic challenges common 
to rare, genetic diseases; and on considerations for implementing this conceptual 
framework of the diagnostic process in other empirical research.   
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CHAPTER 2: ASSESSING THE ACCURACY AND TIMELINESS OF THE 
SCHWANNOMATOSIS DIAGNOSTIC PROCESS 
Introduction 
 Diagnostic error is a common problem in medicine, with as estimated error rate of 
2-5% in radiology and pathology and an estimated error rate as high as 15% in other 
clinical specialties (Berner and Graber, 2008).  However, many prior studies of 
diagnostic error have been limited by a lack of a conceptual framework to guide 
definitions of diagnostic error and diagnostic delay (Weller et al., 2012).  Additionally, 
existing conceptual frameworks of the diagnostic process have largely been developed 
based on cancer and common chronic conditions (for example, Walter et al., 2012).  Less 
attention has been paid to rare, genetic disorders, which likely face additional barriers to 
timely, accurate diagnosis due to their lower prevalence and providers’ resulting lack of 
familiarity with their signs and symptoms.  In this study, we utilize a comprehensive 
model of the diagnostic process from the National Academy of Medicine (NAM) to 
examine diagnostic error in schwannomatosis, a rare, genetic disease that predisposes 
people to develop multiple nerve sheath tumors.  
Previous data on diagnostic delay and misdiagnosis in schwannomatosis patients 
is limited but suggests these errors may occur frequently.  In a case series of 87 
schwannomatosis patients seen at Massachusetts General Hospital, the median time from 
patients’ first symptom to their diagnosis of schwannomatosis was 7 years, with a range 
as high as 39 years (Merker et al., 2012).  This case series also reported four patients who 
had been previously misdiagnosed with cancerous tumors, one of whom was also 
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previously misdiagnosed with neurofibromatosis type 1 (NF1).  However, these data 
were limited by a lack of clear, conceptually-driven definitions for diagnostic timepoints.  
The authors also did not explore why diagnostic intervals were so prolonged for some 
patients compared to others, and did not investigate the occurrence of other types of 
misdiagnosis in the cohort.     
To address these limitations, we systematically assessed how well the diagnostic 
process functions for patients with probable or confirmed schwannomatosis eventually 
seen at specialized tertiary care clinics.  We reviewed the medical records of 
schwannomatosis patients seen in two neurofibromatoses (NF) clinics and looked at 
multiple dimensions of potential diagnostic error, which is defined by the National 
Academy of Medicine (NAM) as “the failure to a) establish an accurate and timely 
explanation of the patient’s health problem(s) or b) communicate the explanation to the 
patient” (NAM, 2015).  Following this this definition, we specifically sought to assess the 
timeliness, accuracy and ability to establish a diagnosis of schwannomatosis in our cohort 
of patients by 1) quantifying the length of each stage of the schwannomatosis diagnostic 
process; 2) determining the rate and types of inaccurate diagnoses of schwannomatosis-
related signs and symptoms; and 3) assess why patients with probably schwannomatosis 
do not receive confirmation of their diagnosis.   
 We operationalized our definitions of key diagnostic timepoints and intervals 
according to our conceptual framework (Figure 2.1), which is based largely on the NAM 
(2015) model of the diagnostic process, as described in further detail in Chapter 1.  In this 
framework, patients begin the diagnostic process when they experience a health problem 
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and engage with the healthcare system to address it.  Working diagnoses are generated 
and refined through a repeated process of information gathering and interpretation that is 
usually carried out by multiple healthcare professionals.  Crucially, as the diagnosis is 
verified, it is communicated to the patient and used to guide treatment decision-making. 
Figure 2.1 Conceptual Framework Domains Explored in Study 1     
  
In this conceptual framework, our research questions on the timeliness, accuracy, 
and ability to establish a diagnosis of schwannomatosis correspond to when a diagnosis is 
communicated, the accuracy of working diagnoses, and the movement between potential 
working diagnoses and a final confirmed diagnosis [Figure 2.1, dashed box at left].  In 
total, our study reflects on the patient-level outcomes of the diagnostic process, including 
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both timely and accurate diagnoses as well as the experience of diagnostic error [Figure 
2.1, dashed box at right].  We also examined the effect of several disease, patient, and 
provider characteristics (listed at the bottom of Figure 2.1) on diagnostic timeliness.  
Methods 
Methods Overview 
 We performed a retrospective medical record review of 97 patients with 
confirmed or probable schwannomatosis seen at the neurofibromatoses (NF) specialty 
clinics at Massachusetts General Hospital (MGH) and Johns Hopkins Hospital (JH) 
between January 1, 2005 and January 31, 2016.  We reviewed all documentation 
available in patients’ medical records, including internally and externally generated 
provider encounter notes; operative, pathology and imaging reports; and any documented 
patient communications (such as phone calls, emails, and patient questionnaires).  We 
recorded patient demographic and clinical information, the dates of key diagnostic 
timepoints, and descriptive information on diagnostic outcomes, including diagnostic 
communication and potential diagnostic errors.  To ensure clinical accuracy, patient 
symptomology and suspected diagnostic errors were reviewed with an expert NF 
clinician.  We also calculated the length of the schwannomatosis diagnostic process and 
pertinent subintervals thereof, and tested for associations between interval length and 
disease, patient, and provider level characteristics. 
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Patient Sample 
Patients with schwannomatosis seen at the NF specialty clinics at MGH and JH 
were identified using each clinic’s internal patient databases, and assessed for eligibility 
for inclusion in this medical record review.  Inclusion criteria for the study were 1) 
patient has a diagnosis of confirmed or probable schwannomatosis and 2) patient had at 
least one in-person visit at the MGH or JH NF clinic between January 1, 2005 and 
January 31, 2016.  Exclusion criterion for the study was that a patient was told they had 
confirmed schwannomatosis prior to January 1, 2005.     
For this study, we defined patients with ‘confirmed’ schwannomatosis as those 
who met the most recent published diagnostic criteria for schwannomatosis (Plotkin et 
al., 2013).  A diagnosis of confirmed schwannomatosis usually entails the presence of 
two or more schwannomas (at least one with pathologic confirmation) and a lack of 
bilateral vestibular schwannomas as demonstrated by a brain MRI with thin cuts through 
the internal auditory canal (IAC brain MRI), although patients with a first-degree relative 
with schwannomatosis or genetic testing indicating schwannomatosis require only one 
pathologically confirmed schwannoma.  IAC brain MRIs are required as part of the 
diagnostic criteria in order to exclude the presence of bilateral vestibular schwannomas, 
which would indicate a patient has a diagnosis of neurofibromatosis 2 rather than 
schwannomatosis.  While it was not required for study entry, we also assessed how many 
of these confirmed patients met earlier, stricter diagnostic criteria for “definite 
schwannomatosis” published by MacCollin et al. (2005) and Baser et al. (2006).  [Of 
note, all patients who met earlier criteria published by MacCollin et al. (2005) and Baser 
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et al. (2006) meet the criteria published by Plotkin et al. (2013).]  A detailed description 
of how we interpreted the criteria published in these three papers is available in Appendix 
A1.   
We defined patients with ‘probable’ schwannomatosis as those who did not meet 
the Plotkin et al. (2013) diagnostic criteria for schwannomatosis, but for whom 
schwannomatosis was considered the definitive or leading working diagnosis by their 
treating physician (an expert NF clinician).  Assignment to ‘confirmed’ and ‘probable’ 
categories was determined solely by these criteria, regardless of whether the treating 
physician communicated the same level of diagnostic certainty to the patient.  For 
example, if a patient’s treating physician recorded that they patient definitively had 
schwannomatosis, but our review did not indicate that the patient met Plotkin et al. 
(2013) diagnostic criteria, the patient was still considered as ‘probable’ schwannomatosis 
in our study. 
 We choose to include patients seen in clinic in the year 2005 or later because this 
was when the first clinical diagnostic criteria for schwannomatosis was published in the 
peer-reviewed literature (MacCollin et al., 2005).  In addition, electronic outpatient 
medical record data at MGH and Johns Hopkins did not reliably extend beyond this time.  
Finally, because our conceptual model and definition of diagnostic error explicitly 
include a focus on diagnostic communication, we excluded patients who were told they 
definitively had schwannomatosis prior to 2005, regardless of when they objectively met 
published diagnostic criteria. 
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Data Collection 
 For eligible patients, we reviewed medical data available in the MGH and JH 
outpatient electronic medical records through January 31, 2016.  For patients seen at 
MGH, we also reviewed any available paper records from the outpatient NF clinic that 
were archived upon implementation of the electronic medical record system.  
Specifically, we reviewed all clinician encounter notes, imaging reports, pathology 
reports, operative notes, discharge summaries and patient documentation (such as intake 
surveys or documentation or telephone or email contacts).  This included both internally 
generated documentation from providers in the MGH or JH hospital networks as well as 
externally generated documentation from outside providers that was scanned into 
electronic patient files (or included in the paper chart).  Data was abstracted from the 
medical record using a standardized data spreadsheet, which was developed a priori and 
expanded during data collection as additional analyses of interest were conceptualized.  
(When data fields were added, previously reviewed medical records were re-accessed to 
obtain new data as needed, such that all data fields were collected for all patients.)  
Abstracted data included patient demographics, clinical information, key diagnostic 
timepoints and diagnostic outcomes, as detailed below. 
Assessing Diagnostic Timepoints 
In order to examine the timeliness of schwannomatosis diagnosis, we recorded 
dates for the following key events in the diagnostic process: when the patient first 
experienced a health problem related to schwannomatosis, when the patient first engaged 
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in the healthcare system (for a health problem related to schwannomatosis), when the 
patient was first seen in a specialty NF clinic, when a confirmed diagnosis of 
schwannomatosis was established (if at all), and when the confirmed diagnosis of 
schwannomatosis was communicated to the patient (if at all).  In-depth descriptions of 
each of these diagnostic timepoints follows. 
 Given our data source (the medical records at MGH and JH), precise dates were 
not always available for events prior to patients’ contact with these medical systems.  In 
this case, we estimated dates based on a modified version of the protocol developed by 
the Cancer Symptom Interval Measure project (Neal et al, 2014) (Appendix A2).  In 
addition, healthcare professionals sometimes recorded conflicting information about the 
timing and nature of medical events.  In this case, we followed a hierarchy of sources that 
privileged primary documentation and accounts from clinician encounters closest to the 
original event when choosing which dates and events to record (Appendix A3).  
Diagnostic Timepoint: First Experience of a Health Problem 
First experience of a health problem was operationalized according to the Aarhus 
statement as the time point when the patient noticed the first bodily change, sign, or 
symptom that was plausibly related to schwannomatosis (Weller et al., 2012).  This 
wording reflects the fact that while noticing a bodily change and ascribing it as a 
symptom of a disease process are conceptually distinct (Walter et al., 2012), this 
distinction is rarely elaborated upon in the medical record.  As such, we did not attempt 
to distinguish between bodily changes and symptoms, and simply noted the earliest time 
at which either occurred.  The relationship of a bodily change or symptom to 
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schwannomatosis was assessed by the study team (rather than relying solely on the 
assessment of treating physicians).   Discovery of a nerve sheath tumor or experience of 
symptoms attributable to a specific nerve sheath tumor (i.e. pain or neurologic deficit 
occurring in the same nerve distribution as an identified tumor) were automatically 
considered to be related to schwannomatosis.  Cases of nonspecific pain or neurologic 
deficit (i.e. symptoms expanding beyond one nerve distribution, or in an area for which 
no nerve sheath tumor was confirmed) were reviewed with an expert NF clinician to 
determine whether the symptom was plausibly related to schwannomatosis.    
Diagnostic Timepoint: First Engagement with the Healthcare System 
First engagement with the healthcare system was defined as the first medical 
consultation in which a patient reported a bodily change, symptom or sign plausibly 
related to schwannomatosis (as defined above).  Medical consultations were not required 
to be for the same bodily change/symptom as the first health problem (for example, when 
a patient has experienced schwannomatosis-related pain in one body area, but does not 
seek care until feeling a palpable mass in another body area).  Medical consultations 
could be with physicians, advanced practice providers (nurse practitioner or physician 
assistants), or other licensed healthcare providers (e.g.  physical therapists, genetic 
counselors, etc.). 
Diagnostic Timepoint: First Visit to NF Specialty Clinic 
First visit to an NF specialty clinic was defined as the patient’s first in-person 
encounter with a physician in the NF clinic at MGH or JH.  Some physicians working in 
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the NF clinic also worked in another clinic at the same hospital (for example, a general 
neurosurgery clinic or neuro-oncology clinic); however, we included only visits that 
occurred within the dedicated NF clinic when defining this timepoint.  Because some 
patients were initially seen by a nurse practitioner in the NF clinic as part of the NF clinic 
intake process, we also performed a secondary analysis using the date of the first in-
person visit with a physician or advanced practice provider.  Telephone contacts or record 
reviews performed by NF clinic staff prior to the patient’s first in-person visit were not 
included when defining this timepoint. 
Diagnostic Timepoint: Confirmed Diagnosis of Schwannomatosis Established 
A confirmed diagnosis of schwannomatosis was considered to be established on 
the date that a patient first fulfilled diagnostic criteria for schwannomatosis, according to 
any version of clinical diagnostic criteria published at that time.  We considered only 
diagnostic criteria available at the time a patient was seen, in order to reflect the earliest 
possible date a clinician could have accurately communicated to the patient that they had 
confirmed schwannomatosis.  Plotkin et al. (2013) criteria were published online on 
February 7, 2013; thus, patients who prior to this day did not meet earlier, stricter criteria 
published by MacCollin et al. (2005) but did meet Plotkin et al. (2013) criteria were 
assigned February 7, 2013 as their earliest possible diagnosis date.  In recognition of the 
contribution radiologists and pathologists make towards diagnosing schwannomatosis, 
patients meeting diagnostic criteria via imaging or pathology results were dated 
according to when the final radiology or pathology reports were issued.  If the date a 
report was issued was not noted in the medical record, we assumed radiology reports 
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were issued one day after the imaging exam was performed and pathology reports were 
issued three days after surgery was performed (the median reporting period for all known 
cases in our cohort). 
Diagnostic Timepoint: Confirmed Diagnosis of Schwannomatosis Communicated 
Finally, in keeping with the patient-centered principles of our conceptual 
framework, our primary endpoint for the diagnostic process was communication of a 
confirmed diagnosis of schwannomatosis to the patient, rather than ascertainment of 
diagnosis by healthcare professionals.  However, not all elements of communication are 
captured in the medical record – for instance, it is impossible to know if the patient fully 
understood the diagnosis.   For our analyses, we assumed that clinicians adequately 
communicated the diagnosis to the patient at the same time they first indicated that the 
patient had schwannomatosis in an in-person, phone, or electronic encounter note.  If a 
clinician only used wording suggesting a working diagnosis or differential diagnosis (e.g. 
“suspected schwannomatosis”, “probable schwannomatosis”, “some form of 
neurofibromatosis”, etc.), we assumed a confirmed diagnosis had not yet been 
communicated.  If there was no documented communication of a confirmed diagnosis, 
we recorded the date of the patient’s last follow-up in the NF clinic as a measure of the 
time spent in the diagnostic process to date. 
Of note, our assessment of clinician communication was independent from our 
assessment of patients’ status as having confirmed or probable schwannomatosis.  For 
example, if the patient’s treating physician told the patient they had schwannomatosis, we 
considered the diagnosis as communicated, even if our research team felt the patient did 
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not yet meet published clinical diagnostic criteria for schwannomatosis.  Conversely, if 
our research team felt a patient met published clinical diagnostic criteria at certain 
timepoint, but the patient’s treating physician wanted additional diagnostic information to 
further reduce diagnostic uncertainty, we did not consider the diagnosis as 
communicated.  We analyzed the communication date in this way to stay true to patients’ 
lived experience of the diagnostic process, and recorded any discrepancies between our 
assessment of a patient’s diagnosis status and the treating physician’s assessment. 
Assessing Diagnostic Outcomes 
In order to examine the accuracy of the schwannomatosis diagnosis process, we 
reviewed diagnostic errors related to two kinds of inaccurate explanations of a patient’s 
health problem: misdiagnoses (when another diagnosis was given instead of 
schwannomatosis) and incomplete diagnoses due to physician or system errors (when 
schwannomatosis or another tumor suppressor syndrome should have been considered 
but was not).  
Diagnostic Outcome: Misdiagnosis 
Misdiagnoses were defined as instances where a clinician attributed a sign or 
symptom later found to be associated with schwannomatosis to another disease process.  
Misdiagnoses could be for a specific symptom (e.g. misdiagnosing the source of a 
patient’s pain) or for the overall disease (e.g. misdiagnosing a patient as having a 
different genetic syndrome).  Attribution of a sign or symptom to another disease process 
was not considered a misdiagnosis if it was mentioned in the context of a differential 
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diagnosis, wherein multiple possible etiologies were still being considered.  All cases of 
suspected misdiagnosis were reviewed by both the PhD candidate and an expert NF 
clinician to enhance clinical accuracy.  Given that not all clinical information available to 
the diagnosing physician was available to us during data review, the question emerged as 
to what standard of evidence should be used to determine whether a misdiagnosis 
occurred.  Recognizing that retrospective determinations of misdiagnosis are difficult but 
wanting to capture as many suspected misdiagnoses as possible, we decided to use a 
standard of proof analogous to civil law cases, i.e. whether the preponderance of evidence 
suggested that the patient was misdiagnosed.  This standard is similar to studies in which 
reviewers use a Likert scale to assess the likelihood that an adverse event has occurred, 
and any event with a score in the top half of the scale (which is usually a certainty at or 
above “more likely than not” or “more than 50/50”) is counted as an adverse event 
(Brennan et al., 1991; Zwaan and Singh, 2015). 
Diagnostic Outcome: Incomplete Diagnosis 
Incomplete diagnoses can be defined as occasions where a patient was given a 
diagnosis of a sporadic tumor, without mention of the possibility of an underlying genetic 
cause such as schwannomatosis.  In keeping with the NAM focus on outcomes over 
process when defining diagnostic error, incomplete diagnosis can occur regardless of 
whether clinician should reasonably have been expected to suspect an underlying genetic 
disease at that time.  However, in order to better delineate opportunities for diagnostic 
improvement, we focused only on the subcategory of incomplete diagnoses wherein a 
clinician should reasonably have begun investigation into or referral for an underlying 
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genetic syndrome.   
 After consultation with clinical experts, we defined this subcategory of 
‘incomplete diagnosis due to physician or system error’ as any situation where a patient 
had two or more nerve sheath tumors surgically resected or visible on an MRI, with at 
least one pathologically proven as a schwannoma, and the patient was not worked up for 
possible neurofibromatosis 2 (NF2)/schwannomatosis or referred to another provider for 
such workup.  This definition was used because the likelihood of having multiple, 
sporadic nerve sheath tumors in the absence of a genetic syndrome is extremely low, and 
thus referral for additional diagnostic workup in patients fulfilling this criterion is almost 
always clinically warranted.  We attributed the incomplete diagnosis to physician failure 
if there was evidence that the physician was aware of the relevant clinical data (e.g. their 
note mentioned the patient had multiple schwannomas but they did not pursue further 
diagnostic workups) and to system failure if there was no sufficient evidence to suggest 
this, or evidence explicitly suggested a physician was not aware of the patient’s history 
(for example, if documentation of prior surgeries from outside hospitals was never 
received). 
Diagnostic Outcome: Failure to Establish a Confirmed Diagnosis 
Finally, in order to examine the reasons that may lead to failures to establish a 
diagnosis, we examined the reasons why patients with a working diagnosis of 
schwannomatosis did not progress to a confirmed diagnosis.  For all patients who were 
still diagnosed with probable schwannomatosis at their last clinical visit, we recorded the 
diagnostic testing necessary to confirm a diagnosis of schwannomatosis (i.e. we recorded 
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the elements of the diagnostic criteria that the patient did not yet fulfill).  We then 
recorded which required diagnostic testing was not completed and the reason for non-
completion, if known. 
Descriptive and Statistical Analyses  
We present descriptive data on patient demographics, patient clinical 
characteristics, and the specialties of healthcare professionals consulted during the 
diagnostic process.  For patients who were symptomatic at their first experience of a 
health problem related to schwannomatosis, we recorded symptom type (pain, 
neurological deficit, palpable mass, or other) and frequency (intermittent, constant, or 
unknown).  Disease inheritance was classified as familial or sporadic.  Patients were 
considered to have familial if they had a first- or second-degree relative diagnosed with 
schwannomatosis by the time of their most recent clinic visit; familial patients included 
both probands (the first person in the family to be diagnosed) and non-probands.   
We also assessed whether patients had segmental schwannomatosis (i.e. 
anatomically limited disease), which may indicate the patients have genetic mosaicism 
(i.e. only a portion of their cells are affected by the genetic mutation leading to 
schwannomatosis).  Patients were considered as having segmental schwannomatosis if 
they met criteria published in MacCollin et al. (2005), with tumors limited to either one 
limb or five or fewer contiguous segments of the spine.  This determination was made 
regardless of whether the patient’s treating clinician did or did not make a diagnosis of 
segmental or mosaic schwannomatosis. 
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Regarding diagnostic accuracy, we report the rate of misdiagnosis and incomplete 
diagnosis due to physician or system error, and describe the situations in which these 
diagnostic errors occur.  Because there is no consensus on what length of time would 
constitute a delayed diagnosis of schwannomatosis, our examination of the timeliness of 
diagnosis is focused on descriptive data regarding the length of diagnostic intervals 
between key diagnostic timepoints.   
We calculated the following time intervals for each patient: 1) total time to 
diagnosis communicated (patient experiences a health problem to communication of 
diagnosis); 2) initial appraisal and help-seeking interval (patient experiences a health 
problem to patient engages with healthcare system); 3) primary and secondary care 
interval (patient engages with healthcare system to first consultation at the NF specialty 
clinic); and 4) tertiary care interval (first consultation at the NF specialty clinic to 
communication of the diagnosis).   Asymptomatic patients were assigned an initial 
appraisal and help-seeking interval of zero; patients whose diagnosis was communicated 
before consultation at an NF specialty clinic were assigned a tertiary care interval of zero.  
 Since not all patients had a diagnosis of confirmed schwannomatosis 
communicated (either due to communication errors or because they had probable 
schwannomatosis that was never confirmed), we also performed a survival analysis to 
describe the time patients spent in the schwannomatosis diagnostic process.  We used the 
date a diagnosis of confirmed schwannomatosis was communicated as the event, and 
censored participants who did not have documented communication on the date of their 
last NF clinic visit in the study period.      
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 In order to illustrate the effects of using the date of diagnostic communication in 
an empiric study (rather than the more easily ascertainable date a patient objectively met 
diagnostic criteria), we also report our main analysis (total time to diagnosis) using the 
date a confirmed diagnosis of schwannomatosis was established as an alternate endpoint.   
Also, to illuminate potential delays in communicating a diagnosis of schwannomatosis, 
we also report the time interval between the date the diagnosis was established (i.e. the 
earliest date a clinician could have made a diagnosis of confirmed schwannomatosis) and 
the actual date such diagnosis was documented as communicated to the patient.    
 We tested for associations between the length of diagnostic intervals and potential 
contributing factors (noted in Figure 2.1).  Specifically, we assessed disease-level factors 
(disease inheritance, anatomical extent of disease, presenting symptom type, presenting 
symptom frequency, and initial imaging presentation); patient-level factors (gender and 
age at first symptom); and provider-level factors (specialty of clinician initially 
consulted).  We used the Mann-Whitney U test (for dichotomous variables) or the 
Kruskal-Wallis test with pairwise comparisons via the Conover-Iman test (for all other 
categorical variables) to assess for differences in diagnostic interval length between 
patient subgroups.  We used Spearman’s rho to assess for an association between 
continuous variable and diagnostic interval length.  While most statistical tests were 
exploratory, analysis of patient interview data (presented in Chapter 4 of this dissertation) 
suggested that the specificity and frequency of initial symptoms would affect patients’ 
initial appraisal and help-seeking interval.  Specifically, we expected patients with a 
palpable mass to seek care more quickly than those with pain or neurological symptoms 
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only, and we expected patients with intermittent symptoms to seek care more slowly than 
those with constant symptoms. 
 All data collection and analysis was conducted in accordance with Institutional 
Review Board approvals (Partners Human Research Committee Protocol 2014P000633, 
Johns Hopkins Medicine Protocol 00136913, and Boston University Medical Center 
Protocol H-32975).  All statistical analyses were performed using MedCalc version 18.6 
(MedCalc Software, Ostend, Belgium) and all reported p-values are two-tailed.  
Results 
Demographic and Clinical Characteristics  
Ninety-seven patients (71 at MGH and 26 at JH) with schwannomatosis were 
identified who met inclusion and exclusion criteria for this study (Table 2.1).  Sixty-four 
patients had a confirmed diagnosis of schwannomatosis by Plotkin et al. (2013) criteria; 
of these, 52 (81.3%) met MacCollin et al. (2005) diagnostic criteria for definite 
schwannomatosis and 50 (78.1%) met Baser et al. (2006) diagnostic criteria for definite 
schwannomatosis.  Thirty-three patients were classified as having probable 
schwannomatosis.  All patients had electronic medical records for review; paper records 
were available for 23 of 71 MGH patients (32.4%, 14 confirmed and 9 probable cases).  
One-fifth of patients had anatomically limited disease as defined by MacCollin et al. 
(2005). 
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Table 2.1 Patient Demographic and Clinical Characteristics  
 All 
Schwannomatosis 
Patients (n=97) 
Confirmed 
Schwannomatosis 
Patients (n=64) 
Probable 
Schwannomatosis 
Patients (n=33) 
Female, n (%) 49 (50.5%) 30 (46.9%) 19 (57.6%) 
Familial Disease, n (%) 15 (15.4%) 11 (17.2%) 4 (12%) 
Anatomically Limited Disease 20 (20.6%) 14 (21.9%) 6 (18%) 
Age at first experience of a health 
problem, median (range) 
32.9 years 
(5.1 – 68.3 years) 
30.8 years 
(5.1 – 64.1 years) 
39.7 years 
(12.5 – 68.3 years) 
First Symptom, n (%) 
    Pain 
    Palpable Mass 
    Neurological Symptoms 
    Pain and Palpable Mass 
    Pain and Neurological 
Symptoms 
    Other 
    Unknown 
    N/A: Asymptomatic at first  
        experience of health problem 
 
51 (52.6%) 
10 (10.3%) 
  4 (4.1%) 
11 (11.3%) 
  8 (8.2%) 
   
  1 (1.0%) 
  2 (2.1%) 
 10 (10.3%) 
 
34 (53.1%) 
  7 (10.9%) 
  0 (0.0%) 
  6 (9.4%) 
  7 (10.9%) 
   
  1 (1.6%) 
  2 (3.1%) 
  7 (10.9%) 
 
17 (51.5%) 
  3 (9.1%) 
  4 (12.1%) 
  5 (15.2%) 
  1 (3.0%) 
   
  0 (0.0%) 
  0 (0.0%) 
  3 (9.1%) 
 
First Symptom Frequency, n (%) 
    Constant 
    Intermittent 
    Unknown 
    N/A: Asymptomatic at first  
    experience of health problem 
 
 
33 (34.0%) 
29 (29.9%) 
25 (25.8%) 
10 (10.3%) 
 
 
21 (32.8%) 
18 (28.1%) 
18 (28.1%) 
  7 (10.9%) 
 
 
12 (36.4%) 
11 (33.3%) 
  7 (21.2%) 
  3 (9.1%) 
Age at first medical consultation, 
median (range) 
35.4 years 
(5.3 – 68.4 years) 
34.8 years 
(5.3 – 64.1 years) 
40.5 years 
(13.3 – 68.4 years) 
Clinician specialty at first medical 
consultation, n (%) 
    Primary Care  
    Surgeon 
    Neurologist 
    Emergency 
    Other 
    Unknown 
 
 
27 (27.8%) 
12 (12.4%) 
  7 (7.2%) 
  6 (6.2%) 
  4 (4.1%) 
41 (42.3%) 
 
 
22 (34.4%) 
  8 (12.5%) 
  3 (4.7%) 
  3 (4.7%) 
  1 (1.6%) 
27 (42.2%) 
 
 
  5 (15.2%) 
  4 (12.1%) 
  4 (12.1%) 
  3 (9.1%) 
  3 (9.1%) 
14 (42.4%) 
Initial Imaging Workup, n (%) 
    Single tumor discovered  
    Two or more tumors discovered  
    Unknown 
    N/A – no tumors discovered  
 
54 (55.7%) 
40 (41.2%) 
  2 (2.1%) 
  1 (1.0%) 
 
38 (59.4%) 
25 (39.1%) 
  1 (1.6%)  
  0 (0%) 
 
16 (48.5%) 
15 (45.4%) 
  1 (3.0%) 
  1 (3.0%) 
Age at first NF clinic visit,  
median (range) 
45.5 years 
(11.4 – 79.5 years) 
41.5 years 
(11.4 – 81.3 years) 
48.1 years 
(18.7 – 79.5 years) 
Age when confirmed diagnosis 
communicated, n, median (range) 
N=60, 44.2 years  
(15.1 – 81.6 years) 
N=54, 41.0 years 
(15.1 – 81.6 years) 
N=6, 54.2 years 
(46.2 – 69.6 years) 
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First Experience of a Health Problem 
Patients were a median of 32.9 years old (range, 5.2 to 68.3 years old) at the time 
of their first experience of a health problem related to schwannomatosis.  Overall, 70/97 
patients (72.2%) experienced pain, alone or in combination with a mass or neurological 
symptoms.  Twenty-one patients (21.6%) experienced a palpable mass and eleven 
(11.3%) experienced neurological symptoms, alone or in combination with pain.  
Neurological symptoms included numbness, paresthesias, muscle weakness and 
hypophonia.  One patient experienced other types of symptoms; he/she had severe 
coughing spells due to a schwannoma compressing the esophagus.  Ten patients were 
asymptomatic at the time their health problem was discovered; eight patients had an 
incidental finding on imaging, one patient had an incidental finding on physical exam, 
and one patient elected to undergo presymptomatic genetic testing after a family member 
was diagnosed with schwannomatosis. 
First Engagement with the Healthcare System and Initial Diagnostic Workup 
 Patients were a median of 35.4 years old (range, 5.3 – 68.4 years old) at the time 
they first engaged in care for a sign or symptom related to schwannomatosis.  Sufficient 
information to determine the specialty of the first healthcare provider consulted was 
available in 56 (57.7%) of patients.  Primary care providers were most commonly 
consulted, followed by surgeons (specializing in otolaryngology, orthopedic surgery, 
general surgery or plastic surgery), neurologists, and emergency room physicians.  Eighty 
patients (82.5%) sought care for their first symptom or sign of schwannomatosis; 
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seventeen patients developed additional signs or symptoms before seeking care 
(neurological deficits in eight people, pain in four people, a palpable mass in three 
people, and incidental imaging findings of a mass in two people). 
 Upon initial imaging workup, 65 patients had a single nerve sheath tumor 
identified and 40 patients had multiple nerve sheath tumors identified.  Of the 65 patients 
with a single nerve sheath tumor initially, 11 had additional tumor(s) discovered via 
during monitoring or post-operative imaging follow-up of their initial tumor and 40 had 
additional tumor(s) discovered completely independently due to additional symptoms or 
incidental imaging findings in a different area of the body. 
 Patients consulted a median of five different outpatient healthcare providers 
(range, 0-20) for diagnosis and treatment of schwannomatosis-related signs or symptoms 
prior to being diagnosed with confirmed schwannomatosis (or, for patients without 
confirmed schwannomatosis, their most recent follow-up).  There were 554 unique 
patient/provider pairings documented in the medical record; the specialty of the provider 
could be determined in 517 (93.3%) of cases.  Patients most commonly consulted 
neurosurgeons (n=65, 67%), primary care providers (n=62, 63.9%), orthopedic surgeons 
(n=42, 43.3%), neurologists (n=40, 41.2%), and general surgeons (n=28, 28.9%).  
First Visit to a Specialty NF Clinic 
 Patients were a median of 45.5 years old (range, 11.4 – 79.5 years old) at the time 
they first were seen by a physician in a dedicated neurofibromatosis clinic.  Seven 
patients at JH and zero patients at MGH were initially seen in-person by a nurse 
practitioner in the NF clinic, one to four months prior to meeting with an NF clinic 
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physician.  The source of referral to the NF clinic could be determined for 85/97 patients 
(87.6%).  Of this group, most patients were referred by neurosurgeons (32/85 patients, 
37.6%), self-referred (26/85 patients, 30.6%), or were referred by neurologists and neuro-
oncologists (9/85 patients, 10.6%). 
Diagnostic Communication 
Sixty patients (54 confirmed patients and six probable patients) had 
communication of a diagnosis of confirmed schwannomatosis documented in the medical 
record.   These patients were a median of 44.2 years old (range, 15.1 to 81.6 years) at the 
time their diagnosis was communicated.  
Ten out of 64 (15.6%) confirmed schwannomatosis patients did not have 
communication of a confirmed schwannomatosis diagnosis.  For at least 8 patients, 
physicians deliberately limited communication to a working diagnosis of 
schwannomatosis, while in 2 patients, no communication event was documented in the 
medical record (because the patients were lost to follow-up after obtaining necessary 
diagnostic evidence to meet criteria).  Details of the 8 elective non-communications of a 
confirmed diagnosis follow.  For four patients, the treating physician wanted additional 
diagnostic evidence beyond what was required by diagnostic criteria, in order to more 
conclusively rule out possible alternative diagnoses of NF1 and NF2; this evidence was 
not obtained before the patients were lost to follow-up or the study period ended.  For 
two patients, the treating physician adhered to older, alternate diagnostic criteria which 
the patients did not meet, and so a confirmed diagnosis was not communicated.  For one 
patient, the treating physician wanted diagnostic evidence from an outside institution re-
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reviewed before issuing a final diagnosis, which did not occur before the end of the study 
period.  One patient did not meet diagnostic criteria available at the time of his NF clinic 
visit, and was lost to follow-up before newer, less restrictive criteria were published and a 
final diagnosis could be communicated.   
Six out of 33 (18.2%) probable schwannomatosis patients had communication of 
a diagnosis of confirmed schwannomatosis documented in the medical record.  For each 
of these six patients, treating physicians (one NF clinic physician and two outside 
neurologists) explicitly recorded that the patient met diagnostic criteria for 
schwannomatosis.  In five cases, physicians accepted a standard brain MRI as sufficient 
diagnostic evidence, rather than an IAC brain MRI.  In one case, the physician accepted 
palpation of lesions, rather than MRI or other diagnostic imaging, as sufficient diagnostic 
evidence that the patient had additional schwannomas. 
Assessing Diagnostic Intervals 
Total Time to Diagnosis Communicated and Total Time in the Diagnostic Process  
 Sixty patients (54 confirmed patients and six probable patients) had 
communication of a diagnosis of confirmed schwannomatosis documented in the medical 
record.  In these sixty patients, the median total time to diagnosis communicated (from 
first experiences of a health problem to communication of diagnosis) was 7.9 years 
(range, 0.2 to 48.0 years; 25th – 75th percentile: 4.5 – 14.0 years).   At 5, 10, and 20 years 
from first experience of a health problem related to schwannomatosis, the percentage of 
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people without documented communication of the diagnosis was 70%, 35%, and 18.3%, 
respectively (Figure 2.2).  Total time to diagnosis communicated in confirmed  
Figure 2.2 Total Time to Diagnosis Communicated (n=60) 
 
schwannomatosis patients only (n=54) was a median of 7.6 years (range, 0.2 to 48.0 
years; 25th – 75th percentile: 4.5 – 15.8 years). 
We also assessed the effect of using an alternate endpoint definition (date 
diagnosis was established) on estimates of total time to diagnosis.  In the 64 patients with 
confirmed schwannomatosis, the median interval from first experiences of a health 
problem to date a diagnosis of confirmed schwannomatosis was established was 6.9 years 
(range, 20 days to 47.8 years, 25th – 75th percentile: 3.8 – 16.5 years).  In the 54 
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confirmed patients who also had documented communication of their diagnosis, it took a 
median of 8.1 years to establish the diagnosis.  For these 54 patients, the median interval 
between the date the diagnosis was established and was communicated was 68 days.  
However, seven patients had documented communication of a confirmed diagnosis prior 
to meeting diagnostic criteria.  In the 47 patients in whom documented communication 
followed meeting diagnostic criteria, the median delay in communication was 86 days. 
Since not all patients had documentation of communication of a confirmed 
diagnosis of schwannomatosis, we also performed a survival analysis of total time to 
diagnosis in all 97 patients, censoring patients with communication of a confirmed 
diagnosis at the time of their last follow-up in NF clinic (Figure 2.3).  Using this method, 
which accounts for the time spent in the diagnostic process by patients who have not yet 
had a confirmed diagnosis communicated, the median total time spent in the diagnostic 
process was 11.5 years (95% CI, 8.4 – 18.9 years). At 5, 10, and 20 years from first 
symptom, the percentage of people without documented communication of the diagnosis 
was 80.4%, 56.4%, and 38.3%, respectively.   Using this same hybrid endpoint (date of 
diagnosis communication or date of last follow-up in NF clinic) we observed that patients 
with probable schwannomatosis spent a significantly longer time in the diagnostic 
process than patients with confirmed schwannomatosis (13.1 years vs. 8.2 years, U=778, 
p=0.034).   
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Figure 2.3 Kaplan Meier Curve of Total Time Spent in the Diagnostic Process (n=97) 
 
Diagnostic Subintervals:  Initial Appraisal/Help-Seeking Interval, Primary/Secondary 
Care Interval, and Tertiary Care Interval 
In the overall cohort of 97 patients, the median length of the initial appraisal and 
help-seeking interval (patient experiences a health problem to patient engages with 
healthcare system) was 91 days (range, 0 days to 29.9 years; 25th – 75th percentile: 23 
days – 1.9 years).  However, 10 patients had an initial appraisal and help-seeking interval 
of zero (due to being asymptomatic at the time the first sign of schwannomatosis was 
discovered, through an incidental finding or the initiation of pre-symptomatic genetic 
testing).  In the 87 symptomatic patients, the median length of the initial appraisal and 
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help-seeking interval was 103 days (range, 1 day to 29.9 years; 25th – 75th percentile: 58 
days – 2.0 years).  Thirty percent (29/97) of patients had an initial appraisal/help seeking 
interval longer than one year; 14.4% (14/97) of patients had one longer than 5 years. 
In the overall cohort of 97 patients, the median length of primary/secondary care 
interval (patient engages with healthcare system to first consultation with a physician at 
the NF specialty clinic) was 4.0 years (range, 0 days to 42.1 years; 25th – 75th percentile: 
1.3 – 9.9 years).  One patient had a primary/secondary care interval of zero; this patient 
was referred directly to an NF clinic for genetic testing after the diagnosis of an affected 
family member.  As a sensitivity analysis, we also calculated the primary/secondary care 
interval using the first consultation with a physician or advanced practice provider in the 
NF Clinic; the estimate remained essentially unchanged (median, 4.0 years; range 0 to 
42.1 years; 25th – 75th percentile: 1.2 – 9.9 years). 
In the 60 patients with documentation that a confirmed diagnosis of 
schwannomatosis was communicated, the median length of the tertiary care interval (first 
consultation at the NF specialty clinic to communication of the diagnosis) was 166 days 
(range, 0 days to 8.53 years; 25th – 75th percentile: 18 days – 2.3 years).  However, 9/60 
patients (15%, 7 confirmed and 2 probable patients) had a tertiary care interval of zero 
due to having their diagnosis communicated prior to being seen in the JH or MGH NF 
clinics.  In the 51 patients who had a diagnosis communicated by clinicians in the NF 
clinic, the median tertiary care interval was 292 days (range, 0 days to 8.53 years; 25th – 
75th  percentile: 93 days – 2.8 years).  
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In the 37 patients who did not have documentation that a confirmed diagnosis was 
communicated, the median interval between first consultation at the NF specialty clinic 
and most recent follow-up was 358 days (range, 0 days to 11.5 years; 25th – 75th 
percentile: 0 days – 3.9 years).  However, 12 of these patients had no follow-up in the NF 
clinic (i.e. they had only a single in-person visit).  In the 25 patients who did return for 
additional follow-up in NF clinic, the median interval between first consultation at the NF 
specialty clinic and most recent follow-up was 3.31 years (range, 37 days to 11.5 years; 
25th – 75th percentile: 358 days – 4.6 years). 
Association between diagnostic intervals and disease, patient, and provider 
characteristics 
We examined the influence of various potential contributing factors on the total 
time to diagnosis communicated, total time spent in the diagnostic process (time to 
diagnosis communicated or last follow-up in NF clinic), and initial help-seeking and 
appraisal interval (Table 2.2).  There was no statistically significant effect of disease 
inheritance (sporadic vs. familial patients); anatomical extent of disease (full vs. 
anatomically limited distribution of tumors); patient gender (female vs. male); or the 
specialty of the provider at the first engagement with the healthcare system (primary care 
vs. other specialty vs. unknown) on any diagnostic interval. 
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Table 2.2 Association between Disease, Patient, and Provider-Level Contributing Factors 
and Length of Schwannomatosis Diagnostic Intervals 
  Total Time to 
Diagnosis 
Communicated 
(n=60) 
Total Time in the 
Diagnostic 
Process1 
(n=97) 
Initial Appraisal 
and Help-Seeking 
Interval 
(n=97) 
Disease Characteristics 
Disease Inheritance 
Sporadic vs. Familial  
8.24 vs. 5.87 
U=167, p=0.37 
10.03 vs. 8.02 
U=517, p=0.33 
0.25 vs 0.08 
U=434, p=0.07 
Extent of Disease 
Full vs. Anatomically Limited 
7.27 vs. 8.46 
U=235, p=0.51 
9.74 vs 8.02 
U=516.5, p=0.52 
0.25 vs. 0.30 
U=712, p=0.60 
Initial Symptom Type 2 
Asymptomatic vs. Palpable 
Mass vs. Other Symptoms 
4.64 vs. 5.73 vs. 
8.58 
H(2)=7.04,  
p=0.03 
4.65 vs. 8.45 vs. 
11.23 
H(2)=12.50, 
p=0.002 
0 vs. 0.35 vs. 0.25 
 
H(2)=26.62, 
p<0.0001 
Initial Symptom Frequency 
Asymptomatic vs. Constant 
vs. Intermittent vs. Unknown 
4.64 vs. 5.64 vs. 
8.84 vs. 10.98 
H(3)=13.13, 
p=0.004 
4.65 vs. 7.16 vs. 
10.29 vs. 12.31 
H(3)=16.05, 
p=0.001 
0 vs. 0.25 vs. 1.9 
vs. 0.33 
H(3)=31.90, 
p<0.0001 
Initial Imaging Presentation 3  
Single Tumor vs. Multiple 
Tumors 
 
8.46 vs. 5.64 
U=274, p=0.04 
 
10.16 vs. 8.35 
U=846, p=0.07 
 
0.20 vs. 0.61 
U=884.5, p=0.13 
Patient Characteristics 
Female vs. Male 6.02 vs. 9.75 
U=348, p=0.133 
7.16 vs 11.39 
U=913, p=0.06 
0.17 vs 0.31 
U=1009.5, p=0.23 
Age at First Symptom Rho = -0.299 
p=0.02 
Rho = -0.361 
p=0.0003 
Rho = -0.400 
p<0.0001 
Provider Characteristics 
Provider Specialty at First 
Encounter: Primary care vs. 
Other vs. Unknown 
 
7.86 vs. 4.95 vs. 
4.67 
H(2)=5.37, p=0.07 
 
8.15 vs. 9.67 vs. 
11.55 
H(2)=4.97, p=0.08 
 
0.17 vs. 0.17 vs. 
0.28 
H(2)=1.94, p=0.38 
Table Legend: For categorical variables, median diagnostic interval length is reported in years.  
Test statistics and p-values are reported using Mann Whitney U (for dichotomous variables), 
Kruskal-Wallis H test (for other categorical variables), and Spearman’s Rho (for continuous 
variables). 
1 Time spent in the diagnostic process extends to the time a diagnosis was communicated, or if 
that did not occur, the time of the patient’s last follow-up in NF clinic. 
2 “Palpable mass” includes mass with or without additional symptoms; “other symptoms” 
includes pain, neurological or other symptoms only; and 2 patients with unknown symptoms were 
excluded from analysis. 
3 Three patients with either zero or an unknown number of tumors were excluded from analysis.  
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We grouped patients’ initial symptoms at first experience of a health problem by 
specificity into 1) asymptomatic (incidental finding or presymptomatic testing); 2) 
palpable mass with or without other symptoms; and 3) pain, neurological or other 
symptoms only.  Kruskal-Wallis H tests showed that there was a statistically significant 
difference in interval length between subgroups (H(2) = 7.04, p = 0.03 for diagnosis 
communicated; H(2)=12.50, p=0.002 for time spent in the diagnostic process; H(2) = 
26.62, p<0.0001 for initial appraisal/help-seeking interval).  Post-hoc Conover tests 
showed that patients with pain/neurological symptoms only had significantly longer time 
to diagnosis communicated than asymptomatic patients, and significantly longer time 
spent in the diagnostic process than both asymptomatic patients and those who initially 
experienced a palpable mass (p<0.05 for all).  By definition, asymptomatic patients had 
an initial appraisal/help-seeking interval of 0.  While patients with a mass and patients 
with pain/neurological symptoms only had significantly longer appraisal/help-seeking 
intervals than asymptomatic patients, these two groups did not significantly differ from 
each other.   
Initial symptom frequency was also significantly associated with the length of all 
three diagnostic intervals (H(3)=13.13, p=0.004 for diagnosis communicated; 
H(3)=16.05, p=0.001 for time spent in the diagnostic process; H(3)=31.90, p<0.0001 for 
initial appraisal interval).  Post-hoc Conover tests for all three intervals indicated that 
patients with intermittent symptoms had significantly longer diagnostic intervals than 
patients with constant symptoms or those who were asymptomatic (p<0.05 for all).   
Patients in whom initial imaging workup revealed multiple suspected nerve sheath 
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tumors had significantly shorter time to diagnosis communicated, and a trend towards 
shorter time spent in the diagnostic process than patients who had a single nerve sheath 
tumor (Mann Whitney U=274, p=0.04 for diagnosis communicated and U=846, p=0.07 
for time spent in the diagnostic process).  This did not appear to be driven by differences 
in symptoms or help-seeking behavior, as there was no statistically significant difference 
in length of the initial appraisal interval between these two groups. 
Finally, patients with a younger age at first symptom had significantly longer 
diagnostic intervals (Rho = -0.299, p=0.02 for time to diagnosis communicated; Rho =     
-0.361 p=0.0003 for total time in the diagnostic process; and Rho = -0.400 for initial 
appraisal/help-seeking interval).  However, age at first symptom was moderately and 
statistically significantly correlated with the year in which the patient first experienced 
their first symptom (rho = 0.41, p<0.0001), such that patients who were 50 or older at 
first symptom were exclusively diagnosed after the year 1995 (Figure 2.4). 
Since research diagnostic criteria for schwannomatosis were first published in 
1997 (Jacoby et al., 1997), we felt that patients who experienced symptoms prior to this 
time could have prolonged diagnostic intervals due to under-recognition of the disease 
rather than their age.  For this reason, we performed a subset analysis of the effect of age 
at first symptom on diagnostic interval length in patients diagnosed after 1997 (n=43 for 
time to diagnosis communicated, and n=67 for time spent in diagnostic process and initial 
appraisal/help-seeking interval.)  In this smaller subset of individuals, the negative 
association between age at first symptom and diagnostic interval length remained, but 
was only statistically significant for the initial appraisal/help-seeking interval (rho= -0.22, 
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p=0.16 for time to diagnosis communicated; rho = -0.13, p=0.31 for time spent in 
diagnostic process; rho = -0.353, p=0.005 for initial appraisal/help-seeking interval.) 
Figure 2.4 Association Between Patient Age at First Symptom and Year First Symptom 
Occurred 
 
Assessing Diagnostic Outcomes 
Misdiagnosis 
Thirty-five patients (36.1%, 23 confirmed and 12 probable) likely had a 
schwannomatosis-related sign or symptom(s) misdiagnosed at least once.  Sixteen 
patients had the etiology of their pain misdiagnosed, 11 patients had the nature of a mass 
misdiagnosed, and 18 patients had their overall genetic condition misdiagnosed (non-
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mutually exclusive categories). 
Sixteen patients (16.5%) had the etiology of their pain likely misdiagnosed.  Pain 
was most commonly misattributed to neuromuscular or orthopedic issues such as 
degenerative disc disease, carpal tunnel syndrome, sciatica, bursitis, plantar fasciitis, 
tendonitis, and arthritis.  Less commonly, pain was attributed to an injury (such as 
abdominal strain, after-effects of childbirth, and a rotator cuff injury) or to psychological 
issues (such as psychosomatic pain).  For most patients, later identification and removal 
of a schwannoma led to pain reduction, lending credence to the idea that alternate 
diagnoses, even if they existed as comorbidities, were not the primary source of patients’ 
pain. 
Eleven patients (11.3%) had a nerve sheath tumor misdiagnosed.  Six patients had 
nerve sheath tumors that were misdiagnosed on pathology, while five patients had masses 
that were misdiagnosed based on the presence of radiological and/or physical exam 
characteristics alone.   Six patients had resected masses which were classified as 
neurofibromas by pathologists at outside hospitals, but were re-classified as schwannoma 
(five cases) or hybrid nerve sheath tumor (one case) upon review by an expert pathologist 
at MGH or Johns Hopkins.  Two of these patients had additional, later schwannomas 
misdiagnosed as NF1-related lesions (malignant peripheral nerve sheath tumor in one 
case and gastrointestinal stromal tumor in one case).  In the five patients with masses 
misdiagnosed on imaging/physical exam (all later resected with pathology of 
schwannoma), physicians initially suspected enlarged lymph nodes, cysts, or vascular 
lesions. 
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Eighteen patients (18.6%) had their overall genetic condition misdiagnosed: 13 
with NF1, 4 with NF2, and one was both NF1 and NF2 (by different providers).  Eleven 
of these patients were misdiagnosed by neurologists or neurosurgeons, one was 
misdiagnosed by an orthopedic surgeon, and the specialty of the diagnosing physician 
could not be determined in the remaining five cases.  Fifty percent (7/14) of patients 
misdiagnosed with NF1 had at least one pathologically sampled tumor that was originally 
reported as neurofibroma at an outside hospital.  Three of these seven patients had their 
pathology re-reviewed and revised to schwannoma (as noted above); the other four 
patients did not have pathology re-reviewed but did have one or more subsequent tumor 
resections that were classified as a schwannoma.    
Incomplete diagnosis due to physician or system error 
We observed 19 patients (19.6%, 13 confirmed and 6 probable) with an 
incomplete diagnosis due to physician or system error.  In 13/19 cases, there was 
sufficient detail to suggest physician error, i.e. documentation showed that individual 
physician had knowledge of the patient’s multiple schwannomas (at least one that was 
pathologically confirmed) and neither began workup for potential NF2/schwannomatosis 
nor referred the patient to a specialist for further workup.  Physicians who missed this 
opportunity to further the patient’s diagnostic workup for schwannomatosis ranged across 
eight specialties, with no clear predominance of any one specialty.  In the remaining 6/19 
cases, it was unknown whether the physician had knowledge of the patient’s multiple 
schwannomas, meaning the error could have been due to system error (for example, a 
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failure to transmit documentation of patient’s prior schwannoma, such that the physician 
was unaware the patient met criterion for further NF2/schwannomatosis workup).  
Inability to establish a confirmed diagnosis 
Thirty-three patients (34.0% of our cohort) did not yet meet published diagnostic 
criteria for schwannomatosis, and 27/33 (81.8%) of these patients had not been given a 
definitive diagnosis by their treating physician.  In the 33 patients with probable 
schwannomatosis, patients did not meet diagnostic criteria for the following reasons:  17 
(51.5%) did not have an IAC brain MRI; 9 (27.3%) did not have a pathologically 
confirmed schwannoma; 5 (15.2%) did have either an IAC brain MRI or a pathologically 
confirmed schwannoma; and 2 (6.1%) did not have clear evidence of a second 
schwannoma on appropriate imaging.    
An IAC brain MRI is required as part of the diagnostic criteria to confidently 
exclude even very small vestibular schwannomas, which if present, could suggest an 
alternative diagnosis of NF2.  Nineteen of the twenty-two patients lacking an IAC brain 
MRI had a standard brain MRI; none of which demonstrated evidence of a vestibular 
schwannoma.  In at least 14/19 of these patients, the standard brain MRI was specifically 
ordered for evaluation after the patient was found to have multiple masses (with a leading 
working diagnosis of NF1, NF2, schwannomatosis, or drop metastases), a situation in 
which IAC brain MRI would be indicated. 
Of the 22 patients without an IAC brain MRI, 8 did not have IAC brain MRIs 
ordered by their treating physician because the physician accepted a negative standard 
brain MRI and the patient’s lack of hearing loss and tinnitus (potential symptoms of 
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vestibular schwannoma, which would suggest a diagnosis of NF2) as sufficient diagnostic 
evidence to prove the patient had schwannomatosis.  In 2 patients, IAC brain MRI was 
not ordered due to contraindications (pacemaker in one patient and dental braces causing 
significant artifact in another patient).  Two patients did not complete the ordered IAC 
brain MRI (one because she did not want to pursue further diagnostic workup and one 
due to insurance issues).  Eight patients were lost to follow-up before receiving their IAC 
brain MRI and two did not have sufficient time to receive the IAC brain MRI before the 
end of our study period. 
Of the 14 patients without pathological confirmation of a schwannoma, six did 
not have pursuit of tissue diagnosis recommended by their treating physician unless 
surgery became clinically indicated (to treat pain or neurologic dysfunction).  One patient 
did not have pathologic confirmation recommended by the treating physician because 
alternate diagnostic evidence (germline pathogenic mutation of SMARCB1) was 
accepted as sufficient for diagnosis.  Four patients declined surgery.  One person did 
receive surgery, but pathologic examination was inconclusive for diagnosis (pathology 
was a hybrid nerve sheath tumor).  One patient was lost to follow-up before having 
surgery and one patient did not have time to complete surgery before the end of our study 
period.   
Discussion 
In this study, we reviewed the medical records of 97 people with 
schwannomatosis in order to determine the accuracy and timeliness of schwannomatosis 
diagnoses in patients eventually seen in specialized, tertiary care clinics.  We found that 
  
66 
median time from first symptom to communication of a diagnosis of schwannomatosis 
was more than 7 years, with the majority of this time spent in primary and secondary care 
settings prior to referral to dedicated NF clinics.  Patients with incidental findings leading 
to discovery of schwannomas and patients with multiple tumors discovered upon initial 
imaging were diagnosed faster; patients with intermittent symptoms and younger patients 
were diagnosed more slowly.  One-third of patients likely had schwannomatosis 
symptoms misdiagnosed; 14% of patients were misdiagnosed with NF1, often due to 
incorrect pathology interpretations of schwannomas as neurofibromas. One-fifth of 
patients had a clear, missed opportunity for appropriate investigation into 
schwannomatosis (an incomplete diagnosis due to physician or system error).  Finally, 
one third of patients did not have a confirmed diagnosis of schwannomatosis established, 
most often due to failure to obtain appropriate diagnostic imaging (IAC brain MRIs). 
Timeliness of Schwannomatosis Diagnosis  
Our research shows that prolonged diagnostic intervals are common in 
schwannomatosis.  The median time from first symptom to diagnosis communication was 
7.9 years, with 35% of patients still not diagnosed at 10 years.  These estimates are even 
greater when accounting for the large number of patients who have not received a 
confirmed diagnosis of schwannomatosis.  In a survival analysis accounting for the time 
patients without a communicated diagnosis have already spent undergoing diagnostic 
workup, we found that the median time spent in the diagnostic process for all patients 
was 11.5 years, and more than a third of patients did not have a confirmed diagnosis 20 
years after their first symptom.   While there is no clearly accepted dividing line between 
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what constitutes a timely or delayed diagnosis of schwannomatosis, it is clear that a 
significant number of patients face extended diagnostic intervals, and that significant 
room for improvement exists. 
We identified several disease and patient-related factors that were associated with 
time to diagnosis, many of which acted on patients’ initial appraisal and help-seeking 
interval.  Asymptomatic patients with incidentally found lesions or those who electively 
underwent presymptomatic screening for schwannomatosis due to an established family 
history of the disorder were diagnosed more quickly.  Conceptually, these patients were 
able to ‘skip’ the initial symptom appraisal/help-seeking stage and began the diagnostic 
process already connected to medical care and in the information gathering stage.  
Conversely, patients with intermittent symptoms had especially prolonged symptom 
appraisal/help-seeking stages, with a median time to receive initial medical care of almost 
2 years.  Presumably, patients did not perceive these intermittent symptoms as 
sufficiently abnormal or as bothersome enough to warrant medical attention, leading to 
what Andersen, Cacioppo and Roberts (1995) called appraisal and illness delays in 
receiving care. 
Younger patients also had longer diagnostic intervals, with the strongest effects 
apparent in the initial appraisal and help-seeking interval.  Due to confounding of age 
with year of diagnosis, it is possible that younger patients had longer times to diagnosis 
because they also tended to experience their first symptoms many years ago, when 
medical technology was less advanced and schwannomatosis was less widely known.  
However, this explanation seems less plausible when considering the initial appraisal and 
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help-seeking interval, which is more dependent on patients’ interest in seeking and ability 
to obtain care than clinical knowledge and technology.  Previous research has shown that 
younger adults are more likely to avoid seeing a doctor even when they suspect medical 
care is necessary, perhaps due to increased belief that symptoms will improve on their 
own and being less likely to have a pre-existing usual source of care with whom to 
consult (Kannan and Veazie, 2014; Taber, Levya and Persoskie, 2015).  Given that 
adolescents and young adults with other tumor types have also been shown to experience 
longer diagnostic intervals than either older adults or young children, further research 
into why younger patients with schwannomatosis may have delayed diagnoses is 
warranted (Schnurr et al., 2008; Veneroni et al., 2013; Lyratzopoulos et al., 2015). 
  While we did not demonstrate a statistically significant effect of disease 
inheritance on diagnostic interval length, this may be because our assessment of familial 
disease included both probands and non-probands.  We observed a trend towards familial 
patients having shorter appraisal and help-seeking intervals, and this would likely be 
more pronounced if we examined only patients with a previously established family 
history.  Patients with a known family history may be more aware of the relevance of 
schwannomatosis signs and symptoms, and more easily able to access appropriate 
specialists who are also managing their family members’ care. 
Finally, while we attempted to assess the effect of the provider specialty at initial 
medical encounter on diagnosis intervals, the high percentage of specialties that were 
unknown (due to lack of primary documentation about these encounters and lack of 
specification in later documents) limits our ability to draw conclusions on this point.  
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Patients saw a wide variety of medical professionals during their diagnostic workup, and 
future studies on the most effective care pathways for patients with schwannomatosis 
may reveal other effects of physician specialty on diagnostic outcomes. 
Accuracy in Diagnosing Schwannomatosis-Related Signs and Symptoms 
 Misdiagnosis of schwannomatosis-related signs and symptoms were common, 
with more than one-third of patients likely experiencing a misdiagnosis.  Misdiagnoses 
fell into three broad categories: pain etiology being misattributed to a more common 
disease process; tumors being mis-classified based on physical exam, imaging, or 
pathological characteristics; and patients’ underlying genetic disorder being 
misdiagnosed.  
While retrospective ascertainment of misdiagnosis is difficult, particularly given 
that patients’ clinical history and physical exam was only observable to the extent that it 
was accurately recorded by the original treating provider, we believe this represents a 
conservative estimate of misdiagnoses, particularly regarding pain etiology.  In multiple 
cases, potential pain misdiagnoses were not assigned after discussion between the PhD 
candidate and expert NF clinician, due to lack of sufficient evidence in the medical 
record to prove whether a misdiagnosis did or did not occur.  However, we believe with 
additional documentation or observation, some of these cases would be proven to be 
actual misdiagnoses.  And while it is possible that patients did have other pain-causing 
comorbidities (which would lead us to misclassify the comorbidity as a misdiagnosis), 
the frequent reduction or elimination of patients’ pain after schwannoma resection would 
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indicate that alternate diagnoses were not the primary reason for patients’ symptoms, and 
thus truly represented a misdiagnosis.   
    Surprisingly, misdiagnoses of NF1 (in which patients are prone to multiple 
neurofibromas) were more common than misdiagnoses of NF2 (which like 
schwannomatosis, predisposes patients to developing multiple schwannomas).   NF1 
misdiagnoses were often related to prior pathological misdiagnoses of schwannomas or 
hybrid nerve sheath tumors as ‘neurofibromas’.  Hybrid nerve sheath tumors, which 
display features of both neurofibroma and schwannoma, were described in the late 1990s 
(Feany, Anthony and Fletcher, 1998), but have only recently received more widespread 
recognition (Rodriguez et al., 2012).  These tumors are common in schwannomatosis 
(Harder et al., 2012), and it is likely that other ‘neurofibromas’ in our series which could 
not be re-reviewed were actually hybrid tumors or cellular schwannomas, explaining 
some of the diagnostic confusion and subsequent NF1 misdiagnoses.  Careful review of 
pathology in patients with multiple ‘neurofibromas’, particularly those who do not 
display other clinical features of NF1, is warranted.   
 Other NF1 and NF2 misdiagnoses also point to the difficulty of diagnosing 
genetic diseases, which may present in a mosaic pattern – that is, affecting only a portion 
of the body – or with different symptoms/signs based on the unique genetic mutation.  
Even when treating physicians noted that patients lacked the characteristic skin findings 
of NF1 (café au lait spots, skin fold freckling, and cutaneous neurofibromas), patients 
could still be misdiagnosed with mosaic NF1 or a variant of NF1 that primarily causes 
spinal tumors (with the assumption that these genetic features explained the lack of 
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cutaneous findings).  Similarly, even in patients without vestibular schwannoma (a 
defining characteristic of NF2), patients could be assumed to have mosaic NF2, which 
indeed displays extensive phenotypic overlap with schwannomatosis (Kehrer-Sawatzki et 
al., 2018).  More widespread use of genetic testing may be the only reliable way to 
distinguish these possibilities, and recommendations for wider use of genetic testing are 
currently under consideration by an international consensus panel. 
 Clinicians’ lack of familiarity with NF1, NF2 and schwannomatosis also likely 
contributed to some misdiagnoses and incomplete diagnoses.  Given that a single nerve 
sheath tumor should not necessarily prompt consideration of an underlying genetic 
predisposition, we specifically looked at a narrow subset of incomplete diagnosis 
situations (where patients had multiple tumors radiographically and at least one 
pathologically confirmed as schwannoma).  Even in this situation, in which NF2 and 
schwannomatosis should clearly have been the leading differential diagnosis, a fifth of 
patients were not worked up for a genetic syndrome or referred to another provider for 
such workup.   In some cases, this may have resulted from information failures where 
providers were unaware of patients’ full clinical history; however, in at least two thirds of 
cases, providers recorded the patients’ schwannoma history in their own encounter notes, 
showing that the relevant information was indeed available. 
 Given how rare the occurrence of multiple nerve sheath tumors would be in the 
absence of a genetic disorder, appearance of a second potential schwannoma should serve 
a trigger symptom to initiate further neurogenetic consultation.  To avoid solely relying 
on clinicians to remember and act on this trigger symptom, thoughtful use of electronic 
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medical record alerts may be helpful.  For example, patients with pathology records 
showing more than one nerve sheath tumor and patients with radiology reports 
mentioning multiple potential nerve sheath tumors could be flagged for neurogenetic 
workup.  Similar electronic trigger algorithms have already been developed to evaluate 
delays in follow-up after abnormal lung CT and mammography findings (Murphy, 
Thomas et al. 2015; Murphy, Meyer, Vaghani et al. 2018) and a randomized controlled 
trial of an electronic trigger-based intervention demonstrated reduced diagnostic delay in 
colorectal and prostate cancer (Murphy, Wu et al. 2005). 
Ability to Confirm a Diagnosis of Schwannomatosis 
 Approximately one-third of patients in our cohort (33/97, 34.0%) did not yet meet 
diagnostic criteria for schwannomatosis.  Patients with probable schwannomatosis tended 
to be older than patients with confirmed schwannomatosis at all stages of the diagnostic 
process, although it is unclear how patients’ age may affect ability to confirm a diagnosis.  
Half of probable schwannomatosis patients did not meet diagnostic criteria solely 
because they did not have a brain MRI with the correct sequence performed (thin cuts of 
the IACs), despite the fact that most had brain MRIs ordered in clinical situations in 
which schwannomatosis should have been considered (i.e. during workup for multiple 
potential nerve sheath tumors and/or neurofibromatosis).  This may point to a lack of 
knowledge about the availability of or reasoning for dedicated imaging of the IAC (to 
rule out small vestibular schwannomas that would suggest the patient actually has NF2).  
Confidently distinguishing between patients with NF2 and schwannomatosis is clinically 
important, given the difference in prognosis and management strategies between the two 
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disorders.  For example, patients with NF2 have a high risk of hearing loss due to 
vestibular schwannomas and may require periodic surveillance MRIs and audiology 
testing.  Future studies could evaluate the effect of automatically adding dedicated IAC 
sequences to brain MRIs ordered for workup of multiple neurological tumors on the 
detection rate of vestibular schwannomas and ability to speed up diagnosis of 
schwannomatosis. 
About a quarter of patients with probable schwannomatosis did not meet 
diagnostic criteria because they were lost to follow-up before diagnostic testing was 
completed.  It is possible that these patients viewed their visit to a dedicated NF clinic as 
a one-time or limited-time consult with a specialist, and carried out the rest of their 
confirmatory diagnostic testing and follow-up with local providers.  In fact, 12/37 
patients without documented communication of a confirmed diagnosis had no follow-up 
in NF clinic (i.e. they were seen for only a single in-person visit.)  Future research 
conducted using clinical records from specialized, tertiary clinics should take into 
account clinic-specific practice patterns (i.e. what percentage of patients are one-time 
consults vs. continuing patients) when assessing if adequate documentation of final 
diagnosis will be available. 
 In some cases, treating physicians electively chose not to adhere to diagnostic 
criteria, either by not recommending further testing in probable patients, or by 
recommending additional testing beyond what published diagnostic criteria required in 
confirmed patients.  This reflects that pre-specified diagnostic criteria do not always 
coincide with expert clinical judgement surrounding the degree of acceptable diagnostic 
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uncertainty in individual patient cases.  For example, clinicians sometimes did not 
recommend biopsy/resection of asymptomatic lesions or low-yield diagnostic testing (e.g. 
IAC brain MRIs in an older patient with a negative standard brain MRI and normal 
hearing, who is thus extremely unlikely to be harboring a small vestibular schwannoma).  
In such cases where diagnostic testing is invasive or a definitive diagnosis will not alter 
treatment, patients may thus have intentionally delayed diagnoses that actually reduce the 
potential for harm (Zwaan and Singh, 2015).  As noted by the NAM committee, the point 
of the diagnostic process is not to reduce diagnostic uncertainty to zero; rather it is to be 
sufficiently certain of a patient’s diagnosis to effectively guide clinical management 
decision-making (NAM, 2015).  So, for patients who do not value additional diagnostic 
certainty, not recommending additional diagnostic testing simply to meet diagnostic 
criteria may actually be appropriate, rather than representing a failed diagnostic outcome. 
Additional Considerations for Measuring Diagnostic Communication 
Empirically, using the date of diagnostic communication instead of the date the 
diagnosis was established (i.e. the date patients formally met diagnostic criteria) as our 
primary endpoint moderately affected our estimates of the length of diagnostic intervals, 
both by changing the sample of people eligible for inclusion in the interval and changing 
the length of the interval.  For our primary interval of interest - total time to diagnosis - 
the estimate of median interval length differed by 1 year depending on whether the 
endpoint was diagnosis communication or diagnosis established (7.9 years in a sample of 
60 patients for total time to diagnosis communicated vs. 6.9 years in a sample of 64 
patients for total time to diagnosis established.)    
  
75 
However, in the subset of patients eligible for inclusion in both intervals (n=54 
patients who met published diagnostic criteria and had documented diagnostic 
communication), the difference in median interval length was only 6 months (7.6 years 
for diagnosis communicated vs. 8.1 years for diagnosis established).  While the 
importance of diagnostic communication is clear from our conceptual model, this 
relatively small, 6% difference in estimates begs the question of whether assessment of 
diagnostic communication is empirically worthwhile when using a data source such as 
medical records, which already imperfectly capture communication events.   Based on 
our experience, we suggest that researchers explore the quality of documentation around 
diagnostic communication in the medical records of interest in their particular study 
before deciding this point.  Documentation of communication by the NF clinic providers 
in our study was generally fairly detailed, but this did differ between physicians, 
particularly across different specialties.  As such, there may be differences in ability to 
measure diagnostic communication based the physician specialty most likely to make a 
particular diagnosis. 
Surprisingly, when looking at the subset of 54 patients eligible for both versions 
of our total time to diagnosis interval, using the date the diagnosis was established 
lengthened our estimate compared to using date of diagnosis communication.  This was 
because seven individuals were told they had schwannomatosis before they actually met 
published diagnostic criteria.  Other researchers considering using diagnosis 
communication as an endpoint should consider whether to account for these situations.  If 
on the one hand, researchers assume that published diagnostic criteria are a gold standard 
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for diagnosis, and any communication inconsistent with such criteria is incorrect, they 
may want to record only diagnostic communication dates that occur after a patient meets 
diagnostic criteria.  However, if researchers assume that published criteria are a 
guideline, subject to modification based on clinical judgement and patient preference, 
such inconsistencies in communication would represent acceptable variation in 
communication practices.  In our view, the latter assumptions are more relevant for 
schwannomatosis, particularly because clinical knowledge about both the phenotype and 
genotype of this disorder was rapidly evolving over the time period of interest, making it 
more likely that the judgement of NF physicians may actually have been more rigorous 
than potentially outdated, published diagnostic criteria.  Indeed, physicians provided a 
clear clinical rationale for requiring more or less diagnostic evidence than published 
criteria suggested in the majority of discrepant communication cases in our study. 
 Finally, the ability of researchers to assign a single, finite date to diagnosis 
communication is worth interrogating.  As recognized by our conceptual framework, 
communication is an ongoing process, in which healthcare providers continuously refine 
a working diagnosis and communicate the accompanying level of diagnostic certainty to 
the patient until optimally, a final, correct diagnosis is reached.  However, attempting to 
determine when communication shifted from probable schwannomatosis (that is, a 
partially uncertain working diagnosis) to confirmed schwannomatosis (when there was 
little to no diagnostic uncertainty) was not always clear from medical records.  
Additionally, diagnostic communication for a patient could change over the course of 
multiple visits with a single provider (as scientific knowledge about schwannomatosis 
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advanced) and across visits with different providers (who had differing views on the 
certainty of the patient’s diagnostic status).  While we dealt with this issue by recording 
the first presumed date of communication, further research should examine how patients 
perceive differences in working vs. confirmed diagnoses and how inconsistent 
communication across providers influences how patients understand their diagnosis. 
Study Limitations 
Our research findings should be evaluated with the following limitations in mind.  
Completeness of medical documentation varied from patient to patient, in particular 
regarding documentation from providers outside the MGH and JH hospital networks.  
This particularly limited our ascertainment of the precise date of and physician specialty 
seen at patients’ first engagement in the healthcare system, as well of the occurrence of 
misdiagnoses or incomplete diagnoses that happened early in the diagnostic process.  As 
a result, we may have missed associations between physician specialty and diagnostic 
interval length, we may overestimate the initial appraisal and help-seeking interval, and 
we may underestimate the rate of diagnostic errors in our cohort (since borderline cases 
without sufficient documentation to demonstrate error based on a “preponderance of 
evidence” standard were not included).  
 Our assessment of the date of diagnostic communication assumed that all 
communication events are documented in the medical record.  While in-person visits to 
communicate diagnosis were generally well documented, we may have missed phone 
calls or electronic communications that are less reliably recorded in the medical record.   
We also assumed that clinicians’ verbal communication to the patients matched what was 
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documented in medical record notes, which may not always be the case.   Essentially, we 
used the first time a confirmed schwannomatosis diagnosis was recorded in a note 
describing a patient encounter as a proxy measure for communication, and the degree to 
which this reflects both what the clinician said and what the patient understood is 
currently unknown.   
Patients with probable schwannomatosis did not yet meet formal diagnostic 
criteria for schwannomatosis, so our inclusion of these patients assumes that the clinical 
judgment of the expert treating physicians were correct.  While most probable patients 
had diagnostic evidence making alternate diagnoses unlikely (such as lack of 
signs/symptoms or imaging evidence consistent with the most likely alternate diagnoses 
of NF1 and NF2), it is possible that some of these patients do not actually have 
schwannomatosis.  However, we felt inclusion of these cases was important, as they 
represent an inability to more confidently rule in or rule out schwannomatosis, and if 
needed, identify the correct alternate diagnosis.   
 Finally, our results may not be generalizable to all schwannomatosis patients, 
since our sample includes only those people who eventually attend a dedicated NF clinic 
at large academic medical centers.  There is likely a large proportion of patients with 
schwannomatosis who are currently undiagnosed and/or not connected to specialty, 
tertiary care (as demonstrated by the large mismatch between the number of 
schwannomatosis patients estimated to be living in the U.S. (2,540) and the number 
actually seen by specialized NF clinics (182) in 2015 (Merker et al., 2018).  However, 
while the delays and diagnostic errors that patients at tertiary care clinics have 
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experienced may not be identical to those of patients who are still undiagnosed or 
diagnosed but not seen at specialty centers, these errors still represent important targets 
for future process improvement. 
Conclusions 
Despite these limitations, our study is the first comprehensive assessment of 
diagnostic quality in schwannomatosis.  By assessing the key dimensions of a good 
diagnosis identified by the NAM (2015) committee — timeliness and accuracy in 
establishing a diagnosis and communicating it to the patient — we have established 
benchmarks for future quality improvement efforts in the areas most likely to be 
impactful to patients.  Our work highlights several clinical targets for improvements in 
schwannomatosis, including increasing awareness of schwannomatosis; facilitating 
pathologists’ ability to differentiate neurofibromas, schwannomas, and hybrid nerve 
sheath tumors; and prompting ordering of dedicated IAC sequences in brain MRIs in 
appropriate clinical situations.  This research also serves as an example of the 
possibilities and limitations of assessing diagnostic error via medical records, including 
the difficulties in assessing diagnostic communication and the relative empirical benefit 
of doing so.  Future studies assessing the accuracy and timeliness of other rare, genetic 
diseases will hopefully result in identification of additional, cross-disorder factors 
contributing to diagnostic quality that can be applied more broadly. 
  
80 
CHAPTER 3: IDENTIFYING FAILURES IN THE SCHWANNOMATOSIS 
DIAGNOSTIC PROCESS 
Introduction 
 The diagnostic process is composed of a complex set of activities undertaken by 
patients and their teams of healthcare professionals, and breakdowns in this process are 
common (NAM, 2015).  Failures in the diagnostic process have been defined in different 
ways in the literature, but broadly, they represent problems in the diagnostic workup that 
often result in missed opportunities to make the correct diagnosis earlier (Newman-
Toker, 2014; Singh, 2014).  Diagnostic process failures may take a myriad of forms, 
including an action never occurring, an action being done incompletely or incorrectly, 
and an action being meaningfully delayed (NAM, 2015).  While some failures in the 
diagnostic process result in diagnostic errors, other failures can represent “near misses”, 
which are characterized by their potential, rather than actual, negative effects.  
Importantly, diagnostic process failures are not necessarily the fault of any specific 
healthcare providers.  Indeed, disease factors (such as atypical disease presentation), 
patient factors (such as individual health beliefs), physician factors (such as cognitive 
reasoning biases), and system factors (such as organizational barriers preventing effective 
care coordination) can all contribute to the occurrence of diagnostic process failures 
(Graber et al., 2005; NAM, 2015).  
Diagnostic delay and diagnostic errors are common in rare, genetic diseases 
(Shire Human Genetic Therapies, 2013; EURORDIS, 2009), likely to due to a confluence 
of many diagnostic process failures.  For example, in a large survey of Australian parents 
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of children with rare diseases, parents attributed diagnostic delay to clinician’s lack of 
knowledge about rare diseases, parent’s lack of awareness of rare disease symptoms, and 
difficulty accessing appropriate diagnostic testing (including genetic testing).  While 
specific diagnostic process failures might be inferred from some of these difficulties (for 
example, lack of symptom awareness likely leads to delays in presenting to care), most 
research in rare disease diagnosis has not used a predefined, conceptually grounded 
framework to define or assess diagnostic process failures.  Our research seeks to address 
this gap in the field by systematically examining diagnostic process failures in the rare, 
genetic disease of schwannomatosis using a coding schema based on the National 
Academy of Medicine (NAM) model of the diagnostic process 
Preliminary results from Merker et al. (2012) and more detailed research from 
Chapter 2 of this dissertation have shown that diagnostic error and delays are common in 
schwannomatosis.  Evaluation of the specific diagnostic process failures that lead to these 
errors and delays is a necessary precursor for effective targeting of quality improvement 
efforts designed to improve patient outcomes.  For this reason, we sought to identify the 
process failures that occur during the schwannomatosis diagnostic process and determine 
the degree to which these failures negatively affect diagnostic process outcomes.  
Specifically, we sought to 1) develop a unified taxonomy of diagnostic process failures 
based on the NAM model and use it to identify failures in the schwannomatosis 
diagnostic process; 2) assess how diagnostic process failures affected timeliness, 
accuracy, and communication of the schwannomatosis diagnosis; and 3) preliminarily 
identify contributing factors that may promote the occurrence of diagnostic failures. 
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Our research approach was guided by our conceptual framework, which is 
described in detail in Chapter 1 and is based largely on the NAM (2015) model of the 
diagnostic process (Figure 3.1).   
Figure 3.1 Conceptual Framework Domains Explored in Study 2 
 
In this framework, patients begin the diagnostic process when they experience a 
health problem and engage with the healthcare system to address that health problem.  
Healthcare professionals engage in a continuous cycle of information gathering, 
interpretation, and integration in order to generate and refine a working diagnosis.  
Information may be gathered through multiple means — clinical history, physical exam, 
diagnostic testing, and referrals to other providers.  Patients are equal partners in this 
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diagnostic team, and they must repeatedly choose to re-engage in the healthcare system 
each time they see new providers for the diagnostic process to continue.  Ultimately, 
when enough information has been collected, a diagnosis is communicated to the patient 
and used to guide clinical management decisions.  Optimally, this is a timely, accurate 
diagnosis that has been adequately communicated in a way the patient understands.  
However, when the diagnostic process fails (which sometimes, but not always, results in 
diagnostic errors), it can be used as a learning opportunity for future improvement. 
  Given that our data source is medical records, this study primarily addresses how 
steps taken by healthcare professionals to gather, interpret and integrate diagnostic 
information affect the timeliness, accuracy, and communication of schwannomatosis 
diagnoses (Figure 3.1, dashed boxes).  However, our taxonomy of diagnostic process 
failures spans the entire diagnostic process, and to the extent that patients’ experience of 
a health problem, patients’ engagement with the healthcare system, and the quality of 
diagnostic communication (Figure 3.1, dotted boxes) is documented in the medical 
record, these areas will also be examined.  Additionally, we will look at how factors at 
the disease, patient, provider, and healthcare system level contribute to diagnostic process 
failures (with examples of potential factors that may be discovered listed at the bottom of 
Figure 3.1). 
Methods 
Methods Overview 
Using clinician encounter notes and other data available in the Massachusetts 
General Hospital (MGH) and Johns Hopkins Hospital (JH) medical records, we created 
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narrative summaries detailing the diagnostic journeys of 52 patients with confirmed or 
probable schwannomatosis.  We also created a coding framework to classify diagnostic 
process failures, based on the NAM committee’s proposed classification and 
supplemented with categories from other published studies which have assessed 
diagnostic error based on medical records.  Using a directed content analysis approach, 
we applied the framework to the narrative summaries to identify and characterize 
diagnostic process failures in schwannomatosis.  We also holistically assessed the impact 
of these failures on the timeliness, accuracy, and communication of schwannomatosis 
diagnoses, and recorded factors that potentially contributed to the failures occurring. 
Patient Sample 
We created narrative summaries of the diagnostic process for a subsample of the 
97 patients with confirmed or probable schwannomatosis who were assessed in Chapter 2 
of this dissertation.  As a brief reminder, patients were eligible for inclusion if they 1) had 
a diagnosis of confirmed or probable schwannomatosis; 2) had at least one in-person visit 
at the MGH or JH neurofibromatosis (NF) clinics between January 1, 2005 and January 
31, 2016; and 3) did not have a diagnosis of confirmed schwannomatosis communicated 
to them by any provider prior to January 1, 2005.   
Due to the labor-intensive nature of the data collection process, we created 
narrative summaries on 52/97 patients (53.6% of the original sample).  We selected an 
equal number of patients (n=26) from both MGH and JH, so that any institution-specific 
differences in the diagnostic process would not unduly influence our results.  As such, we 
reviewed all 26 JH patients (which included 15 confirmed and 11 probable 
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schwannomatosis cases) and a subsample of 26/71 (36.6%) MGH patients from the prior 
chapter.  The subsample of MGH patients was selected so that the proportion of 
confirmed and probable schwannomatosis diagnoses in the subsample matched the full 
MGH sample (i.e. 68% confirmed and 32% probable cases), leading us to select 18 
confirmed and 8 probable cases from MGH for this study.  Within these diagnostic 
categories, MGH patients were selected pseudo-randomly, without respect to year of 
diagnosis, length of diagnostic interval, or presence of diagnostic errors. 
Data Collection 
Rationale for Creating Narrative Summaries 
We constructed narrative summaries detailing patients’ schwannomatosis 
diagnostic journey based on medical record data.  By creating these narratives, we 
condensed the medical record into a single document that captures the essential elements 
of the diagnostic process in chronological order, facilitating an understanding of events as 
they were experienced by the patients.  Individual medical record notes often highlight 
information from various prior timepoints, and each new note (particularly from 
clinicians of a different specialty) may focus on different sets of information from 
overlapping timelines.  Because our narrative summaries rearrange events in 
chronological order, they allow for a more coherent representation of the patient’s 
diagnostic journey and facilitate observation of any delays in care.  
Creating narratives also highlights the gaps between events captured in medical 
record, allowing for inference of diagnostic process failures that are acts of omission 
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rather than commission.  For example, narratives can highlight when ordered diagnostic 
tests are not actually performed or recommended follow-up occurs later than originally 
planned.  Similarly, creation of narrative summaries requires the explicit comparing and 
contrasting of notes from different clinicians, which helps highlight areas of clinical 
disagreement (e.g. when one clinician recommends surgery and another recommends 
observation for the same tumor) and instances in which medical record data conflicts 
(e.g. when two clinicians report different dates or rationales for the same surgical 
procedure).   
Overall, we deemed creation of narrative summaries to be a richer and more 
feasible data source with which to analyze failures in the diagnostic process, particularly 
since the volume of most subjects’ medical records made direct, line-by-line qualitative 
coding of each note impractical.  While we are unaware of other researchers who have 
created a dataset in this way, qualitative analysis of narrative accounts of patients’ care 
(such as patient safety incident reports) has been successfully used before to identify 
process failures leading to medical errors (Carson-Stevens et al., 2016; Aaronson et al., 
2017). 
 Methods for Creating Narrative Summaries 
We constructed narrative summaries detailing patients’ schwannomatosis 
diagnostic journey based on structured extraction of medical data from the MGH and JH 
outpatient medical records.  Summaries were based primarily on clinician encounter 
notes, with additional information extracted from operative reports, imaging reports, 
pathology reports, patient communications (e.g. emails, intake questionnaires, etc.) and 
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any other documentation available in the electronic medical records (and in the case of 
MGH, outpatient NF clinic paper records as well).  Summaries spanned from patients’ 
first sign or symptom of schwannomatosis until their diagnosis with confirmed 
schwannomatosis (or for probable schwannomatosis patients, the last follow-up visit at 
the MGH or JH NF specialty clinics.) 
Data extraction was structured through use of a ‘narrative summary guide’ 
(available in full in Appendix B1).  This guide, similar in concept to a semi-structured 
interview guide or case study protocol, specified the general areas of focus and key 
details required in each narrative summary.  Key details included patient symptomology, 
reason for presentation to care, date and location of care, clinician providing care, 
diagnostic examinations performed, referrals made, and physician’s diagnostic 
assessment for each medical visit related to schwannomatosis.  When relevant, the 
narrative summaries include direct quotations from the source data, particularly regarding 
clinicians’ diagnostic assessment and plans. 
Recognizing the possible biases in creating narrative summaries, we took a 
number of steps to ensure that our narrative summaries were credible, dependable, and 
confirmable (Lincoln and Guba, 1985).  Narrative summaries were created by two 
researchers - the doctoral candidate and a physician assistant - each with at least five 
years of clinical and/or research experience with schwannomatosis.  The researchers’ 
prior experience with the disease facilitated their assessments of medical information 
(such as determining which medical record notes referenced schwannomatosis-related 
signs and symptoms).  Unclear clinical symptoms (such as pain not proven to be caused 
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by a schwannoma) were reviewed with an expert NF clinician, as noted in the prior 
chapter.  Additionally, another expert NF clinician reviewed the first 10 narrative 
summaries (19.2% of all narratives created) and compared them to original source data 
(the electronic and paper medical records).  Only minor adjustments in clinical 
descriptions were suggested, reflecting an extremely high level of perceived accuracy and 
completeness of the summaries.   
Both researchers creating the narrative summaries had prolonged engagement 
with the source data and the health systems in which the data were generated, enhancing 
credibility.  Both researchers were trained to use the ‘narrative summary guide’ to 
enhance consistency in data collection across subjects, increasing the dependability of the 
research process.  As specified in our narrative summary guide, the researchers also 
created an audit trail detailing the source data for each part of the narrative summary and 
any instances of missing or conflicting data.  Review of this audit trail, as well as the 
audit of the first 10 narrative summaries described above, served to enhance the 
confirmability of the research process (Creswell and Miller, 2000).  
Finally, to fulfill qualitative reporting guidelines, reviewers also recorded the 
number of documents from the medical record that contained information pertinent to the 
schwannomatosis diagnostic journey, and thus contributed data to the narrative summary 
(O’Brien et al., 2014).  Counts were performed for clinician encounter notes, imaging 
reports, operative notes/procedure reports, pathology reports, and any other 
documentation (for example, documentation of phone or email contacts, patient 
questionnaires, referral requests, discharge summaries from inpatient stays.)  We also 
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recorded the number of documents that were generated internally at MGH or JH versus 
those that were generated externally and scanned into their electronic medical records. 
Directed Content Analysis 
We performed a directed content analysis of narrative summaries to identify and 
describe failures in the diagnostic process.  We use the term ‘diagnostic process failure’ 
broadly to signify any problem in the diagnostic workup (Newman-Toker, 2014) or 
missed opportunity to make the correct diagnosis earlier (Singh, 2014).  We chose a 
directed rather than conventional content analysis in order to capitalize on the NAM’s 
existing classification of diagnostic process failures, which is closely aligned to our 
conceptual framework (Hsieh & Shannon, 2005; NAM, 2015).  For each diagnostic 
process failure identified in our analysis, we also assessed the impact of the failure on the 
patient’s diagnosis (if any) and identified factors at the disease, patient, provider or 
system level that may have contributed to the failure occurring.  Our methodological 
approach is thus an implicit assessment of both whether the process of care was adequate 
and whether better care could have improved patient outcomes (Brook, McGlynn and 
Cleary, 1996).    
Our coding framework was based primarily on the typology of diagnostic process 
failures proposed by the NAM committee, which includes six major categories: 1) failure 
to engage in the healthcare system or in the diagnostic process; 2) failure in information 
gathering; 3) failure in information interpretation; 4) failure in information integration; 5) 
failure to establish an explanation (diagnosis); and 6) failure to communicate the 
explanation to the patient (NAM, 2015).  Sub-categories of failures were created using 
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examples provided in the NAM report (See Table 3-2 in NAM, 2015 for additional 
details) and previously published literature (Schiff et al., 2005; Singh et al., 2013; 
CRICO, 2014).   
The doctoral candidate then piloted the coding framework on three summaries 
using a 2-step coding method, as suggested by Hsieh and Shannon (2005) and similar to 
that employed by Schiff et al. (2009) in their categorization of diagnostic errors.  The first 
step consisted of reading through each narrative summary and highlighting each potential 
diagnostic process failure.  The second step consisted of coding each highlighted process 
failure according to our established framework, and adding new codes if no a priori 
codes adequately captured the observed failure.  Using this 2-step method, we enhanced 
the trustworthiness that we have identified all process failures (regardless of whether they 
fit our initial coding schema), while still benefitting from the targeted classification 
scheme guided by our conceptual framework.  Pilot results were discussed between two 
researchers (the doctoral candidate and an expert NF clinician), and coding categories 
were adjusted through consensus discussion.   
After our codebook was finalized, these two researchers separately coded the 
same five summaries to ensure the coding framework could be effectively and reliably 
implemented.  After coding, the researchers met and any discrepant codes were resolved 
via consensus discussion.  At this time, the researchers also discussed the impact of each 
failure, noting the impact of the failure on the timeliness, accuracy, and/or 
communication of the diagnosis of schwannomatosis, or recording it as a ‘near miss’ with 
no discernable impact on diagnostic outcomes.  The researchers also discussed potential 
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contributing factors to the occurrence of each process failure, classifying each factor as a 
disease, patient, provider, oy systems level issue.   
Coding agreement was judged to be sufficiently high after this stage for the 
remainder of the summaries to be coded by a single rater (the doctoral candidate).  
Occurrence of diagnostic process failures were coded using the 2-step coding method 
described above, and each failure was annotated with its associated impact on diagnosis 
(if any) and potential contributing factors.  Any potential diagnostic process failures 
requiring clinical expertise were reviewed with an expert NF clinician for adjudication. 
Quantitative Analyses 
We report both the number of unique diagnostic process failures and total number 
of diagnostic process failures coded in each patient’s narrative summary.  The number of 
unique process failures incorporates the actual context of the process failure, rather than 
just the type of failure per se.  For example, if two providers at the same institution failed 
to obtain the pathology report of a patient’s first schwannoma, this was considered to be 
one unique process failure that was repeated twice.  If a different provider later failed to 
obtain the MRI report showing a patient’s second schwannoma, this was considered a 
second unique process failure, despite that fact that it is coded the same way in our 
content analysis (as “a failure to obtain or review previous medical documentation”). 
 We compared the frequency of failures between MGH and JH patients and 
between patients with confirmed or probable schwannomatosis using the Mann-Whitney 
U test.  We report the relative proportions of each category of process failure and the 
number of unique process failures with an identified impact on schwannomatosis 
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diagnosis.  Finally, we describe all factors identified as potentially contributing to the 
occurrence of diagnostic process failures. 
Statistical analyses were performed using MedCalc version 18.6 (MedCalc 
Software, Ostend, Belgium); all reported p-values are two-tailed.  All data collection and 
analysis was conducted in accordance with Institutional Review Board approvals 
(Partners Human Research Committee Protocol 2014P000633, Johns Hopkins Medicine 
Protocol 00136913, and Boston University Medical Center Protocol H-32975). 
Results 
Narrative Summaries 
 Narrative summaries were created for 52 patients (26 each from MGH and JH; 
consisting of 33 confirmed and 19 probable cases.)  Across all patients, 1,404 documents 
were identified in the medical record as pertaining to the diagnosis and treatment of 
schwannomatosis-related signs and symptoms and used to create the narrative summaries 
of patients’ schwannomatosis diagnostic journeys.  The largest proportion of these notes 
were clinician encounter notes (n=596, 42.4%), followed by imaging reports (n=402, 
28.6%), other encounter notes (n=224, 16.0%), operative and procedure notes (n=96, 
6.8%), and pathology reports (n=86, 6.1%).  Other encounter notes included documents 
of phone or email conversations with patients, scanned patient questionnaires, discharge 
summaries from inpatient hospitalizations, referral requests, and ER or urgent care triage 
notes.  Two-thirds of documents (n=930) were generated internally at MGH or JH; one-
third of documents (n=474) were generated by outside providers and scanned into the 
MGH or JH electronic medical records or included in MGH paper records. 
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 Overall, narrative summaries were based on a median of 19 medical record 
documents.  However, this differed by hospital, with a median of 28 documents for MGH 
patients and 17.5 documents for JH patients.  Since patients at both hospitals had a 
similar number of internally generated documents (MGH median = 10.5; JH median = 
12), this appeared to reflect a difference in the number of documents from outside 
providers available at each hospital (MGH median = 12.5; JH median = 2), which may be 
related to the availability of paper records at MGH only.  This resulted in longer 
summaries for MGH patients (median word count 2,492) than for JH patients (median 
word count 1,681).   Overall, summaries were a median of 2,049 words (range, 770 to 
6,434 words) and word count was significantly correlated with the number of medical 
record documents used to generate the summary (Spearman’s rho = 0.846, p<0.001). 
Diagnostic Process Failure Coding Framework 
Our final list of diagnostic process failures is presented in Table 1, with the full 
codebook used in the directed content analysis (including coding definitions and 
examples) available in Appendix B2.   
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Table 3.1 Coding Framework of Failures in the Diagnostic Process 
Failures to Engage in the Healthcare System or in the Diagnostic Process 
Failure/delay in patient presenting 
Failure/delay in patient accessing care 
Failures in Information Gathering 
Failure/delay to elicit key history finding 
Failure/delay to elicit key physical exam finding 
Failures in Diagnostic Testing 
     Failure/delay to order needed tests 
     Failure/delay in performing ordered tests 
     Technical errors in the handling, labeling, or processing of tests 
     Failure/delay in transmission, receipt, review or documentation of test results 
Failures in Referrals/Consultations 
     Appropriate consult/referral to specialists is not made or delayed 
     Consult/referral to specialist is not adequately managed 
Failure/delay in monitoring response to treatment 
Failures in Information Interpretation 
Inaccurate or failed interpretation of medical data by treating provider 
Inaccurate or failed interpretation of medical data by interpreting provider 
Failures in Information Integration and Establishing an Explanation 
Failures in Information Integration 
    Failure/Delay in considering correct diagnosis 
    Suboptimal weighting and prioritization 
    Failure to recognize or weight urgency 
Failure/delay to follow up 
Scientific knowledge limitations 
Failures to Communicate the Explanation to the Patient 
Failure/delay in patient notification 
Incomplete explanation 
Patient does not understand explanation 
 
After initial piloting of the coding framework in three narrative summaries, we 
collapsed the NAM (2015) domains of “failure in information integration” and “failure to 
establish an explanation (diagnosis)” into a single category, as we were unable to 
confidently distinguish between these failure types using medical record data alone.  We 
added ‘failure to transmit, obtain or review previous medical documentation’ to the 
definition of ‘failure/delay to elicit key history finding’, in order to more clearly 
  
95 
encompass situations where a provider does not have inaccurate or incomplete 
information about a patient’s prior medical history due to lack of primary source 
documentation.  Finally, we split “inaccurate or failed interpretation of medical data” into 
two categories based on who misinterpreted the data, treating providers (clinicians who 
have direct contact with the patient) or the original interpreting providers (radiologists, 
pathologists, and laboratory professionals). 
Through consensus discussion after coding of the first 5 narratives, we made the 
following minor adjustments to coding definitions.  Eye exams, audiology tests, and other 
testing performed by non-physicians were considered “diagnostic testing” rather than 
“referral/consults”.  We decided that failures to communicate the explanation to the 
patient included both working diagnoses and the final diagnosis of schwannomatosis.  
Finally, we clarified that if a patient did not attend an appointment, it would be classified 
as a ‘failure to engage in the healthcare system’ if the appointment was with a new 
provider or clinic, and a ‘failure to follow up’ if the appointment was with an existing 
provider or clinic. 
Diagnostic Process Failures 
 A total of 177 diagnostic process failures were identified in our directed content 
analysis.  Forty-nine of 52 patients (94.2%) had at least one diagnostic process failure 
identified.  The median number of unique process failures identified per person was 3 
(range, 0-8); counting repeated instances of the same process failures across multiple 
visits with the same provider or multiple providers at the same institution, there were 244 
total process failures, with a median of 4 per person (range, 0-16).  The number of unique 
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process failures identified per person was significantly correlated with the number of 
schwannomatosis-related documents in the medical record (Spearman’s rho = 0.415, 
p=0.002) and the length of the narrative summary (Spearman’s rho = 0.418, p=0.002). 
 The number of unique process failures identified in MGH patients (n=26, total 
failures identified = 104, median failures per person = 4) was significantly higher than in 
JH patients (n=26, total failures identified = 73, median failures per person = 3) as 
determined by a Mann-Whitney U test (U=207.5, p=0.017).  However, given that MGH 
patients also had more source documents in the medical record and longer narrative 
summaries, it is unclear if this represents true differences in care processes or simply a 
difference in our ability to detect process failures across institutions.  There was no 
difference in the number of unique process failures observed in patients with confirmed 
schwannomatosis compared to patients with probable schwannomatosis (median failures 
per person = 3 for both groups, Mann Whitney U=327.5, p=0.79). 
The narrative summaries were sufficiently detailed to allow 170/177 (96.0%) of 
diagnostic process failures to be assigned to a single process failure domain (Table 3.2).   
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Table 3.2 Frequency of Failures in the Schwannomatosis Diagnostic Process 
Diagnostic Process Failures n=177 
Failures to Engage in the Healthcare System  21 
Failure/delay in patient presenting 11 
Failure/delay in patient accessing care 1 
*Failure/delay in patient presenting to OR accessing care 9 
Failures in Information Gathering 78 
Failure/delay to elicit key history finding 29 
Failure/delay to elicit key physical exam finding 0 
Failures in Diagnostic Testing 39 
      Failure/delay to order needed tests 17 
      Failure/delay in performing ordered tests 14 
      *Failure/delay to order OR perform needed tests 4 
      Technical errors processing tests 3 
      Failure/delay to review test results 1 
Failures in Referrals/Consultations 9 
      Appropriate referral not made/delayed 9 
      Referral not adequately managed 0 
Failure/delay in monitoring response to treatment 0 
Unassigned failure in information gathering 1 
Failures in Information Interpretation 16 
Inaccurate interpretation by treating provider 7 
Inaccurate interpretation by interpreting provider 9 
Failures in Information Integration/Establishing an Explanation 46 
Failures in information integration 20 
      Failure/delay in considering correct diagnosis 6 
      Suboptimal weighting and prioritization   8 
      *Failure to consider correct diagnosis OR suboptimal weighting 6 
      Failure to recognize or weight urgency 0 
Failure/delay to follow up 24 
Scientific knowledge limitations 2 
Failures to Communicate the Explanation to the Patient 9 
Failure/delay in patient notification 5 
Incomplete explanation 3 
Patient does not understand explanation 0 
*Incomplete explanation or patient doesn’t understand explanation 1 
Miscellaneous Failures 7 
 
Table Legend: “Miscellaneous Failures” could not to be assigned to a single major category; 
“unassigned failures” could not be assigned to a single minor category.  * denotes combined 
categories, where a failure could be assigned to one of two categories, but insufficient 
information was available to further distinguish the exact process failure. 
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In decreasing order of relative frequency, we observed the most process failures 
in information gathering (78), information integration/establishing a diagnosis (46), 
engaging in the healthcare system (21), information interpretation (16), and 
communicating the explanation to the patient (9).  Within the domain of information 
gathering, 77/78 (98.7%) of failures could be assigned to a specific subdomain; failures 
related to diagnostic testing were the most common (39), followed by failures related to 
the clinical history/interview (29) and failures in referral/consultation (9).  Within the 
area of diagnostic testing, failures were largely due to not ordering or performing tests 
(35/39, 89.7%).  Within the area of clinical history/interview, 28/29 (96.6%) were related 
to failures to obtain or review previous medical documentation, such as MRI images, 
pathology reports, or other diagnostic testing results.  Within the domain of information 
integration/establishing a diagnosis, failures in follow-up (24) and failures in considering 
the correct diagnosis and/or suboptimal weighting and prioritization of diagnoses (20) 
were the most common.  
Impact of Diagnostic Process Failures 
 Out of the 177 unique process failures, 119 (67.2%) had an impact on the 
timeliness, accuracy, and/or communication of a diagnosis of schwannomatosis.  Forty-
eight patients (92.3% of the total sample and 98.0% of those with an identified process 
failure) had at least one process failure with an impact on schwannomatosis diagnosis.  
Patients had a median of 2 failures with impact (range, 0-6).   
 Twenty-one diagnostic process failures across 16 patients had an impact on 
diagnosis accuracy, resulting in misdiagnosis of pain etiology, tumor pathology, or 
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patients’ underlying genetic diagnosis in 14 patients and inappropriate working diagnoses 
in 2 patients.  Failures with impacts on diagnostic accuracy were split evenly between 
information gathering, information interpretation, and information 
integration/establishing a diagnosis (7 each).   
Of note, three patients with misdiagnoses identified in the prior dissertation 
chapter did not have any preceding process failures identified which caused the 
misdiagnosis.  Two patients had pathology reported as neurofibroma, leading physicians 
to conclude that they had NF1.  It is likely, but not certain, that pathology re-review 
would reveal both lesions to be schwannomas or hybrid nerve sheath tumor.  But since 
such re-review was never undertaken during the patient’s clinical care, we did not code 
this as a “failed interpretation of medical data by interpreting provider.”  One patient had 
pain misdiagnosed as degenerative disc disease; however, the patient’s physicians acted 
in accordance with care guidelines in her assessment, initially performing a non-contrast 
MRI for the patient’s lower back pain (which did not reveal the schwannoma ultimately 
found to be causing her pain).  For this reason, we did not code any process failures 
during this portion of the patient’s diagnostic workup.  
Eighty diagnostic process failures across 42 patients had a negative impact on the 
timeliness of patients’ diagnostic workups.  Definitions of delay were context-dependent 
based on the processes/events that were delayed, but across 71 failures with defined time 
impacts, the median delay in diagnostic workup was 11 months (25th to 75th percentile, 3-
35 months).  Nine process failures in six patients with probable schwannomatosis did not 
have a defined time impact, because they led to an indefinite delay in establishing a 
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confirmed diagnosis of schwannomatosis (i.e. they were the reason the patient never 
transitioned from probable to confirmed schwannomatosis).  Failures with impacts on 
diagnostic timeliness were most commonly failures in information gathering (37), 
followed by failures in information integration (18) and failures to engage in the 
healthcare system (14).   
Thirty diagnostic process failures across 24 patients had a negative impact on the 
patients’ diagnostic communication.  There was a significant delay in communication of 
a diagnosis in 19 cases, a failure to communicate a confirmed diagnosis of 
schwannomatosis in 8 cases, and inadequate communication in 4 cases.  Failures with an 
impact on communication were most commonly failures in information integration (12) 
or failures to communicate the explanation to the patient (9).  Of note, all 9 instances of 
“failures to communicate the explanation to the patient” observed in the dataset had an 
impact on diagnostic communication, because the impact was the only way they could be 
observed via medical record data. 
Fifty-eight diagnostic process failures across 32 patients had no identified impact; 
this could happen for several reasons.   One reason is that one process failures could be 
secondary to another process failure, and thus, have no impact of its own.  For example, a 
patient delayed following-up with a physician (process failure 1); when the patient 
eventually followed-up, the physician did not consider a diagnosis of schwannomatosis 
(process failure 2) leading to a delay in diagnosis until the patient was referred to another 
physician (impact on timeliness).  In this scenario, process failure 1 was assigned no 
impact and process failure 2 was assigned an impact on diagnostic timeliness.   
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Another reason process failures may not have an impact was when they were 
quickly corrected or compensated for by other diagnostic activities, such that there was 
no significant delay in the patient’s diagnostic workup.  For example, some failures to 
elicit key history findings (e.g. failure to obtain pathology reports from an outside 
institution to verify if a patient had a prior schwannoma or not) had no impact because 
sufficient alternate diagnostic information was available or was quickly obtained (ex: the 
patient had another schwannoma resected at the same institution as the diagnosing 
provider, confirming their diagnosis without need for prior documentation).  Finally, we 
identified several process failures that prevented patients with probable schwannomatosis 
from meeting published diagnostic criteria, but because treating physicians 
communicated the diagnosis of confirmed schwannomatosis anyway, the failure did not 
have a measurable impact on patients’ diagnostic experience.  
Contributing Factors to Diagnostic Process Failures 
 Sixty-six of 177 (37.3%) process failures had at least one factor that contributed 
to the occurrence of the process failure (Table 3.3).   At the disease level, atypical disease 
presentations affected the ability of providers to accurately diagnosis masses as 
schwannomas, and to accurately diagnose patients with schwannomatosis.  Schwannomas 
with atypical appearance on radiology images or atypical pathology features contributed 
to failures in information interpretation (which were discovered based on re-review of 
images or pathology slides by another provider during the course of patients’ clinical 
care).  Inaccurate interpretations could in turn lead to delayed referrals (for example, 
when a radiology image was interpreted as a ganglion cyst instead of a nerve sheath 
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tumor, delaying the patient’s referral to a neurosurgeon) and misdiagnoses (for example, 
when misinterpretation of a schwannoma as a neurofibroma lead to a patient being 
diagnosed with NF1).  Another common disease-level contributing factor was low 
symptom severity (e.g. asymptomatic palpable lesions or mild neurological symptoms) 
and low symptom frequency (e.g. intermittent pain), which contributed to failures or 
delays in patients presenting to care. 
Table 3.3 Factors Contributing to the Occurrence of Diagnostic Process Failures 
Disease-Level Factors  
Atypical disease presentation 
Symptom Severity 
Symptom Frequency 
Patient-Level Factors 
Comorbidities 
Competing priorities 
Ability to tolerate diagnostic testing  
Perceptions of clinical benefit 
Provider-Level Factors 
Clinical Knowledge 
Reliance on Judgement of Other Providers 
Personal Standards for Clinical Evidence 
System-Level Factors 
Problems transferring information between institutions 
Inadequate communication within an institution 
Accessibility of Healthcare Services (including Cost) 
 
At the patient level, patients’ comorbidities (particularly of other pain-causing 
conditions) could make it difficult for both patients and providers to correctly ascertain 
the source of symptoms, leading to delays in presenting to care and inaccurate 
interpretations of medical data, respectively.  Patients also had competing priorities, such 
school/work obligations or caring for children or ill family members, which led to 
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delays/failures in presenting to care and following-up.  Patients’ inability to tolerate 
certain diagnostic testing modalities (for example, claustrophobia or contrast allergies 
making MRI acquisition difficult) contributed to delays in performing ordered diagnostic 
testing.  Finally, patient beliefs regarding the clinical benefit of further diagnostic workup 
could lead to failures in performing ordering testing and following up.  For example, in a 
phone conversation with a nurse that was documented in the medical record, one patient 
stated that she didn’t think the NF clinic had much to offer, so there was no point in 
coming back for follow-up or further workup.   
 At the provider level, lack of clinical knowledge regarding NF1, NF2, and 
schwannomatosis and their associated features likely contributed to inaccurate 
interpretations of medical data, suboptimal weighting and prioritization of differential 
diagnoses, and failures to consider the correct diagnosis.  Reliance on other providers’ 
(sometimes inaccurate) interpretations of data, rather than personally re-examining 
medical information, could lead to delays in ordering diagnostic testing or making 
appropriate referrals.  NF clinic providers could also have different standards of evidence 
for making a schwannomatosis diagnosis than published, consensus diagnostic criteria.  
In cases where providers had lower standards of evidence, this could lead to failure to 
order diagnostic testing (ex: failure to order an IAC brain MRI to confirm diagnosis 
because a non-IAC brain MRI was accepted as sufficient evidence).  In cases where 
providers had higher standards of evidence, this could lead to suboptimal weighting and 
prioritization (in which a patient met diagnostic criteria for schwannomatosis, but 
potential alternate diagnoses were given too much weight). 
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 At the healthcare system level, diagnostic information (specifically, diagnostic 
images and associated reports, pathology slides and associated reports, and genetic 
testing results) was commonly not transferred between institutions in a timely fashion, 
resulting in delays or complete failures of providers to elicit key history findings.  This 
could lead to misdiagnoses (when clinicians relied on inaccurate secondhand information 
in lieu of the missing primary source documentation) and diagnostic delay (when 
clinicians could not review primary source documentation to confirm that patients met 
diagnostic criteria).  We also observed a single instance of inadequate communication 
between physicians and administrative staff within the same institution (whereby the 
physical form documenting a referral was lost, leading to a significant delay in 
scheduling and obtaining an appointment with the specialist).   
 Additionally, the geographical, temporal, and financial accessibility of specialized 
care and diagnostic testing contributed to process failures.  The distance and/or time 
required to travel to a specialized NF clinic could contribute to failures to follow-up, and 
long wait times at the same clinic could lead to delays in patient accessing care.  The cost 
of health care could also lead to process failures; we observed one patient delay 
presenting to care due to lack of health insurance and another patient with a failure to 
perform ordered diagnostic testing due to insurance coverage issues. 
Discussion 
In this study, we performed a directed content analysis on narrative summaries 
detailing the diagnostic journey of 52 patients with schwannomatosis, in order to identify 
diagnostic process failures and determine the degree to which these failures negatively 
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affect diagnostic outcomes.  We found that failures in the diagnostic process for 
schwannomatosis were common, with 94% of patients showing evidence of at least one 
process failure.  Failures in information-gathering and information integration were 
observed most frequently, with the most common failures related to diagnostic testing, 
the clinical history/interview, and follow-up.  Two-thirds of process failures had negative 
impacts on the diagnostic process, most often by delaying the receipt of appropriate 
diagnostic workup and/or communication of a final diagnosis of schwannomatosis.  
Almost all patients with a misdiagnosis of schwannomatosis-related signs and symptoms 
had a preceding diagnostic process failure which caused the misdiagnosis; problems in 
information gathering, interpretation, and integration were equally likely to cause 
misdiagnoses.  Finally, we identified a range of disease, patient, provider and system 
factors that contributed to the occurrence of diagnostic process failures. 
Failures in the Schwannomatosis Diagnostic Process 
The number of diagnostic process failures identified in each patient case was 
correlated with the number of medical records available for review for each patient.  This 
may reflect that patients who have more encounters with the medical system (and thus 
generate more medical documentation) have more opportunities for the diagnostic 
process to fail, with the number of failures being mainly a function of exposure to the 
healthcare system.  However, it could be that patients with the most complicated clinical 
presentations experience more diagnostic process failures and need more diagnostic visits 
and testing (which generates more medical documentation) due to the complexity of their 
case.   
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Likely, both factors are at play, and the frequency of diagnostic process failures 
reflects both an underlying, natural error rate in the inherently uncertain diagnostic 
process as well as additional failures related to individual diagnostic difficulty.   
Concordant with published literature, we identified several contributing factors that may 
indicate diagnostically complex cases, such as atypical disease presentations on imaging 
and pathology, and the presence of other pain-causing comorbidities (Kostopoulou, 
Delaney and Munro, 2008).  Future research could assess all cases for presence/absence 
of these contributing factors, and then determine to what degree diagnostic ‘level of 
difficulty’ is responsible for different kinds of diagnostic process failures.  This would be 
valuable in guiding process improvement strategies, since failures due to case complexity 
are likely less amenable to improvement efforts that those related to systematic failures in 
physician reasoning and behavior or organizational structures and processes. 
At the physician level, lack of clinical knowledge about schwannomatosis and 
similar tumor suppressor syndromes (as evidenced by quotes in the narrative summaries, 
often taken from the assessment/plan sections of clinician encounter notes) led to 
impaired information gathering, interpretation, and integration.  Given these wide-
ranging effects, targeted education may be needed for the specialists most likely to 
encounter patients with schwannomatosis (which, as indicated by the prior dissertation 
chapter, appear to be neurosurgeons, orthopedic surgeons, and neurologists).  Real-time, 
integrated decision support and easy access to relevant reference information may 
improve physician’s information interpretation and integration skills (Bates and 
Gawande, 2003; Graber et al., 2012), particularly with rare diseases (Alves et al., 2016), 
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although more real-world testing of this type of interventions would be necessary before 
widespread implementation (Lambe et al., 2016).   
At the organizational level, failures in information transfer between institutions 
was common.  As described by Singh et al. (2008), impaired informational 
communication affected both initial information gathering efforts used to generate 
working diagnoses and later information gathering efforts used to verify working 
diagnoses.  The former could lead to missed opportunities to consider a diagnosis of 
schwannomatosis, while the latter could lead to patients with probable schwannomatosis 
failing to receive confirmed diagnoses.   
Unfortunately, the narrative summaries (and underlying medical record notes) 
usually could not distinguish the ultimate cause of process failures related to impaired 
informational communication.  In some cases, the institution where the information was 
generated may have had inefficiencies in processing patient requests for information, 
retrieving medical information and/or sending the information (message transmission 
errors).  In other cases, the receiving institution may have had problems in processing and 
routing the information to the requesting physician (message reception errors).  In either 
case, inter-operable health IT systems and health information exchanges that allow for 
more streamlined sharing of records across institutions may help mitigate these process 
failures in the future (Kaelber and Bates, 2007; Hersh et al., 2015).  Additionally, 
granting patients easier access to their own medical record data could allow patients to 
assist with transfer of information across institutions, with potential added benefits of 
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better engaging patients on the diagnostic team and enhancing patient-physician 
communication (Ross and Lin, 2003; Esch et al., 2016; Goldzweig, 2017). 
Additional Considerations Regarding Our Conceptual Framework 
In this research, we used a classification of diagnostic process failures suggested 
by the NAM committee (2015), with added subcategories based on existing literature that 
assessed the prevalence of diagnostic errors using medical records (Schiff et al., 2005; 
Singh et al., 2013; CRICO, 2014).  Our biggest hurdle in applying the NAM 
classification to an empirical investigation of diagnostic process failures was our inability 
to distinguish between some subtypes of failures related to ‘information integration’ and 
‘establishing an explanation (diagnosis)’, which led us to collapse these categories.  For 
instance, failures in hypothesis generation (an information integration failure) and delay 
in considering the correct diagnosis (a failure to establish an explanation) both manifested 
identically in the medical record.  Similarly, suboptimal weighting and prioritization of 
information gathered in the diagnostic process (an information integration failure) could 
not be distinguished from suboptimal weighting and prioritization of clinical 
signs/symptoms (a failure to establish an explanation).  Efforts to redesign electronic 
medical records to facilitate recording of differential diagnoses and detailed clinical 
assessments (Schiff and Bates, 2010) may enable more detailed, medical-records based 
research on these areas.  Until then, investigators using medical records should consider 
collapsing these conceptual categories to enhance coding consistency.  If further 
examination of these domains is desired, using alternate methods (such as clinical 
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debriefing and diagnostic conferences) better suited to observing clinicians’ cognitive 
processes is recommended (NAM, 2015). 
In addition, the amount and quality of documentation available in the medical 
record was sometimes insufficient to distinguish between subcategories of diagnostic 
process failures.  For example, the reasons for patients’ delayed engagement in the 
healthcare system could only be subdivided into ‘failure of patient presenting’ and 
‘failure of patient accessing care’ if the reasons for the delay were mentioned by a 
clinician.  Lack of primary documentation from providers could lead to an inability to 
distinguish ‘failures to order needed test’ from ‘failures in performing ordered tests’ 
(because we could not verify whether the test was ordered).  Similarly, missing clinician 
encounter notes or notes that lacked sufficient detail about diagnostic reasoning could 
lead to failures to distinguish between ‘failures to consider correct diagnosis’ and 
‘suboptimal weighting/prioritization’ (because we could not verify if schwannomatosis 
was not considered, or if it was considered and inappropriately weighted). 
Overall, however, our conceptual framework provided a useful scaffold with 
which to identify diagnostic process failures and understand the factors that contribute to 
their occurrence.  These contributing factors tended to affect discrete domains of the 
diagnostic process, further demonstrating the model’s utility in understanding this 
complex system.  For example, patients’ willingness and ability to engage in the 
healthcare system was adversely affected by low symptom severity or intermittent 
symptoms; the presence of competing priorities for patients’ time, such as work or 
caregiving responsibilities; patients’ inability to tolerate diagnostic testing; patients’ 
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perceptions that care would have limited benefit; high healthcare costs; and limited 
geographic or temporal accessibility of healthcare services.  Problems with 
communication and information transfer within and between institutions negatively 
affected clinician’s planned information gathering efforts.  Atypical disease presentation 
and patients’ comorbidities challenged clinicians’ information interpretation skills.  
Finally, even providers knowledgeable about schwannomatosis could have differing 
standards regarding the amount of diagnostic information needed to establish a diagnosis, 
reflecting disagreements within the NAM conceptual framework area of “Has sufficient 
information had been collected?” 
Study Limitations 
 Our assessment of diagnostic process failures is limited to diagnostic actions and 
processes that were captured in our narrative summaries, which were based solely on the 
medical record documentation at MGH and JH.  For this reason, the summaries are 
incomplete representation of patients’ actual diagnostic journeys.  Furthermore, medical 
records do not contain information about all types of diagnostic process failures equally.  
As noted by the NAM committee (2015), medical record reviews are best suited to 
detecting failures in information gathering and failures in establishing an explanation, and 
these domains are indeed where we discovered the greatest number of process failures.  
Failures in information interpretation regarding radiology and pathology results were 
discovered based on clinically requested re-reviews (rather than an independent 
assessment undertaken by our research team), and failures in communicating an 
explanation to the patient were only discovered when a negative impact of such failure 
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was noted in the medical record.   Together, this means that our study captured only a 
portion of the diagnostic process failures that patients truly experience.  While such data 
is still valuable to guide process improvement efforts, we must interpret our estimates of 
process failure frequency with these caveats in mind.  Future research combining 
multiple avenues of process failure assessment, such as medical record reviews 
supplemented with physician and patient interviews, would be valuable in getting a more 
complete assessment of the challenges in diagnosing schwannomatosis. 
 Additionally, our coding of diagnostic process failures used only a single rater.  
We attempted to mitigate this bias by having the first five narrative summaries 
independently double-coded by an experienced NF clinician, with all coding choices 
reviewed and any discrepancies resolved by consensus discussion.  The expert NF 
clinician was also consulted ad hoc on clinical questions that arose in subsequent 
narrative summaries.  However, using two coders, preferably including at least one 
person with clinical experience evaluating and managing nerve sheath tumors, would be 
preferred in future work.   
Our assessment of the impact of diagnostic process failures included only those 
domains directly relevant to the NAM definition of diagnostic error (related to accuracy, 
timeliness, and adequate communication of the diagnosis), and does not encompass other 
potentially significant impacts of process failures, such as psychological distress or 
administration of potentially ineffective treatments.  Additionally, our assessment of 
communication relied on written documentation about communication, with the 
assumption everything recorded about the diagnosis was adequately explained to the 
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patient.  Future work on diagnostic communication should use observation of clinical 
encounters coupled with patient de-briefing interviews to better understand what 
information physicians communicate and whether patients understand this information.  
Finally, our assessment of factors contributing to diagnostic process failures should be 
considered preliminary.  While all process failures were evaluated for contributory 
factors, we do not know how often these same factors were present during portions of the 
diagnostic workup that did not engender process failures. 
Conclusions 
Despite these limitations, our study is the first systematic assessment of diagnostic 
process failures in a rare, genetic disease.  We confirmed that diagnostic process failures 
are extremely common in schwannomatosis, and that these failures have significant 
negative impacts on the accuracy and timeliness of patients’ diagnoses.  Many of the 
process failures we identified with schwannomatosis diagnosis likely affect people with 
other rare, genetic disease as well, including problems in efficiently transferring 
diagnostic testing results across institutions and failures to consider rare diseases in the 
differential diagnosis (often due to a lack of awareness of rare diseases among clinicians).  
Thoughtful deployment of health IT interventions may help correct these failures in the 
future; however, appropriate human factors evaluations will be necessary to ensure these 
features streamline clinician’s information gathering efforts and enhance their 
information interpretation and integration skills as intended (Singh et al., 2008; Schiff 
and Bates, 2010).  Finally, our research also demonstrates the utility of the NAM (2015) 
model of the diagnostic process for understanding where problems in the diagnostic 
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process failures occur and how contributing factors at the disease-, patient-, provider-, 
and system-level affect specific areas of the diagnostic process.  Use of this model to 
study other rare and genetic diseases will hopefully shed light on which diagnostic 
process failures are common across diseases, so that process improvement efforts may be 
targeted to address failures with the highest cross-disorder impact.
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CHAPTER 4: UNDERSTANDING THE PATIENT EXPERIENCE OF THE 
SCHWANNOMATOSIS DIAGNOSTIC PROCESS 
Introduction 
To date, research on the diagnostic process and diagnostic error has primarily 
utilized administrative data sources such as health insurance or malpractice claims, or 
clinical data sources such as medical record reviews, autopsy exams, and secondary 
review of diagnostic tests (National Academy of Medicine (NAM), 2015).  These data 
sources, while useful for providing quantitative estimates of the incidence of diagnostic 
error, cannot capture the full complexity of clinical situations or patient experiences.  As 
noted by the NAM committee (2015, pg. 117), direct patient input via surveys or 
interviews is especially needed in diagnostic error research to “understand failures at the 
front end of the diagnostic process (failure to engage) and [failures] in the process of 
delivering an explanation to the patient.  Both are critical steps, and patients are uniquely 
positioned to report on those elements of diagnostic performance.”   
To explore these diagnostic failures, and more holistically understand how 
patients experience being diagnosed with a rare, genetic disease, we interviewed patients 
with schwannomatosis from across the United States (U.S.) about their diagnostic 
journey.  Previous research has shown that patients with schwannomatosis often have 
prolonged diagnostic intervals; a review of schwannomatosis patients seen at a single 
U.S. academic medical center reported a median of 7 years between first symptom and 
diagnosis (Merker et al., 2012).  However, the factors contributing to this long diagnostic 
interval have never been explored, nor have there ever been interviews conducted directly 
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with patients to learn from their diagnostic experiences.  Rigorous qualitative analysis of 
patient interviews adds important context to the clinical data explored in prior dissertation 
chapters, deepening our emerging description of the schwannomatosis diagnostic process.  
Patient interviews provide us with a unique window into the areas of the diagnostic 
process that are typically not well documented in administrative and clinical records; 
namely, patient self-appraisal and help-seeking behaviors; patient-provider 
communication; and the real-world, lived impact of being diagnosed with a rare, genetic 
disease. 
In this study, we sought to explore what the schwannomatosis diagnostic process 
is like from patients’ perspectives.  We specifically sought to understand 1) how people 
appraise their symptoms and seek health care, both initially and throughout the diagnostic 
process; 2) how the diagnosis of schwannomatosis is communicated throughout the 
diagnostic process; and 3) what impact a diagnosis of schwannomatosis has on patients’ 
lives, including the impact of diagnostic errors and prolonged diagnostic intervals.  Our 
research approach was guided by our conceptual framework, which is described in detail 
in Chapter 1 and is based largely on the NAM (2015) model of the diagnostic process 
(Figure 4.1).  In this framework, patients begin the diagnostic process when they 
experience a health problem and engage with the healthcare system to address that health 
problem.  Importantly, patients must keep re-engaging with the healthcare system each 
time they undergo diagnostic testing or are referred to other healthcare providers to 
gather more information about their condition.  Throughout this information gathering 
process, healthcare providers are expected to communicate with patients about the 
  
116 
working diagnosis/diagnoses under consideration, including the level of certainty 
attached to each.  Ultimately, a final diagnosis is made and communicated to the patient, 
which guides the care they receive and thus affects their ultimate health outcomes. 
Figure 4.1 Conceptual Framework Domains Explored in Study 3   
  
Relative to this framework, our study focused on patients’ initial experience of a 
health problem related to schwannomatosis and their engagement in the healthcare 
system (both initially and with specialty neurofibromatosis (NF) clinics); communication 
of working diagnoses and a final diagnosis of schwannomatosis; and the outcomes of the 
diagnostic process as experienced by the patient in their day-to-day lives (Figure 4.1, 
dashed boxes). While investigating these topics, we also encouraged patients to discuss 
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barriers and facilitators to seeking care and to obtaining a diagnosis, potentially ranging 
across all four levels of contributing factors affecting diagnostic performance (shown at 
the bottom of Figure 4.1).  
Methods 
Methods Overview 
We interviewed 18 people with schwannomatosis from across the United States 
about their diagnostic process using a semi-structured interview guide.  Participants were 
selected from the International Schwannomatosis Database, which enrolls patient across 
multiple academic medical centers, as well as patients who are not currently receiving 
care from a schwannomatosis specialist physician.  The interview guide was developed 
based on pilot interviews with two schwannomatosis patients (who were not included in 
this study), our conceptual framework, and preliminary analysis of medical record 
reviews presented in prior chapters of this dissertation.  Interviews covered participants’ 
entire diagnostic journey from perceptions of their first symptom to diagnosis of 
schwannomatosis, including their experiences seeking care and discussing their 
diagnosis.  Interviews were conducted over the phone and audio-recorded with 
participant consent.  We analyzed interview transcripts using a grounded thematic 
approach, in which codes are emergent from the data (Braun and Clarke, 2006).  All 
transcripts were double-coded by two researchers in an iterative, consensus-based 
process.  Emerging analytic ideas were explored via memoing, collaborative discussion, 
and systematic extraction of transcript text into templates based on the study code book 
and our specific aims (Birks, Chapman and Francis, 2008).  Themes were developed 
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using a constant comparison method between cases and are presented here with 
supporting quotations (Charmaz, 2014). 
Participant Sample 
Our participant sample was drawn from the International Schwannomatosis 
Database (ISD).  The ISD is an online registry exclusively for individuals with 
schwannomatosis, with approximately 400 patients enrolled worldwide (Ostrow et al., 
2017).  This registry contains limited, de-identified information about patients with 
schwannomatosis and serves primarily as a mechanism through which researchers can 
identify potential research subjects and their available biological samples.   
Enrollment in the ISD requires a diagnosis of schwannomatosis from a specialist 
physician knowledgeable about the disorder.  The ISD primarily enrolls patients from 
neurofibromatoses (NF) clinics at academic medical centers in the United States, Canada, 
and across Europe.  However, patients who do not attend one of these clinics may enroll 
by submitting appropriate medical documentation to medical staff at the ISD central 
coordinating office, where it is reviewed by a collaborating physician-investigator.  
Patients who enroll into the ISD in this manner are referred to as being “long-distance 
enrolled”, and for the purposes of this dissertation, we consider their enrollment site to be 
the ISD central coordinating office.   
Given the desire to maintain comparability of our results to those of the rest of the 
dissertation (which is based on patients attending two large U.S. clinics), we chose to 
sample only ISD participants who self-identified as receiving the majority of their 
schwannomatosis-related care in the United States.  We felt international differences in 
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healthcare financing and organization would introduce additional variation into our 
analysis that was not warranted at this time. 
Within the total pool of available U.S. based subjects enrolled in the ISD (n=116), 
we planned to conduct stratified purposive sampling.  We stratified sampling at the level 
of enrollment site, in order to ensure geographic diversity and adequately explore any 
issues caused by differences in healthcare referral patterns at different medical 
institutions.  We planned to interview at least three patients from each enrollment site, 
and hoped to engage 6 to 7 enrollment sites for a total enrollment of 18 to 21 participants.  
This enrollment target was chosen because approximately 20 participants are usually 
sufficient to ensure thematic saturation - the point where no new concepts are being 
generated (Charmaz, 2014).  After enrolling the initial cohort of 18 to 21 patients, we 
planned to assess for thematic saturation; if this was not yet reached, we planned to 
iteratively enroll additional patients up to a total of 25 participants.  Within sites, we 
initially planned to recruit patients in reverse chronological order of their date of 
schwannomatosis diagnosis to minimize patients’ potential recall bias regarding 
diagnostic events. 
Recruitment 
Recruitment of subjects from the ISD followed established procedures (Ostrow et 
al., 2017).  In brief, our research team submitted a Letter of Intent for this project to the 
ISD Steering Committee for approval.  After approval, ISD operations staff contacted 
investigators at all sites with potentially eligible patients to notify them of the project.  
Given that we were interested in patients who received the majority of their medical care 
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in the United States, we only contacted investigators at U.S. based clinics.  At the time 
our study began recruitment, five U.S. NF clinics had received local Institutional Review 
Board (IRB) approval to participate in the ISD and had enrolled at least one participant: 
Johns Hopkins University, Massachusetts General Hospital (MGH), MD Anderson 
Cancer Center, New York University, and the University of Alabama at Birmingham.  
Our research team contacted staff at each of these five clinics to describe the project and 
seek support for recruiting patients; all five centers agreed to recruit patients for this 
study.  In addition, the central coordinating office agreed to recruit long-distance enrolled 
patients.   
 Patients at clinical enrollment sites were told about the study from their local 
clinical team, either in-person after a regularly scheduled clinic visit or via a telephone 
call or email.  Local clinical staff then instructed patients to contact the doctoral student 
directly (via phone or email) if they were interested in participating.  Long-distance 
enrolled patients received an email from the ISD central office director and were asked to 
contact the doctoral student directly if they were interested in participating.    
 Interested patients were screened for eligibility using pre-established criteria via 
email or telephone.  Inclusion criteria for the study were 1) diagnosis of schwannomatosis 
and enrollment in the ISD, 2) having received most of one’s medical care in the United 
States; and 3) the ability to understand and speak English at or above the 6th grade level.   
Exclusion criteria were inability or unwillingness to give informed consent and refusal to 
allow audio-recording of interview.  Patients meeting eligibility criteria were scheduled 
for a phone interview at a time convenient to them. 
  
121 
Interview Guide 
 Interviews were conducted using a semi-structured interview guide that covered 
the patients’ entire journey to diagnosis, including symptomology, experiences seeking 
and receiving care from providers, problems accessing or coordinating care, 
communication with providers, and the impact of receiving a diagnosis of 
schwannomatosis.  The interview guide was developed based on review of the literature, 
our conceptual framework, the doctoral candidate’s personal experience observing 
schwannomatosis patients’ clinical appointments, pilot interviews with two 
schwannomatosis patients from MGH, and emerging insights from concurrent analysis of 
medical records of schwannomatosis patients at MGH and Johns Hopkins described in 
Chapters 2 and 3 of the dissertation.  Neither of the MGH patients interviewed in the pilot 
were included in the final study sample.  The interview guide, along with a detailed 
description of the reasoning behind each question’s inclusion, is presented in Appendix 
C1. 
Data Collection 
 Prior to the start of all interviews, patients provided verbal informed consent to 
participate, following the procedure approved by our IRBs (Partners Human Research 
Committee Protocol 2016P000069 and Boston University Medical Center Protocol H-
35121).  The doctoral candidate conducted all interviews with participants via telephone 
as per the interview procedures described above and wrote field notes immediately 
following each interview (Phillippi and Lauderdale, 2017).  These field notes 
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summarized salient points made by interviewees and included any pertinent contextual 
information, such as participants’ tone of voice and emotions, other people present with 
the participant as they spoke on the phone, and personal background shared during the 
interview scheduling and informed consent process. 
 All interviews were audio-recorded with participants’ consent, and audio files 
were transcribed near-verbatim by a professional transcription company.  Paraverbal 
markers such as stutters and filler words, as well as interviewer sounds of understanding 
and encouragement (such as mm-hmm, yeah) were largely omitted, per instructions to the 
transcriptionists.  However, filler phrases that seemed to be imbued with meaning 
because of the participants' tone, timing, or surrounding statements were retained in the 
transcript.  This style of transcription facilitates analysis by retaining the most important 
linguistic markers without overly cluttering the transcript with filler words that may cloud 
the meaning of the utterance.   
 All transcripts were spot-checked against the original audio files for accuracy, 
after which the names of participants, their friends and family members were redacted.  
After analysis but prior to publication in this dissertation, additional identifying 
information was redacted including names of clinicians, hospitals, cities and states.  In all 
quotes presented, square brackets are used to replace redacted information with a 
pseudonym or description (e.g. changing “Dr. Mary Smith” to [Dr. Jones, 
neurosurgeon]).  In addition, square brackets are used to identify information inserted to 
clarify the context of participant statements (e.g. changing “She ordered an MRI” to 
“[The neurosurgeon] ordered an MRI.”) 
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Data Analysis 
 Interview transcripts were analyzed using grounded thematic analysis, a 
methodology informed by grounded theory (Braun and Clarke, 2006).  Grounded 
thematic analysis allows researchers to focus on the conceptual categories interview 
subjects employ themselves, rather than imposing predefined criteria developed by 
researchers onto the data. This ensures that investigators are not limited by pre-conceived 
notions about the data, and remain open to new and unexpected findings. We chose a 
grounded thematic approach over one in which we developed a deductive coding system 
dictated by our conceptual framework, because so little is known about the 
schwannomatosis diagnostic process, and we did not want to inadvertently ignore new 
phenomenon relevant to patients’ diagnostic experiences.   Additionally, keeping our 
analysis firmly grounded in the data keeps our findings faithful to the patients’ actual 
lived experiences, and capitalizes on the unique view patients provide (as opposed to the 
administrative and clinical data sources in prior chapters of this dissertation.) 
 Analytic codes – the labels used to identify, name, and categorize phenomena - 
were developed by two researchers (the doctoral candidate and an experienced qualitative 
researcher).  Following the principles of grounded thematic analysis, all analytic codes 
were emergent from the data and not predetermined by investigators.   Specifically, we 
reviewed the first interview transcript line-by-line to decide on analytic codes that 
represented the meaning of the text and used this information to create our initial 
codebook.  This initial codebook contained code names, a brief definition of the code, 
and a longer description of each codes’ content with guidelines on when and when not to 
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use a certain code, as well as tips on when to consider a related code instead of the given 
code.  Two examples from our codebook, including exemplar coded text from interviews, 
are presented below in Table 4.1; the full codebook is presented in Appendix C2. 
 
Table 4.1. Interview Codebook Examples 
Information 
Integration 
Short 
Definition 
Healthcare professional connects (or fails to connect) 
information from multiple sources or about multiple 
symptoms to inform diagnostic reasoning 
Long 
Definition 
Healthcare professional exhibits diagnostic reasoning that 
brings together disparate information to move closer to a 
unifying diagnosis that connects a patient's multiple 
symptoms/tumors.  Alternatively, participant specifically 
comments on healthcare professionals’ failure to integrate 
information in this way.  In this context, "information" 
includes a patient's personal clinical symptoms and family 
history, as well as more general medical information such as 
diagnostic criteria or care guidelines.  
Exemplar 
Text 
“Well, after when my ear surgery in June, and when the 
biopsy came back as a schwannoma, right off the bat, that’s 
when [the surgeon] mentioned. He said, ‘Okay. Well, we 
need to look a little further as to why you're getting all these 
schwannomas.’ Then, that’s about the same time that I 
wanna say he, on his own, was probably looking up and 
Googling multiple schwannomas, as I was.” 
Psychological 
Distress 
Short 
Definition 
Emotional or psychological distress engendered by 
diagnostic process 
Long 
Definition 
Participant discusses psychological/emotional distress 
experienced by themselves or other (such as family 
members) as a result of receiving their diagnosis or activities 
in the diagnostic process (for example, diagnostic testing or 
treatments for schwannomatosis signs or symptoms). 
Exemplar 
Text 
“I just wanna mention that I think MRIs can also be scary 
because you go in MRI for one thing, and then you find other 
things that goes on. Yeah, because I went to MRI on my 
back, and then they found, oh, that’s another possible [tumor] 
in my left chest wall . . . MRIs can be reassuring, but they 
can also be really scary when they find other unrelated things 
going on.” 
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We then coded each interview transcript separately, meeting afterwards to discuss 
the application of codes to the text in an iterative, consensus-based process.  At each 
meeting, we reconciled our coding of text passages via in-depth discussion and refined 
the codebook as necessary to include new codes or more precisely define existing codes.  
We then used the revised codebook to code subsequent interviews, repeating this process 
until all transcripts were double-coded and discussed in their entirety.  Our final, 
consensus-based coding framework was entered into NVivo 11.0 (QSR International), a 
computer software program that facilitates the organization and analysis of text.  
 During the coding process, we tentatively grouped codes into categories 
suggested by our conceptual framework.  For example, four codes related to patients’ 
description of symptoms, self-appraisal of symptoms, and the impact of symptoms on 
their lives were grouped together under ‘Patient Experiences a Health Problem’.  
Grouping codes in this way helped us identify when codes mirrored the timeline and 
categorization of diagnostic activities presented in our conceptual framework.  To stay 
true to grounded thematic principles, we applied this categorization flexibly and 
maintained a separate category of “Other” for codes that spanned multiple areas of the 
conceptual framework or did not immediately seem to fit into the conceptual framework.  
In this way, we could maintain fidelity to the source data, while still taking advantage of 
our conceptual model as a way to organize our analysis and bring prior research findings 
on diagnostic delay to bear on our understanding of participants’ experiences.  During 
analysis, minor changes to these code groupings were made as we reflected on the 
nuances of participants’ accounts and compared the use of codes between transcripts. 
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 During the coding and analysis of transcripts, we used constant comparison within 
and between interviews in order to reveal larger themes and common patterns that 
characterized patients’ experiences (Charmaz, 2014).  Analytic memos captured our 
thinking on the relationship between codes, how codes related to or expanded upon our 
conceptual framework, commonalities and differences in participant experiences, and any 
surprising or novel concepts related to the diagnostic process (Birks, Chapman and 
Francis, 2008).  For example, a memo on “Coping with a schwannomatosis diagnosis” 
compared how participants psychologically experienced receiving diagnostic or treatment 
information, noting how some limited their exposure to information in response to 
psychological distress.  The memo contrasted participants’ observed behavior with our 
conceptual model’s depiction of diagnostic communication, leading us to reflect on ways 
that clinicians may adapt their communication to patients’ perceived or actual coping 
ability.  This and other memos were recorded in NVivo so that they could easily be 
linked to supporting quotes in interview transcripts.  Repeatedly moving back and forth 
between source data and analytic memos in this way, a feature of constant comparative 
analysis, helped ensure our findings were grounded in participants’ words and 
experiences. 
 During analysis, we recorded summary data and/or pertinent quotes from each 
interview into templates derived from the study code book and specific aims of the study.  
For some analytic questions, this facilitated the collection of descriptive or quantitative 
data.  For example, in order to explore the code of “Early Symptoms” and our specific 
aim of understanding how patients appraise their symptoms and seek health care, we 
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extracted data on each subject’s initial symptom, how they and others interpreted that 
symptom, the approximate length of time until they sought health care for that symptom, 
and what type of heath care professionals (if any) they consulted.  For other analytic 
questions, data extraction into templates facilitated the classification and comparison of 
qualitative information.  For example, in order to explore the codes “Impetus to Seek 
Care” and “Delay in Seeking Care”, we extracted quotes coded under these labels and 
categorized them into similar reasons that participants perceived they were pushed 
towards or pulled away from seeking care.  In this way, data extraction into templates 
facilitated a systematic search for relevant evidence across cases, increasing the validity 
of our findings by ensuring that all coded text was accounted for and any disconfirming 
evidence was identified (Creswell and Miller, 2000). 
Results 
Participant Recruitment 
Recruitment for this study ran from December 2016 to July 2017.   Investigators 
at five enrolling sites successfully recruited the planned sample of three participants each. 
The remaining site was unable to fully implement recruitment procedures due to short 
staffing; no subjects from this site participated in our study and it is unknown how many 
(if any) potential subjects were approached for recruitment.  In order to compensate for 
the lack of subjects from this site and reach our minimum study recruitment target of 18 
subjects, we over-sampled patients at the remaining five enrolling sites on a convenience 
basis.   
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Recruitment within each enrolling site followed variable procedures according to 
local IRB regulations.  One site was able to implement the planned purposive sampling, 
and contacted subjects in reverse order of date of diagnosis.  Two sites recruited a 
convenience sample, first contacting patients as they came in for regularly scheduled 
medical appointments and then emailing additional patients.  Lack of local data on date 
of diagnosis and limits on staff availability did not permit purposive sampling based on 
date of diagnosis at these sites.  Due to lower numbers of potential subjects available, two 
sites contacted all potentially eligible patients simultaneously, in order to most efficiently 
recruit at least three participants. 
Detailed response rate information was available from three enrolling sites.  At 
one medical center, seven patients were contacted, five of whom were participated in this 
study (71%).  At another medical center, nine patients were contacted, three of whom 
participated in this study (33%).  Via the central coordinating office, seven long-distance 
enrolled patients were contacted, five of whom expressed interest in participating and 
four of whom actually participated in this study (57%).   The fifth subject was found to be 
ineligible due to receiving the majority of her medical care outside of the United States, 
and was not interviewed. 
Codebook Development and Analysis of Thematic Saturation 
Interview recruitment was paused at 18 participants as planned to assess for 
thematic saturation.  After double-coding the first sixteen transcripts, both coders agreed 
that thematic saturation had been reached (i.e. that no new codes or substantive themes 
were emerging from additional interviews) and the study enrollment was officially 
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closed.  Detailed records of codebook changes showed that most codes were established 
after review of the first seven transcripts, with only one new code added after this point.  
The final codebook contained 38 codes across 10 domains; a full list of codes and 
domains is presented in Appendix 3-2. 
Participant Characteristics 
Across all sites, 18 participants (7 female, 11 males) were interviewed between 
December 2016 and August 2017.  Interviews lasted an average of 49 minutes (range, 31 
to 66 minutes), not including time at the beginning of the phone call used to obtain 
informed consent.  At the time of the interview, participants had a median age of 51 years 
(range, 30 to 68).  Exact date of diagnosis was not ascertained for each participant, but 
based on interview accounts, participants had a median length of time between diagnosis 
of schwannomatosis and interview of approximately 3.4 years (range, 1.5 months to 27 
years).  All but two participants had been diagnosed within the last eight years; the 
participant diagnosed 27 years ago reported being diagnosed while participating in 
genetic research for schwannomatosis.   Participants were not explicitly asked about 
schwannomatosis inheritance, but 3 participants (16.6%) reported a confirmed (two 
participants) or suspected (one participant) family history of schwannomatosis. 
Thematic Analysis 
Our analysis generated eleven major themes, which we have organized according 
to the specific research question they address (Table 4.2).  Themes 1-4 relate to 
participants’ symptom appraisal and care-seeking; Themes 5-7 relate to diagnostic 
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communication; and Themes 8-11 relate to the impact of the diagnostic process on 
participants’ lives.  
Table 4.2 Thematic Analysis Results by Research Question 
How do people with schwannomatosis appraise their symptoms and seek healthcare, 
both initially and throughout the diagnostic process? 
Theme 1 Patients’ first symptom of schwannomatosis is often pain, which is difficult 
for both patients and clinicians to assess 
Theme 2 Disease-related and personal characteristics can push or pull people towards 
seeking medical care for schwannomatosis symptoms 
Theme 3 External barriers and facilitators affect whether and when people with 
schwannomatosis receive care 
Theme 4 Referrals from healthcare professionals and patients’ own online research are 
key to connecting schwannomatosis patients with providers at dedicated 
neurofibromatosis clinics 
How is a diagnosis of schwannomatosis communicated throughout the diagnostic 
process? 
Theme 5 Diagnostic communication encompasses both an educational/informational 
component as well as a social/emotional component 
Theme 6 Patients cope with diagnostic information differently, and clinicians may 
modulate how and what they communicate to accommodate patients’ real or 
perceived coping ability 
Theme 7 Surgeons occupy a distinctive role on the diagnostic team for 
schwannomatosis; their communication may reflect different priorities 
regarding diagnosis and treatment 
What impact do schwannomatosis diagnoses and diagnostic errors have on peoples’ 
lives? 
Theme 8 Receiving a diagnostic label of “schwannomatosis” can have positive and 
negative impacts on patients’ lives 
Theme 9 Information integration is a crucial but difficult step in diagnosing 
schwannomatosis; failures in information integration can lead to diagnostic 
errors 
Theme 10 Diagnostic errors in schwannomatosis can lead to both physical and 
psychosocial harms 
Theme 11 Patients with schwannomatosis may experience stigma during the diagnosis 
and treatment of their pain 
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Theme 1: Patients’ first symptom of schwannomatosis is often pain, which is difficult for 
both patients and clinicians to assess  
Participants self-identified their first symptom of schwannomatosis.  Participants’ 
median age at initial symptom was 30 years (range, 13 - 46 years), with the majority 
(14/18) of participants’ experiencing their first symptoms in the year 1990 or later.  
Fifteen people (83%) experienced pain and three people (17%) felt a mass, with one 
person in each group also concurrently experiencing localized numbness.  However, by 
the time participants sought care, six had developed both pain and a palpable mass 
(including five people who initially had pain only and one person who initially only had a 
mass). 
Participants largely attributed their symptoms to benign etiologies, including a 
pulled muscle, “just hitting a nerve”, residual pain from a prior accident/injury, or general 
aches and pain from an active lifestyle, manual labor or old age.  A minority of patients 
attributed their symptoms to a specific medical problem, which were an ear infection, 
bone spur, medication side effect, or gastrointestinal problem. 
Most participants sought care within a few months of symptom onset, but two 
people waited a year or longer, and two people never sought health care for their initial 
symptom.  All four of these participants had intermittent pain, often only elicited when a 
certain body area was bumped or struck (although 5/14 people who sought health care 
more quickly also had intermittent pain).  Three of these four participants also self-
identified as not the kind of person who complains about pain or goes to see a doctor 
much.   
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Most participants (13/18) went to a primary care practitioner initially, but five 
went directly to specialists, including an otolaryngologist, a pain management specialist, 
an orthopedist, an unspecified spine specialist, and a dentist.  Healthcare professionals 
(HCPs) most commonly ascribed patients’ initial schwannomatosis symptoms to more 
common musculoskeletal or neuromuscular problems, including a pulled muscle, pinched 
nerve, cartilage tear, inguinal hernia, temporomandibular joint disorder, carpal tunnel, 
herniated disc, sciatica, or degenerative disc disease.  After initial investigations into 
symptoms revealed no obvious cause, two patients had HCPs suggest their pain was 
either psychosomatic in nature or exaggerated because they were seeking prescription 
pain medication. 
For five participants, imaging workup of initial symptoms revealed multiple 
tumors, leading to the diagnosis of a tumor predisposition syndrome (three of whom were 
correctly diagnosed as having schwannomatosis, one of whom was initially misdiagnosed 
as having neurofibromatosis type 1 (NF1), and one of whom who was initially 
misdiagnosed as having neurofibromatosis type 2 (NF2)).  The remaining patients were 
worked up for additional symptoms at a later date before being diagnosed with 
schwannomatosis.  These new symptoms were largely due to separate tumor(s) in other 
area(s) of the body, which presented similarly to participants’ first symptoms (as pain 
and/or a palpable mass, occasionally also associated with neurological symptoms such as 
weakness or numbness).   
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Theme 2: Disease-related and personal characteristics can push or pull people towards 
seeking medical care for schwannomatosis symptoms 
Participants discussed multiple factors that either pushed them towards or away 
from seeking health care for the diagnosis and treatment of schwannomatosis-related 
signs and symptoms (see Table 4.3 for a full listing of these factors with illustrative 
quotes).  “Health care” in this context includes a doctor appointment, diagnostic test, or 
treatment.   
Table 4.3 Factors That Push People Towards or Away from Seeking Health care  
Impetus to Seek Care 
Symptoms worsen Pt. 18: “I’d been aware of it as a small lump and then over 
time became aware that that lump actually had grown some 
over the course of years and became increasing more 
sensitive to being bumped, making contact or force, which 
had the sensation of a very sharp pain. Sometimes it felt like 
an electric shock. I reached a point where I had shown it to a 
doctor.” 
Original explanation of 
symptoms is refuted 
Pt. 1: ““When I switched dentists . . .  I said, ‘Yeah. I have 
this pain here.’ He said, ‘Oh.’ He goes, ‘Well, that’s a weird 
kind of pain. I don't think that that’s TMJ.’ That helped 
prompt me into going, ‘Okay. I think I need to go see an ear 
person now.’” 
Friend or family 
member suggests 
seeking care 
Pt. 15: “When I got married when I was 24, I remember my 
husband saying, ‘You really should, even though you’re 
healthy and you don’t think it’s anything. I would like it if 
you just went to a doctor and figured out what it was.’” 
Already have 
appointment for 
another reason 
Pt. 5: [The mass in my arm] wasn't that big of a concern. I 
think, I had this dermatology appointment set up for what, I 
don't even remember, and I brought it up to him saying, 
"Hey, can you do a biopsy to see what this [mass] is?" 
Barriers to Seeking Care/Reasons to Delay Seeking Care 
Symptoms Aren’t 
Bothersome Enough 
Pt. 5:  “It was, probably, five or six months before I went to 
the dermatologist because it was just something that, if I 
touched it, it hurt . . . I just wasn't having any of the other 
symptoms of it being a schwannoma, and it just wasn't—it 
was an annoyance. It wasn't that big of a concern.” 
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Alternate Explanation 
of Symptoms Available 
Pt. 8: “I just sorta said, ‘I was diagnosed ten years ago, 
degenerative disc,’ so I just sorta lived with the pain.” 
Too busy/competing 
priorities 
Pt. 1: “Just being a mom of two kids, and busy practice, and 
just not having the time . . It’s one of those things that—not 
having the time, I just put it off.”    
Personality  Pt. 3:  “I don’t go really—I’ve never gone to the doctor 
much. I’m not a worrier. I’m also just, this is the way life is 
and I just keep goin’.” 
Avoidance of Care as 
Coping Mechanism 
Pt. 11: (In response to a question about why he waited a year 
or two to visit an NF clinic): “Sometimes, if I don’t know 
what’s going on, then it’s not bad if I don’t know about it.” 
Health 
Insurance/Money 
Pt. 16: “I had no insurance, so it didn’t matter what it was. I 
really couldn’t even really have it checked out. It was 
something I — also, the economy had tanked at that point in 
time. I really didn’t even have any work. Destitute may be 
the wrong word, but damn close to it at that point in time.” 
 
Three common factors that pushed people to seek care were the worsening of 
symptoms, a family member or friend suggesting seeking care, and having one’s original 
explanation for symptoms refuted.  Symptoms worsened either by becoming more 
intense/frequent or by interfering with the person’s ability to do activities (such as sleep 
or play sports).  Friends and family members prompted care-seeking both by general 
suggestions that the participant have a symptom examined and by specifically 
recommending certain physicians or diagnostic tests.  Finally, participants’ original 
explanations for symptoms were refuted when a physician disagreed with the original 
explanation; when treatment for the original explanation proved ineffective; or when a 
symptom progressed or a new symptom developed such that the person’s symptoms were 
no longer compatible with the original explanation.  
Participants mostly identified symptom-level or person-level characteristics that 
delayed or prevented care-seeking.  Participants did not seek care for symptoms that were 
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not perceived as bothersome enough to warrant intervention, usually because they only 
occurred intermittently.   Participants also delayed seeking care if an alternate 
explanation for their symptoms was available, particularly when that explanation 
indicated that the symptoms would resolve without treatment (e.g. a medication side 
effect that would wear off within a few months) or could not be treated at all (e.g. aches 
and pains related to getting older).   On the personal level, participants reported delaying 
care because they were too busy with competing priorities (such as work or family 
obligations) or because of their personality (i.e. being someone who doesn’t worry or 
complain about symptoms).  One participant indicated that in addition to being busy with 
work, he also delayed care in order to avoid learning potentially negative information 
about his health.  
Theme 3: External barriers and facilitators affect whether and when people with 
schwannomatosis receive care 
Once participants decided to seek health care, they still faced various forces that 
either facilitated or impeded their receipt of care (see Table 4.4 for a full listing of these 
factors along with illustrative quotes).   Facilitating and impeding factors affected how 
fast participants received care, whether they could obtain their desired care (for example, 
seeing a specialist or getting a certain procedure), and in the most extreme cases, whether 
the received any care at all for a particular health problem. 
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Table 4.4 Factors That Facilitate or Impede Receipt of Health care  
Facilitating Factors to Receive Care 
Health insurance Pt. 2: “We’re with [name of insurance company].  It’s an HMO 
type of thing. We can get in to see the general practitioner 
relatively easy. Getting a referral to a neurosurgeon or a specialist, 
if they’ve got a reason to they’ll pull the trigger. I mean they won’t 
do it for a hangnail. But if they’ve got a compelling reason that you 
need to see a specialist of one person or another, they don’t mind 
doing the referral. Referrals go pretty quick. Once they put the 
referrals in, usually those are approved within a few days or less.” 
Personal 
connections to 
medical 
professionals 
Pt. 15: “At that point, I think I called my pastor. We had a doctor 
that he was very friendly with in the congregation. . . . The pastor 
called the doctor and said, ‘Get her to the right person.’ . . .  [After 
looking at her imaging, the doctor] said ‘This is a subspecialty 
called skull-base surgery.’ He said, ‘Forget what the ENT is telling 
you. I’m sure there’s another [surgical] approach. There’s a guy 
who I know at [an academic medical center] who does this kind of 
thing.’ He called that guy and I had an appointment within a few 
days with that guy.” 
Access to 
Specialists 
and/or Imaging 
Pt. 5: “[The neurologist] was willing to write the script to get the 
MRI and back then it wasn’t as hard to get MRIs as is it today. 
Ironically there’s a lot more MRI machines out there, but I mean 
bluntly, he could just have easily have said, “Well, let’s just see 
what happens, I don’t have enough that I can justify to send you for 
an MRI.” It was more of a matter of we’ve tried everything else, 
let’s give this a whirl. If he hadn’t, I don’t know when [the 
schwannoma] would have been found.” 
Support from 
friends/family 
Pt. 14: “I have two children. They’re 22 months apart. At the time, 
my husband traveled a ton. I was a stay-at-home mom. My parents 
live close by. If it weren’t for my parents being able to watch my 
kids, I don’t know what I would have done, because I had so many 
appointments.” 
Factors Impeding Receipt of Care 
Lack of health 
insurance or 
problems with 
insurance 
company 
Pt. 12: “. . . what was frustrating about that was that for every 
procedure I had to have—[hospital] had to get the authorization 
from the insurance company. They put in for it, then they have to 
wait for the insurance company to say yes. Then I had to get 
scheduled, and so that was the frustrating part, but, not much you 
can do about that, I mean.” 
Problems 
Finding a 
Specialist or 
Pt. 8: ““At that point, I then just went to the web, and I Googled . . .  
I saw [NF doctor’s] website, his bio in the NF clinic . . . [Now] I 
look at him and go, ‘Damn, I sorta wish I would have met with him 
because he's engaging, personable, obviously passionate about NF.’ 
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Receiving 
Imaging  
[But] I didn't even call his clinic cuz just the marketing on their 
website, it didn't say adult on it. I don't even know if he said 
schwannomatosis in there.” 
Long Wait 
Times for 
Appointments 
Pt. 3: “From there we found that there are clinics for 
[neurofibromatosis]. There was one at Duke.  So we called them . . 
. It was gonna take, again, months to get an appointment. I mean 
months, six or eight months. And it was dragging on.”    
Too 
busy/competing 
priorities 
Pt. 16: “They’re chasing me to have this tumor removed. I said, ‘I 
can’t. I just started work. I can’t take any time off.’ At the time, the 
economy was still in the tank. Any work I could get, I was trying to 
work to keep the wolf away from the door. I put ‘em off until 
November.” 
 
The most commonly discussed factor that impeded or facilitated the receipt of 
care was health insurance and related financial issues surrounding payment for health 
care.  Negative experiences with health insurance largely manifested as a delay in receipt 
of care while patients or their care teams appealed unfavorable insurance coverage 
decisions.   However, as shown in Table 4.2, at least one participant did not even seek 
care in the first place due to lack of insurance coverage and inability to pay out of pocket 
costs.  (This overlap reflects that some factors could both delay patients from seeking 
care and prevent them from receiving care they had sought, depending on each patient’s 
unique situation.)  Conversely, some participants explicitly noted that health insurance 
benefit design could facilitate faster receipt of care (e.g. when referrals to specialists were 
processed promptly) or allow them to seek care with providers they preferred (e.g. when 
plans covered out-of-network providers).  Six other participants said health insurance was 
not a problem when explicitly asked by the interviewer, but did not attribute any 
particularly positive or negative influence of health insurance on their diagnostic journey. 
Common facilitating factors to receive health care were personal connections to 
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the medical field and access to specialists and advanced imaging.  At least half of 
participants worked in a medical field themselves or had a family member or other 
connection who did, which facilitated finding appropriate specialists and getting quicker 
appointments.  Multiple participants commented on how access to specialists (because 
they were conveniently located nearby) and access to advanced imaging (either through 
doctors who were willing to order imaging, insurance that would cover the costs of 
imaging, or schedulers who helped fit them in for imaging appointments) facilitated their 
timely receipt of diagnostic care.  Conversely, common impeding factors included long 
wait times for appointments, and difficulty in finding appropriate specialists or obtaining 
advanced imaging. 
Theme 4: Referrals from healthcare professionals and patients’ own online research are 
key to connecting schwannomatosis patients with providers at dedicated 
neurofibromatosis clinics 
 All but two participants (who were both long-distance enrolled in the ISD) had 
received care at least once from a specialty NF clinic.  Patients received care from an NF 
clinic through one of three dominant scenarios: referral from a healthcare professional 
who finally ‘put it all together’; self-directed online research; and routine transfer of care. 
 Eight participants received care at an NF clinic after a healthcare professional 
“connected the dots” between their multiple tumors, and decided they needed an expert to 
confirm the underlying diagnosis and/or advise on treatment options.  This key act of 
information integration was usually made by a specialist treating the participant’s nerve 
sheath tumor(s), including five surgeons and one radiation oncologist, but twice was 
made by primary care practitioners.   
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 Six participants received care at an NF clinic after they (or their spouse) started 
their own independent research into schwannomas and/or schwannomatosis.  Two 
patients started doing research before knowing anything about NF/schwannomatosis; two 
patients started doing research after being given a working diagnosis or misdiagnosis of 
NF; and two patients had already been diagnosed with schwannomatosis, but started 
doing research to find out more information about their condition and possible treatment 
options.  One of the two participants who did not seek care at an NF clinic largely 
followed this scenario as well (as she did online research both to diagnose herself and 
contact the International Schwannomatosis Database), but she either never identified or 
never chose to attend an NF clinic.  Participants almost exclusively did their research 
online, although multiple participants noted difficulty accessing information online about 
which healthcare providers/clinics specialized in the treatment of adults with 
schwannomatosis.   
 Two participants received care at an NF clinic only because they needed to 
establish care at a new institution after moving a significant distance.  Both participants 
were diagnosed and received care for many years by a specialist knowledgeable about 
schwannomatosis (but not affiliated with an NF clinic), and seemed largely happy with 
this care.  The participants only made an appointment at an NF clinic near their new 
location after their former care team or a new local doctor suggested it.  One of the two 
participants who did not seek care at an NF clinic largely followed this scenario as well, 
except he has not moved, and so continues to follow with a local specialist who is 
unaffiliated with an NF clinic. 
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Theme 5: Diagnostic communication encompasses both an educational/informational 
component as well as a social/emotional component 
Ten participants were given a confirmed diagnosis of schwannomatosis at an NF 
clinic, five participants were formally diagnosed by other providers, and two participants 
had never been told by their own healthcare providers that they had schwannomatosis 
(both participants were long-distance enrolled into the ISD, whose staff was the first to 
officially confirm their diagnosis).   Participants’ median age at time a confirmed 
diagnosis of schwannomatosis was communicated was approximately 45 years (range, 
28-67 years.) 
Participants were usually told that they might have a tumor predisposition 
syndrome from healthcare providers, most commonly surgeons (11/18; 8 neurosurgeons, 
2 orthopedic surgeons, and 1 general surgeon).  The specificity of these discussions 
varied – some participants were only told that they may develop more tumors over time, 
others were told about neurofibromatosis generally, and some were specifically 
diagnosed with schwannomatosis.   Participants who were given more vague information 
initially often turned to online research; two participants used online research to narrow 
down what type of NF they had and two participants used online research to identify the 
NF clinic where they received their schwannomatosis diagnosis.  This is in addition to 
three participants who initially discovered the possibility of tumor predisposition 
syndromes from online research, rather than from a healthcare provider. 
Sometimes the lack of detailed information initially provided about 
schwannomatosis (particularly regarding the differences between NF1, NF2, and 
schwannomatosis and where participants could receive follow-up specialty care) was 
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extremely distressing to participants.  As participant 9 described when asked how he 
found out about neurofibromatosis for the first time: 
“So, when [my orthopedic surgeon] first mentioned it is when I first started 
looking into it, and doing, essentially unguided, not well-informed research, just 
looking up what they were and identifying with some of the symptoms. That was 
almost paralyzing honestly.  Paralyzing, not in a physical sense, but in a kind of 
emotional, mental sense . . . I literally panicked and became depressed before 
having the appointment [with NF clinic physician] and before him coming to the 
diagnosis because of the severity and the difference between NF1, NF2 and 
schwannomatosis. I was just panicking, just from the thought of becoming deaf or 
just the other side effects with the NF1, NF2 or even possibly schwannomatosis.” 
 
Other participants described similar experiences, with participant 17 noting that a 
combination of online research and accessing one of his own pathology reports via his 
hospital’s electronic portal led him to discover he might have a form of 
neurofibromatosis.  Over the next two months, while he waited for his first appointment 
at an NF clinic so that he could confirm his diagnosis, he 
“just spent a lot of time on the internet reading, and I was searching about other 
people’s experience, reading about doctors, reading about different diagnoses . . . 
It was definitely a very frustrating couple of months, very unproductive because I 
didn’t actually do real work very much at that time. I went to the office, I sat 
down, and I would go, “I’m gonna open some web pages and continue reading 
about these tumors.” 
 
For other participants, the lack of initial information about schwannomatosis was 
less problematic, particularly for those who more easily self-diagnosed as having 
schwannomatosis and those who were able to access specialty follow-up care quickly.  
For example, participant 8’s general surgeon mentioned neurofibromatosis (without 
distinguishing the subtypes) and accidently referred him for follow-up neurological care 
to a Parkinson’s clinic   This participant, however, did not experience much distress; 
using online research, he quickly deduced that he likely had schwannomatosis and 
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identified a number of specialty NF clinics.  He was able to get an appointment with a 
neurologist knowledgeable about schwannomatosis within two to three weeks, at which 
point he received a same-day brain MRI to confirm his diagnosis.   
 When participants did find specialists knowledgeable about schwannomatosis, 
they were often relieved to finally receive detailed information about their disorder.  
Participant 3 noted:  
“Once I got to [NF clinic] and probably just from the first phone call, before the 
MRIs and anything, just that first phone call where I was saying, ‘I think I might 
have this.’ I can remember having a weight lifted off my shoulders and feeling 
that it’s gonna be okay. They’re gonna help me. Then, seeing them face-to-face.  
When they explained things, they spent so much time explaining everything. It was 
great. I felt like I was in a medical class. It was awesome. Not that - I didn’t feel I 
was in a medical class that they used terms like that, but I was being educated. 
Genetically they were breaking it all down, drawing pictures and it was great.” 
 
Participant 9 echoed these remarks, noting how he appreciated his physician’s empathic 
tone and medical knowledge about schwannomatosis: 
“Being able to just speak to [NF physician] on a human level, not even on a 
patient level, was huge too.  Him speaking frankly of what the condition is like, 
what prognosis is like, speaking to the different medications and side effects and 
him not rushing to do surgery, being more conservative on that angle. All of those 
things really helped me a lot . . .” 
 
Participant 14 also noted that beyond receiving more medical information, it was 
comforting to find a physician who understood the social and emotional difficulties of 
being diagnosed with schwannomatosis: 
“[NF Clinic physician] was just very, very reassuring and confident that, ‘We’ve 
got this’—I mean, ‘You have it and we have to deal with it,’ almost like, ‘I know 
how to do this,’ was the feeling I got. I feel like, finally, I’m with a doctor who 
knows what he’s doing and who believed me, because he said to me, ‘I bet you’ve 
been diagnosed with depression, anxiety.’ He ticked off a whole bunch of things 
that I had then.  That was very reassuring that he just seemed to not only really 
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know his stuff medically, but he also understood the struggle going through this, 
this ridiculous misdiagnosis stuff.” 
 
However, it is important to note that even when a diagnosis of schwannomatosis 
was communicated to the patient, the full medical implications of schwannomatosis may 
not have been adequately discussed.  Many participants still had questions about the 
genetics of schwannomatosis and, most urgently, the risk to their children of developing 
the disease.  As participant 10 noted when describing her primary reason for doing online 
research about schwannomatosis and contacting the ISD: “I was thinking about, is there 
some kind of genetic testing? I have three kids. Is there something I should prepare them 
for? What's the hereditary component with this?”    
While this confusion about genetic issues was most notable in participants who 
never went to a dedicated NF clinic or had not been to one in many years, it was also 
apparent in participants followed at major NF centers.  Some participants were unsure 
about genetic facts (for instance, that schwannomatosis is a genetic disease and that it 
could be passed on to their children).  Others knew the disease was genetic, but were 
unsure how they could be the only person in their family to have symptoms (presumably 
because they thought “genetic” implied “inherited”).  Multiple participants were also 
confused about genetic testing – what their own results showed, whether these results 
would have any impact on their medical care, and what pre-symptomatic genetic testing 
options were available for their children. 
  
144 
Theme 6: Patients cope with diagnostic information differently, and clinicians may 
modulate how and what they communicate to accommodate patients’ real or perceived 
coping ability 
While most participants were eager to get as much information as possible about 
their disorder, some participants did reflect on how receiving this information could be 
psychologically difficult. Participant 3 discussed how it was difficult for her to adjust to 
having a chronic condition and the lifetime medical care that would entail: 
I had a big psychological problem moving through the whole thing [being 
diagnosed with schwannomatosis]. I’m not sure if other people have to, but I had 
to see a psychologist for a little while because I started gettin’ depressed . . . The 
therapist said that I—now that I knew what my future could possibly look like and 
what was goin’ on, that I was letting go of a future that I had imagined for myself 
before. Because I have pain to deal with and medication and healthcare system, 
all this stuff, that my life is very different from what I imagined it was going to be 
like. I had to let all that go and grieve through that process. And it made complete 
sense then. Then, I understood why I was feelin’ the way I was. I felt a lot better, 
just knowing that.  
 
Because of this experience, the participant suggested that the psychological care be 
integrated into NF specialty clinics, at least as brief check-ins to make sure that patients 
are adequately coping with their diagnosis. 
Beyond needing to adapt to a chronic condition generally, participants also 
highlighted the difficulty of being diagnosed with a rare and incurable disorder.  
Participant 6 noted the difference between being diagnosed with schwannomatosis and 
being diagnosed with a more common, treatable tumor like prostate cancer, saying: 
“The information that was presented [by my neurosurgeon] was, ‘Hey, some 
people have a propensity to get one of these things [(schwannomas)], and we 
know it’s a genetic disorder. We don’t exactly know why, and there is not—the 
number of people affected is pretty small. We don’t have a lot of information’, 
which at the time, was frustrating, because you obviously want to know what’s 
going on with your body, with yourself.  It was a little bit hard in that, when you 
hear that, ‘Okay, you’re a special person that could see many of these things.’ It’s 
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not the greatest feeling in the world, right? If it was something like, ‘Okay, well 
you have prostate cancer, it’s very treatable, here’s the course of action, at the 
end of it, you’re gonna be fine.’ That’s one thing, right? When you hear, ‘Well 
you have schwannomatosis, you have the propensity to have multiple lesions, and 
we don’t really know enough about it, and there is no cure.’ That’s - you know, 
other than surgery - that’s the point where you kind of have to take a step back, 
and think about, ‘Wow, I guess I’m—there is definitely a problem here.’ 
 
 Participant 15 reiterated this point, even going so far as to say that she preferred 
not learning about schwannomatosis until decades after her first symptom (which 
occurred when she was a teenager), at least in part because there are no effective 
treatments: 
“I don’t know how much earlier I’d want this diagnosis. I don’t know if when I 
was playin’ around in my parents’ pool I would have liked to have someone say, 
‘You might have schwannomatosis’ because at that age, I think it might have been 
depressing and overwhelming to know that, unless—I mean, unless it wasn’t an 
orphan disease, there might be a cure. That would be good. To have someone tell 
me, ‘Here’s your diagnosis. This is an orphan disease. No one cares about it. We 
have no cure.’  When I was a teenager, I definitely would not have wanted that. I 
guess, in consideration of when you talk about early diagnoses, I don’t think you 
can separate it from whether you can do something or not about the disease. If 
you can do anything.” 
 
This participant later added that if she had been diagnosed as a teenager, her initial care 
would have been directed by her parents, who could have potentially brought her to “too 
many alarmist doctors” who could have subjected her to unnecessary tumor resection 
surgeries.  Participants with children also struggled with this point, wondering at what 
age it would be appropriate to tell their children about their genetic risk and pre-
symptomatic testing options.  Participant 18 used similar language to participant 15, 
noting that hoped a genetic counselor could give him “strategies for not being an alarmist 
about it, but just being informative and just planting awareness and not fear” when he 
talked to his children. 
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Supportive communication and education from clinicians facilitated participants’ 
psychologic adjustment to their diagnosis, with multiple participants praising their 
clinician’s empathy and understanding (for example, see quotes under theme 5).  
Interestingly, participant 15 described a situation in which her physician (a neurosurgeon) 
was possibly moderating the level of detail he communicated over time in accordance 
with her perceived coping ability/interest in receiving more detail about her condition.   
At the time of their initial meeting, this neurosurgeon educated her about 
schwannomas and introduced the topic of schwannomatosis, but stopped short of 
diagnosing her, saying only that she had “multiple schwannomas”.  After performing 
surgery (her second schwannoma resection), he followed her with serial imaging, first in 
the area of the surgery and then introducing the idea of scanning her neuroaxis to identify 
occult tumors.  After she had her third schwannoma resected, he more concretely 
communicated that she likely had schwannomatosis and suggested she see a specialist at 
a nearby NF clinic for confirmation and to learn about any non-surgical treatment 
options.  Overall, the participant seemed to appreciate this slow progression of 
information, noting: 
“[My neurosurgeon] was amazing. He really was nailing down the diagnosis 
without overstepping. He was clear with me that he was not gonna make that 
[schwannomatosis] diagnosis himself. It was looking like that. He also indicated 
at times, ‘We could find you someone that knows [schwannomatosis]. If you’re 
not ready, you could just come back here for your imaging.”   
 
It is possible that the surgeon did not officially diagnose her with 
schwannomatosis because he felt he lacked sufficient knowledge about the disorder to do 
so or that it wasn’t important for her clinical management.   However, his statement 
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regarding ordering imaging until she was ready to see a specialist indicates at least some 
awareness of the participant’s reluctance to pursue a more formal diagnosis.  In fact, she 
waited another year to make an appointment at the NF clinic, and was not formally 
diagnosed until her 40s, noting at that age,  
“I think you’ve lived enough of life to know that things are going to start getting 
you. It is depressing that there’s nothing you can do about it. You’re more 
prepared for it . . . I’m able to move towards acceptance a little more easily in 
that whole grace and loss process than someone who’s younger, I think.” 
 
Theme 7: Surgeons occupy a distinctive role on the diagnostic team for schwannomatosis 
and their communication may reflect different priorities regarding diagnosis and 
treatment 
 Participant 15 was not the only interviewee who mentioned that their surgeon did 
not immediately (or ever) discuss schwannomatosis with them, or refer them for follow-
up care.  In some cases, this appeared to be due to a lack of knowledge about this 
disorder.  Participant 10 described doing online research after the resection of her second 
schwannoma, and discussing it with her neurosurgeon post-operatively:  
Interviewee:  I asked this [neurosurgeon], “So does this give me the diagnosis of 
schwannomatosis now that I've had two confirmed?” 'cause he didn't until he 
removed it, obviously. His answer to me was, "I don't know. Let me check 
Wikipedia. [laughter] He didn't, at least at that point, didn't really—whether they 
don't really think it's a condition or just—I don't know . . .  
 
Interviewer: Yeah. In fact, so after you brought up schwannomatosis, and he said 
that he would Wikipedia it, did he sort of pursue that at all or at least agree with 
you? 
 
Interviewee: No, not really. No, he was too busy.  I think it was kind of—I got the 
impression it was like, ‘That's just not a big deal.’ It's kind of like, ‘What does it 
matter?’ It's kind of like, ‘Oh, so if you wanna put a name on it, fine, but it doesn't 
matter.’ . . .  You'd think somebody would say, ‘That's interesting. We don't know 
a lot about it. We don't know what the natural course is.’ That's the kind of thing I 
was looking for, somebody to kind of put some seriousness into this about it, and 
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kind of a flippant response, like, I can't waste my time with it. I guess that's kind 
of my impression. No, I didn't think he was very interested, nor did he really care. 
I'm just kind of like, "Well, I looked it up, sounds like that's what I have. I guess I 
just go on and see if I get another [schwannoma]." 
 
Potentially, this idea of “not wasting time” with schwannomatosis could reflect a lack of 
belief in the importance of diagnosing an underlying genetic syndrome (potentially 
because it involves histologically benign, rather than malignant, tumors), or a belief that 
other physicians on the diagnostic team should be responsible for the investigation and 
communication of such a disorder. 
The experience of participant 17 further illuminates this point.  The pathology 
report from this participant’s first schwannoma resection mentioned that particular 
features of the tumor could be indicative of neurofibromatosis 2 or schwannomatosis.  
However, the participant’s neurosurgeon did not discuss these diagnoses with him, even 
after he returned a few years later with two additional suspected schwannomas.  The 
neurosurgeon resected one of these schwannoma, after which the participant did online 
research that led him to believe he might have a form of NF.  He then made an 
appointment at the NF clinic (located at the same hospital as his neurosurgeon), and 
described his next appointment with his neurosurgeon as follows: 
“From the way that [the neurosurgeon] was talking about it, he didn’t feel 
strongly that I needed to go and see Dr. [Smith, NF clinic physician] for some 
reason. . . . He did say good things about Dr. [Smith] – ‘Oh, Dr. [Smith] is a very 
good doctor’ - but there was no, again, emphasis on, ‘Oh, yeah, you might want 
to see him’, or ‘It was definitely a good idea to go and see him because you could 
have schwannomatosis.’ I wish that he could’ve brought that up earlier, referring 
me to the NF clinic based on the results from the first surgery. I’m not saying that 
what he’s— his surgical field is very great, but maybe a more comprehensive 
approach to the whole condition would have been better than just like, ‘Come see 
me when you have pain.’ 
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 Participant 17 comments highlight that surgeons may be focused on their 
immediate role in schwannoma management – that is to say, resection of symptomatic or 
growing tumors - rather than also considering potential underlying causes of tumors or 
non-surgical management issues (such as genetic counseling).  As participant 18 noted 
when asked if his surgeon connected the dots between his two schwannoma surgeries, 
“[The surgeon] was just pretty much focused on what the immediate complaint was and 
resolving it.”   
Whether this particular focus on symptom management is warranted may depend 
on the particular patient, rather than being an inherent property of surgeon’s role on the 
diagnostic team.  While participants 15 and 17 wished their surgeons had taken more of 
interest in schwannomatosis, participant 5 noted specifically that he was not looking for 
more detailed diagnostic communication from his surgeon, at least initially: 
“I'm someone who, when [the surgeon] the first time told me I could play back on 
the ice, that was it. That's all I needed to hear from the guy in the white coat. My 
wife was with me, started asking technical questions from reading WebMD, and 
my view is, I don't wanna know all those specifics, 'cause I’ll then worry about 
what he's doing. I just want to know he said he can put me to sleep, I'll wake up, 
and I'll be able to play hockey. That's all I wanted. I've tried to keep myself above 
a lot of the details 'cause otherwise, I know I'd worry about that.  So if I seem 
vague on certain areas, that was self-preservation.” 
 
This perspective thus ties back to the idea of providers modulating communication in 
accordance with patients’ interest in and ability to cope with additional health 
information. 
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Theme 8: Receiving a diagnostic label of “schwannomatosis” can have positive and 
negative impacts on patients’ lives 
 Multiple participants found the diagnosis of schwannomatosis reassuring and 
even empowering.  These participants described the time before their diagnosis as 
frustrating, scary, and “like you’re in limbo”, whereas after their diagnosis, they felt 
reassured to have an explanation for their symptoms.  Participant 13 described receiving 
genetic testing results that confirmed she and other family members had 
schwannomatosis: 
Interviewer: “How did you feel when you found out from [NF physician] those 
results? Do you think having a name for what was going on helped at all?” 
 
Pt. 13: “Oh yeah, in a weird way, it was a sense of relief that somebody really 
knew what we had, what my uncle and I had. Because I knew I had it in my spine. 
I was getting scared. I was starting to—and I had it in my brain. I was getting 
really scared that I was starting to be taken over by these things. We had a name 
for it. We knew. [The tumors] were benign at least—[NF physician] said they at 
least always benign. It was comforting to a point, and it was just that piece of the 
picture that we never had. It just made us feel better in a weird way . . . It was 
like, oh, somebody—I finally know what's really wrong. 'Cause if you don't really 
know, you get scared.” 
 
Participants appreciated that a diagnosis allowed them to do research on the 
condition, find appropriate specialists, and together make more comprehensive treatment 
plans.  Participants also noted that knowing they had schwannomatosis helped them 
interpret subsequent symptoms as potentially related to new schwannomas, which 
allowed them to seek appropriate workup and treatment.  As participant 2 noted,  
“Now that I know that I’m prone to this, I can mention that to the doc and that’s 
one of the—not the first thing, but if I have a pulled muscle, or a tendon, or 
whatever, if it’s not healing real reasonably, in a normal timeframe, then a little 
bit more quicker to have them look see if there’s a tumor.” 
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However, even those who found the diagnosis mostly reassuring, acknowledged 
how it could also be difficult to find out they had schwannomatosis, which participant 15 
described as follows: 
 
Interviewer: “I guess I have a question for when you finally did start hearing 
about schwannomatosis, even when it wasn’t totally nailed down. Do you think 
that changed things for you at all knowing about the underlying syndrome?” 
 
Pt. 15: “Yes. Both good and bad. I mean, it’s nice to know what you’re up against 
and what you might be dealing with. I find it very empowering to be able to do my 
own research. To ask questions. To consider things. It did make a difference to 
me. Although, even when [surgeon] said, ‘Multiple schwannomas’, that was very 
empowering for me to think ahead. It’s also very scary because you read. Then 
you know. ‘My God, these things could do a lot of damage. I could have a future 
with a lot of pain.’" 
 
Psychological distress around the schwannomatosis diagnosis could come from 
needing to adjust to having a chronic condition that requires ongoing medical care and 
from worrying about developing more tumors or worse pain in the future.  As participant 
4 described,  
“I met with [NF specialist]. He basically said that your body's full of nerves and 
these tumors are attached to the nerves. They could really grow anywhere in your 
body. That kinda freaked me out, cuz every now and then I'll get a little paranoid 
if I get a little lower back tweakness or anything. I'm like, ‘Oh, God, could that be 
another tumor there?’ He kinda, you know, put me at ease a little bit. It's just, it's 
a little troublesome and worrisome, at times that I think about it.” 
 
This distress could be at least partially alleviated with supportive communication from 
NF specialists and if needed, therapists.  Participant 3 in particular noted the utility of 
seeing a therapist to adjust to her diagnosis, as quoted earlier under theme 6. 
 However, not all participants found the diagnosis of schwannomatosis to be 
distressing, or even particularly impactful on their lives.  These participants expressed the 
idea that “everybody has something to deal with in life”, and often contrasted their 
situation to people with cancerous tumors or with other forms of NF, saying that they 
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would be more upset to have those diagnoses.  Some participants mentioned that because 
there was no cure for schwannomatosis or way to prevent new tumors from arising, the 
diagnosis wasn’t particularly helpful.  When asked if anything changed when the NF 
specialist officially diagnosed him with schwannomatosis, participant 16 said, 
“Nope. Not at all . . . People are worse off than me. I just keep on goin’. Nope, 
psychologically, nothin’ really changed. It is what it is, as they say. Nothing I can 
do about it. I can’t change my past life. I can’t change the fact that I seem to be 
the only one in the family growing these. I can’t do anything. Just live with it.” 
 
Participant 16 and others felt that having an official diagnostic label of 
“schwannomatosis” was not any more relevant than the general awareness they already 
had of being prone to developing multiple schwannomas.  As participant 2 stated about 
his diagnostic label, 
“I would almost say it’s almost a trivia. At this point I don't see the value even 
knowing the diagnosis other than the fact that okay—other than the fact to know 
that I’m predisposed to it. I can be a little bit more alert knowing that I'm 
predisposed. But after having about five of them, I probably could’ve figured that 
out myself without the DNA.” 
 
This participant did not see any value in genetic testing to confirm his disorder, 
stating “If it doesn’t lend itself to a prevention or treatment, then like I said, I didn’t see 
the point in the test. It’s great for research . . . but as a patient this doesn’t do me any 
good.”  However, other participants thought genetic testing, or at least the awareness that 
schwannomatosis is a heritable condition, was useful information in thinking about the 
risk to their children and other family members of developing the disorder.  Participant 
13’s symptomatic uncle and asymptomatic brother were both diagnosed with 
schwannomatosis after the family participated in a research study looking for genetic 
markers for schwannomatosis (for which she was the proband).  Multiple participants had 
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genetic testing specifically so that they could offer presymptomatic screening to their 
children, although not all of participants’ family members were interested in pursuing this 
option. 
Theme 9: Information integration is a crucial but difficult step in diagnosing 
schwannomatosis; failures in information integration can lead to diagnostic errors 
Based on participant descriptions of the timing of their symptoms and diagnosis, 
we estimated that the median time from first symptom to diagnosis of schwannomatosis 
in our participant sample was 9.75 years (range, 2 to 45 years).    As the occurrence of 
more than one non-vestibular schwannoma is a required diagnostic criterion of 
schwannomatosis, we also estimated the time between participants’ second schwannoma 
being discovered and their diagnosis of schwannomatosis.  This took a median of 1.875 
years (range, 2 months to 19.5 years.) 
 Multiple participants commented on how providers did not make a connection 
between their multiple nerve sheath tumors and as such, did not realize they had a tumor 
predisposition syndrome.  For these participants, it often took years before someone 
finally “connected the dots” and brought up schwannomatosis as a possible diagnosis.  
Participants attributed providers’ failure to integrate information about their multiple 
tumors to three major categories of problems: failure to perform diagnostic activities, 
errors in diagnostic reasoning, and system-level constraints. 
 Multiple participants noted thorough history-taking as the key diagnostic activity 
that led to their provider to make a working diagnosis of schwannomatosis, or at least 
recognizing that they might have a tumor predisposition syndrome.  Participant 15 
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described it as follows: 
“When [the orthopedic surgeon] did imaging and looked at [my tumor], he took a 
good history. This is my main point. This is the drum that I wanna beat - is that 
history is 99.9 percent of everything doctors do, and of the diagnosis. It wasn’t 
until I saw him that he took an excellent history and started connecting the dots.”   
 
Participants also more generally attributed failure to perform adequate diagnostic 
workup to providers not “taking the initiative”.  As participant 2 said when asked if he 
ever felt like his doctors didn’t know or have all the important information about him and 
his medical history:  
“No, I think they had the information.  I think for them to put together the history, 
the pattern, that would take a little bit of initiative. That’s more of a personal 
initiative that’s on the—professional initiative that the doctor would have to take. 
When I went in for the calf, he didn’t ask, and I had no reason to suspect to even 
offer that there had been other tumors taken  out. He didn’t look at my records 
too—he didn’t know to look at my records. But if he would’ve asked, we may have 
could’ve put two and two together and come to it. But most of them just treated 
the issue that I came in for at that moment. They didn’t really look at the history, 
except  for the one person there a few years ago . . She was the first one that 
actually looked at the  history and said, ‘You’ve had several of these things. Let’s 
look and see if there’s—there’s definitely a pattern. Let’s see if there’s something 
else going on.’”    
 
Conversely, participants appreciated physicians who did display a special interest 
in their case, describing physicians going above and beyond to do research and figure out 
their diagnosis.  When asked if there was anyone or anything particularly helpful in 
getting her diagnosis, participant 1 replied: 
“Having Dr. [Jones, otolaryngologist] be such an involved doctor that it wasn’t 
just, ’Okay. I don't know what’s going on. Let's just watch this. I’ll keep removing 
these bumps for you. Sure, we’ll just do surgery.’ He really just wanted to figure 
this out as well. He really went to bat for me.” 
 
 As both of these participants alluded to, the tendency for HCPs to focus on only 
the immediate problem in front of them (i.e. one specific tumor) could lead to each tumor 
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being treated as an isolated incident, with no one realizing there was an underlying 
genetic cause that also had to be addressed. Participants also speculated that many HCPs 
were unfamiliar with schwannomatosis, and that this lack of knowledge about tumor 
predisposition syndromes in general and schwannomatosis in particular limited their 
diagnostic ability.  As participant 9 noted,  
“The hardest thing was that most of the doctors along the way didn't even know 
what to look for.  They were seeing it, but they didn't know what they were looking 
at. I don't think they're aware of NF1, NF2 or schwannomatosis, or if they are, 
they're aware, but not well-informed. I don't think they know what steps to take to 
see what it is.” 
 
Regarding system-level constraints, participants noted the limited time physicians 
(particularly PCPs) had to spend with each patient.  This time constraints could then lead 
to failure to perform certain diagnostic activities (such as taking a detailed clinical 
history).  As participant 2 described,   
“You go into a general practitioner and you’ve got a 15 minute appointment. 
They’ve got 15 minutes to check your temperature, and pulse, and everything else, 
talk to you and find out what’s going on, and come up with a solution. Most of the 
time, given that constraint, they probably wouldn’t do the effort to look at the 
history.” 
 
Participants also noted a tension between treating specific symptoms and focusing more 
broadly and holistically on an individual’s health, which could be the fault of individual 
providers or related to misaligned incentives regarding health insurance.  As participant 
18 noted,  
“I suppose after the second one, the second tumor, the one on my hip, it should 
have been potentially a red flag to somebody who was thinking more holistically 
and giving care that was more holistic. I’d have to say this was when I had not as 
good health insurance. It was [Company A]. I’d say the quality of the doctor is 
not one that’s, based on this experience I had, somebody who’s interested in 
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really looking deeper into more holistic patterns and just treating the symptoms 
which is—it’s not investing in broader health.” 
 
Theme 10: Diagnostic errors in schwannomatosis can lead to both physical and 
psychosocial harms 
 Thirteen of eighteen participants were potentially misdiagnosed during their 
diagnostic workup for signs and symptoms related to schwannomatosis.  When analyzing 
potential misdiagnoses, we attempted to exclude physicians’ working diagnoses or 
differential diagnoses which were offered as potential explanations of participants’ 
symptoms rather than a more definite diagnosis.  Eleven participants had one or more 
potential misdiagnoses regarding the cause of their pain before a schwannoma: ten were 
potentially misdiagnosed as having a more common musculoskeletal, neuromuscular, or 
orthopedic issues and three were misdiagnosed as having psychosomatic pain or pain 
secondary to anxiety/stress.  Three participants also had the underlying cause of their 
multiple tumors misdiagnosed as NF1, NF2, and lymphoma, respectively. 
 Participants largely recognized the difficulty of ascertaining pain etiology and 
many understood why these misdiagnoses of schwannoma-related pain occurred.  
However, some participants did observe deficits in HCPs’ knowledge and/or reasoning 
skills that contributed to a failure to ascertain the presence of a tumor.  Participant 17 
noted a failure to generate a broad differential diagnosis saying,  
“I think, in this case, the hard thing was that the symptoms mimicked other more 
common injuries and conditions that people have, which made it hard on the part 
of the physicians to accurately diagnosis [sic] or think that there could be 
something else that’s going on.”   
 
Participants also noted the tendency of specialists to focus on only their own medical 
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practice area as a barrier to diagnosis of tumors, with participant 14 remarking,  
“Seeing all those specialists—the urologist, the gynecologist, the gastrointestinal 
person—for all the testing this past year to rule out different things, they only 
knew or were concerned with their area of specialty. I think that’s probably 
common.  They didn’t know what they didn’t know.” 
 
 As discussed earlier under theme 2, misdiagnoses sometimes delayed participants 
from seeking additional care for symptoms, even as these symptoms persisted or 
worsened.   As participant 1 noted regarding her ear pain (later attributed to a 
schwannoma):   
“When the ear pain first started, I mentioned it to . . .  both of [my dentists] on 
different occasions, and they both thought I had TMJ. That that was what was 
causing the ear issue . . . For years, I kind of—and that was part of, here's a big 
piece of the puzzle, too. When I first started getting the ear pain, part of not going 
to an ENT and stuff was because again, I sort of fell on that.  “Okay. It’s just 
TMJ. It’s just TMJ. You gotta put a warm pack on it, not eat foods that are like 
gum.” 
 
Participants who were probably misdiagnosed often received ineffective 
treatments and/or were delayed in receiving more effective care.  Usually, the ineffective 
treatment was not harmful (for example, over the counter pain medications and physical 
therapy), but occasionally included more invasive procedures or surgeries that were likely 
unnecessary.  Participant 15 had three root canals for jaw pain and participant 17 had 
nerve transposition surgery for what was thought to be cubital tunnel syndrome; both 
participants’ symptoms were later found to be related to a schwannoma.   
Participant 11 had three separate surgeries to repair a labral tear of the shoulder 
that was suspected to be causing his shoulder pain; both the orthopedic surgeon who 
performed the third surgery and the patient’s neurologist agreed that this was not actually 
the cause of the patient’s symptoms (which were later attributed to a C4-5 spinal 
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schwannoma).  The same participant also later underwent an aborted resection attempt 
for a mass near his aorta, which he described as follows: 
“I go to the hospital and do the deal, go under. When I wake up in recovery, my 
wife tells me that they didn’t do anything. I have a gash down my neck eight, ten 
inches long with a tube sticking out for drainage and they didn’t take the tumor 
out. The thoracic surgeon came in and said that it—this is quote from him —“It’s 
above my pay grade, so I called Dr. [Jones] who is a neurosurgeon and he looked 
at it and said that it was tumor inside the nerve sheath.” They sewed me back up. 
I stayed the night in the hospital.” 
 
The participant then had surgery two weeks later with that same neurosurgeon to finally 
resect the mass.  This experience was frustrating for the participant, not only due to the 
extra physical pain, but also due to poor communication about what a nerve sheath tumor 
was and how this affected his prognosis.    
In the absence of a schwannomatosis diagnosis, some participants underwent 
extensive medical work-ups, which could be time and resource intensive and involve 
invasive or uncomfortable procedures.  For example, participant 9 described a 9-year 
long journey to diagnose his schwannomatosis-related symptoms, which started with 
stomach pain, and later included leg pain/weakness and arm pain associated with 
palpable masses: 
“I essentially went to my primary care physician and told her I'm having this 
stomach pain. I don't know what's causing it, and she referred me to a GI 
specialist, so I went to him. He tested my stool. Then I did a sonogram. I did 
MRIs. I mean, you name it, I did it. I went to every type of doctor, and now we're 
encompassing years and years now of going to doctors, trying to figure out what 
was wrong.” 
 
This not only delayed the receipt of effective surgical intervention (the removal of 
multiple schwannomas from between his ribs and from his arm), but also had negative 
financial ramifications for the patient, who explained:  
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“To be frank, once I started knowing—once I knew that something serious was 
going on, chronic, I kind of threw my finances to the wind in that sense. I said I 
need to figure this out and I need to—if I have to go into debt to solve this 
problem or mitigate this situation, I will. That's exactly what I've done. I have 
steep medical debt, even though I have insurance, and a pretty good insurance at 
that.” 
 
Theme 11: Patients with schwannomatosis may experience stigma during the diagnosis 
and treatment of their pain 
Like Participant 9, Participant 14 also had a very extensive workup for severe 
back and pelvic pain which was initially non-informative.  Despite having already had 
two peripheral schwannomas resected in the past, none of her treating healthcare 
providers suspected additional schwannomas might be causing her pain.  She saw 
multiple physicians (including her PCP, a gynecologist, a urologist, and a 
gastroenterologist) and received extensive diagnostic testing (including ultrasounds, CT 
scans, and a colonoscopy), without discovery of the true source of her pain, which was 
later found to be multiple large spinal schwannomas.  The lack of findings from this 
workup led to multiple stigmatizing encounters with healthcare professionals, which she 
described as follows: 
“I mean it’s amazing to me—amazing—how stupid some of the doctors were. The 
urologist I went to was a real jerk to me. They all but accuse you or they make 
you—I was meant to feel like I had that Munchausen’s . . . You know where you 
make yourself sick to seek medical attention, to get attention? There was that. 
Then there was the drug seeking accusations. It was really depressing. Then I was 
diagnosed with depression and anxiety, and treated for that.  Nothing made the 
various pains go away.” 
 
As participant 14 and others discussed, not having an explanation for the source 
of their pain could psychological distressing.  This distress could then be further 
complicated if clinicians perceived patients' pain as a psychosomatic complaint stemming 
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from stress, anxiety, or depression, rather than seeing these symptoms as sequelae of 
unexplained and poorly controlled pain.  This could have further downstream negative 
effects, as the patient’s family members, and even the patient themselves, begin to doubt 
the nature of their pain.   As participant 14 explained, “[Schwannomatosis is] invisible, 
so people don’t—I’m glad people can’t see it, but I think it always begs the question like, 
‘Is she faking it?’  I think I’ve been conditioned to second guess myself, cuz so many 
doctors told me that nothing was wrong or I was seeking medicine I didn’t need or 
whatever.” 
 Participants 14 and 15 both felt like they did not receive adequate diagnostic 
workup because of gender stereotypes about women.  Participant 15 describes how she 
felt stereotyped as a “hysterical female” while being worked up for jaw pain: 
“I went to a local neurologist. This was not a good experience. At this point, I 
really felt, ‘Okay, I need a CT Scan or I need an MRI. I need to see what’s going 
on in there’ because the pain was really getting bad. The neurologist said he 
thought that I had stress. I love this - make a note of this. I said, ‘I really love 
what I’m doing. I’m not experiencing stress.’ He said, ‘Well, I think you just 
might not realize it. I think you might have TMJ.’ I said, ‘Well, I spoke to my 
dentist and the guy that did the root canal. They did not feel I had TMJ. I don’t 
think I have TMJ.’ I was willing to give his way a try. He didn’t order any tests. I 
asked him about it. He said, ‘No, let’s just give you’—I forgot what he gave me at 
the time. Not Valium, but something. Some anti-anxiety medication. 
 
I took it and I still had pain, of course. I went back. Actually, I think I decided not 
to go back to him. I went to an ENT. I told him the long, sad story of the root 
canals and the neurologist who insisted that I had anxiety rather than do any 
further testing. He said, ‘Well, let’s get an MRI. Let’s get a CT Scan.’ Voilà, there 
was a schwannoma on my trigeminal nerve behind my cheekbone. I was good and 
angry at this point. I actually called the neurologist and said, ‘The next time a 
woman, a young woman comes into your office and complains about pain, don’t 
let it be the fact that you think it’s a woman under stress and complaining guide 
your diagnosis. Take a good history. Find out other things.’” 
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 Stigma could also affect the diagnostic process when participants with pain were 
accused of drug-seeking behavior.  Multiple participants took care during the interview to 
stress that they weren’t normally the type of person to take medications or to explicitly 
state that they don’t “get a buzz” off their medication, presumably reflecting an 
awareness that others might negatively judge them for their use of pain medications.  
While receiving a schwannomatosis diagnosis could validate participants’ pain 
experience and justify their need for pain medication, this was not always the case.  Even 
after being diagnosed with schwannomatosis, participant 11 felt stigmatized for his use of 
opioid pain medication, describing the behavior of the providers at his pain clinic as 
follows: 
Pt. 11: “I’m not saying they don’t believe that I’ve got issues or pain, but it seems 
like you’re not—I don’t think they believe that you have that kind of pain. They 
make you feel like you’re just trying to get it to get high. That’s the way it makes 
me feel.  
 
Interviewer: “Yeah. Unfortunately, I have heard that from other patients, as well, 
especially I guess—" 
 
Pt. 11: “Yeah. It’s frustrating because they look at you like you’re a criminal or 
treat you like that, at least.”  
 
These interactions had taken place over the prior two years, coinciding with rising 
awareness of the opioid epidemic in the U.S., and show that even with an accurate 
diagnosis, patients may be stigmatized due to larger contextual factors. 
Discussion  
In this study, we interviewed 18 people with schwannomatosis to explore their 
ability and willingness to engage in care, the quality of their diagnostic communication, 
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and the timeliness and accuracy of their diagnoses.  Initially, both participants and 
providers ascribed schwannomatosis symptoms to more common conditions.  
Participants’ online research and healthcare providers who took a detailed clinical history 
and connected the dots between participants’ tumors were central in finally determining 
the participants’ schwannomatosis diagnoses.  Healthcare providers’ communication 
about tumor predisposition syndromes varied in quality; most participants desired more 
information about schwannomatosis and similar disorders during the diagnostic process, 
particularly surrounding genetic issues.  While being diagnosed with an incurable, rare 
disease could be distressing and require time for psychological adjustment, receiving a 
schwannomatosis diagnosis and being seen by a supportive, knowledgeable specialist 
also had multiple positive impacts, including feelings of reassurance and empowerment, 
an improved ability to interpret symptoms, and diagnosis of other affected family 
members.  However, diagnostic delay and misdiagnosis were common, and could result 
in a myriad of negative consequences including unnecessary surgery, delayed receipt of 
effective pain management, psychological distress and stigmatization.   
Factors Contributing to Diagnostic Quality 
 Throughout our analysis, we identified several contributing factors that affected 
participants’ willingness and ability to engage in care, clinicians’ diagnostic performance, 
and the quality of participants’ diagnostic experience.  To facilitate synthesis of these 
factors across themes, we have summarized them in Table 4.5, separating them into 
disease, patient, provider, and system level as per our conceptual framework. 
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Table 4.5 Factors Affecting Diagnostic Process Quality 
Disease-Level Factors  
Frequency of Symptoms (Constant vs. Intermittent) 
Symptom Severity and Impact of Symptoms on Daily Living 
Disease Inheritance (Sporadic vs. Familial Disease) 
Patient-Level Factors 
Health Literacy and Education 
Personality, Outlook on Life, and Psychological Coping Skills 
Competing Priorities Including Financial and Time Constraints 
Material and Emotional Support from Family and Friends 
Provider-Level Factors 
Clinical Knowledge 
Cognitive Reasoning Skills 
Communication Style 
Ability and Motivation to Go Above and Beyond 
System-Level Factors 
Availability of Health Insurance and Cost of Health Services 
Accessibility of Healthcare Services  
Time Constraints on Physicians 
 
Disease Factors 
At the disease level, symptom frequency and severity primarily affected when 
participants sought care and the treatments they choose to undergo, such that patients 
with intermittent and less severe symptoms were less likely to seek care or pursue 
treatment options (Theme 2).  We did not find that patients with a family history of 
schwannomatosis tended to seek care and obtain appointments at NF clinics faster.  
Presumably, this is because all three participants interviewed in this study with a family 
history of schwannomatosis were either the first in their family to be diagnosed or were 
unaware of their family history until after their diagnosis.  However, disease inheritance 
was still supported as a contributing factor, because a family history of schwannomas 
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served as a diagnostic clue during clinicians’ information gathering activities, facilitating 
physician’s ability to diagnose patients accurately. 
Patient Factors 
Health literacy, education, and prior familiarity with the medical system were 
intertwining factors affecting participants’ symptom appraisal, help-seeking, and 
communication with healthcare professionals (Themes 3 and 5).  Many participants in 
our study did their own research to understand the etiology of their symptoms, get more 
information about their disorder, and identify appropriate specialists with who to consult 
(Themes 4 and 5).  In this way, they demonstrated communicative health literacy (the 
cognitive and social skills that enable a person to locate and discuss health information) 
and critical health literacy (the ability to evaluate health information for accuracy and 
relevance in order to make informed decisions) (Nutbeam, 2000). Previous research has 
shown that communicative and critical health literary are important for self-management 
of chronic disease (Heijmans, 2015).  Our research now further suggests that these skills 
are important for diagnosis, particularly in rare diseases where many non-specialist 
clinicians may not have extensive knowledge about the disorder and patients need to seek 
out additional resources on their own.  Indeed, participants in our study noted that 
increasing the visibility and quality comprehensiveness of online materials about 
schwannomatosis (and other rare diseases) would help affected individuals better 
understand their disorder and connect with appropriate specialists.   
Participants’ psychological characteristics also played a role in symptom appraisal 
and communication with healthcare professionals.  Participants’ personality, 
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philosophical outlook on life, and resiliency particularly affected how they reacted to 
self-identified ‘negative’ events, such as physical pain, distressing diagnostic 
information, recovery after surgery, and even the diagnosis of schwannomatosis itself 
(Themes 2, 6 and 8).   Participants who were less distressed during the diagnostic process 
ascribed their physical ability to cope with symptoms and mental ability to cope with 
diagnostic information to things like having a “Type B personality”, not being “the kind 
of person who worries a lot” and believing that “everyone has their own problems to deal 
with.”  This is consistent with evidence that personality traits can affect coping skills and 
thus psychological distress (Carver and Connor-Smith, 2010; Panayiotou et al., 2014). 
Finally, participants’ social and economic context also played an important role in 
care-seeking behaviors, affecting participants’ ability to access and pay for care (Themes 
2 and 3).  Participants’ family and friends affected when and from whom participants 
sought care; participants’ ability to engage in recommended care; and how well 
participants coped with diagnostic information.  Social support needs interacted with 
patients’ socioeconomic status, in that patients with fewer financial resources relied more 
on social support.  Participants’ financial situation and health insurance coverage affected 
care-seeking choices by modifying the relative affordability of health services; direct, 
indirect and opportunity costs of care-seeking all impacted how affordable care was 
(Levesque et al., 2013).  Of note, some participants choose to forgo care entirely when 
out of pocket costs exceeded their available resources, while others continued seeking 
care but went into debt.  Similarly, participants weighed the time required to engage in 
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healthcare activities against time needed for work or family responsibilities, leading some 
participants to postpone seeking care. 
Provider Factors  
At the provider level, basic clinical knowledge of schwannomatosis and similar 
disorders was the most obvious factor facilitating diagnosis (Themes 9 and 10).  
Information integration and interpretation was key to arriving at a schwannomatosis 
diagnosis, both in connecting participants’ disparate symptoms to an underlying tumor 
and connecting participants’ multiple tumors to an underlying genetic predisposition 
syndrome.  The extent to which physicians’ cognitive reasoning skills affect diagnostic 
performance has been described extensively in the literature, particularly as it relates to 
Type 1 (intuitive) and Type 2 (analytical) thinking (Croskerry, 2009; Norman et al., 
2017).  Cognitive debiasing strategies and real-time decision support may improve 
physicians’ diagnostic reasoning skills as they relate to information interpretation and 
integration, although more real-world testing of many of these interventions is still 
necessary (Croskerry et al., 2013; Graber et al., 2012; Lambe et al., 2016; Ludolph and 
Schulz, 2018).   
Physicians’ communication style strongly affected participants’ diagnostic 
experiences, primarily affecting how well they understood their diagnosis and how much 
psychological distress they experienced during the diagnostic process (Themes 5, 6, and 
8).   Communication style encompassed techniques for discussing and framing medical 
information as well as the ability to establish social and emotional rapport with patients, 
both of which are important factors in patient-centered communication (Mazor et al., 
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2013).  Finally, physicians’ ability and desire to go above and beyond for patients (often 
by devoting extra time outside appointments to do further research or coordinate care) 
also affected participants’ diagnostic experience, both by facilitating timely diagnosis and 
increasing personal rapport (Theme 9).   
Healthcare System Factors 
At the system level, geographical, temporal, and financial barriers (detailed in 
Themes 2 and 3) affected participants’ real and perceived access to care (Fortney et al., 
2011).   Out of pocket healthcare costs, largely driven by health insurance availability and 
benefit design, affected participants’ decisions on what diagnostic workup to pursue (if 
any) and what providers to seek care with.  Insurance-related administrative barriers, 
including the need to obtain prior authorizations for care or appeal unfavorable coverage 
decisions, could delay receipt of diagnostic tests or treatments.  The accessibility of 
healthcare services, including wait times for appointments and ability to travel to 
specialty tertiary care centers, also affected when and with whom participants received 
diagnostic care.   
Systems level factors also affected the quality of care participants received after 
accessing care; participants particularly lamented the limited time spent with providers 
during appointments (Theme 9).  Participants posited that less face-to-face appointment 
time negatively affected HCPs’ ability to determine a diagnosis (because providers did 
not have enough time to gather diagnostic information) and adequately communicate that 
diagnosis to the patient.  Time pressure might also negatively affect diagnosis in other 
ways not observable to the participants; a study of medical residents showed those under 
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time pressure generated shorter differential diagnoses and had less accurate diagnoses 
(AlQahtani et al., 2018). And particularly in primary care, short appointment slots 
coupled with relatively poor reimbursement of care coordination activities may contribute 
to patients not having a diagnostic ‘quarterback’ for their care.  A tendency for providers 
to focus only on the portion of the patient’s health problems that seemed relevant to their 
own specialty could compound this problem, making it less likely that someone would 
connect participants’ multiple tumors to an underlying genetic syndrome (Scott and 
Campbell, 2018). 
Additional Considerations Regarding Our Conceptual Framework  
Beyond identifying the specific contributing factors that can affect diagnostic 
performance in rare, genetic diseases, our analysis and results may also be informative 
for researchers studying diagnostic error across other disease contexts.  We analyzed 
interviews using a grounded thematic approach, in which all codes were emergent from 
the data rather than predetermined by our conceptual framework.  However, the emergent 
codes largely could be mapped to domains of our conceptual framework, suggesting the 
utility of this framework in understanding the diagnostic process.  We arranged our 
codebook to map each code to the conceptual domain with which it was most frequently 
associated (Appendix C2); practically, however, codes could span more than one domain.  
For instance, while “alternate explanation of symptoms” largely explored clinicians’ 
working diagnoses/misdiagnoses after the patient engaged in care, it could also apply to 
patients’ interpretations of their own symptoms during the appraisal interval.  
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 Appraisal and Help-Seeking Intervals 
Mapping our coding schema in this way helped illuminate several interesting 
nuances in our conceptual framework that may be useful to other researchers employing 
the NAM framework.  In the NAM report, comparatively little attention was paid to the 
initial stages of the framework, wherein patients experience a health problem and decide 
to engage with the healthcare system, perhaps because these areas were considered to be 
largely outside the realm of clinician influence and thus less amenable to process 
improvement.  However, for researchers interested in these areas, our analysis of push 
and pull factors influencing participants’ intentions to seek care and ability to access care 
(in themes 2 and 3) largely supports the distinction made by Walter et al. (2013) between 
appraisal and help-seeking intervals.  However, in some cases, these factors did blur 
together, such as when a person assumes that barriers to receiving care will be 
insurmountable and so indefinitely postpones seeking care.   For example, participant 
16’s lack of health insurance and limited financial situation led him to not seek any care 
for years because he expected he would not be able to afford it.     
Diagnostic Team 
When initially describing their conceptual framework, the NAM committee noted 
that the question of “Has sufficient information been collected?” applies to all diagnostic 
team members, but limited discussion of this domain to clinicians’ determinations of 
whether a patient’s diagnosis is sufficiently certain to enable optimal care management 
(NAM, 2015).  Our research highlights that this domain is also highly relevant for 
  
170 
patients, as we observed participants actively considering this same question as they 
chose whether or not to pursue additional testing or seek additional medical opinions 
(Themes 2, 3, and 8).  Participants’ choices strongly interacted with patient level factors 
such as financial resources and time constraints that affected the relative value of 
additional diagnostic testing.  For example, whether participants chose to verify their 
diagnosis via genetic testing was affected by out of pocket costs and the perceived utility 
of results for their own medical care or the care of their family members.  This reinforces 
the idea that patients are critical members of the diagnostic team, and their preferences 
and perceptions impact the functioning of the diagnostic process at all stages (McDonald 
et al., 2013; Berger et al., 2017) 
In addition, further investigation into the role of surgeons on the diagnostic team 
is needed to explore how surgeons conceptualize their diagnostic responsibilities.  
Multiple participants in our study noted inadequate communication regarding tumor 
predisposition syndromes in general and schwannomatosis specifically from surgeons 
(Themes 5 and 7).  Without speaking with surgeons directly, it is impossible to know 
how much of this communication problem stems from providers’ lack of knowledge 
about tumor predisposition syndromes, a belief that evaluation for these syndromes is not 
urgent or clinically beneficial, or a belief that such evaluation should be carried out by 
other healthcare professionals.  Future research should explore how physicians and other 
healthcare professionals conceptualize their roles on the diagnostic team and the 
mechanisms by which diagnostic responsibilities can be effectively shared (Graber et al., 
2017).  
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Communication of the Diagnosis 
Our conceptual framework focuses on clear communication between patients and 
providers that evolves over time as differential diagnoses are generated and working 
diagnoses refined (NAM, 2015).  However, less attention has been paid to the potential 
evolving nature of communication about a patient’s correct, final diagnosis.  Indeed, in 
our medical record review in chapter 2 of this dissertation, and in other research projects 
that attempt to concretely measure time intervals, communication of a final diagnosis is 
treated as a one-time event.  However, our interviews (through Themes 6 and 7) 
demonstrate that diagnostic information is sometimes communicated in stages, in 
accordance with patients’ real or perceived ability to cope with the information provided.   
Diagnostic and prognostic communication has been considered extensively in 
cancer and end-of-life care, where clinicians must balance maintaining hope with 
achieving accurate prognostic awareness (Jacobsen and Jackson, 2009; Step and Ray, 
2011; Mendick et al., 2013).  However, this nuance has received less attention in the 
study of diagnostic delay, which usually regards shorter diagnostic intervals as the most 
desirable outcome (and thus by default privileges earlier diagnostic communication).  
Importantly, the recognition that providing sequentially more detailed information about 
a diagnosis may be easier for some patients does not imply that purposefully withholding 
information is preferable; individually tailored communication strategies are necessary 
(Davies and Higginson, 2003).  Providing relevant education about the diagnosed 
disorder, in tandem with emotional support and referrals for professional psychological 
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care as needed, can drastically improve patients’ communication experience (Carillo et 
al., 2018).  
Our results also highlight an important communication gap in the diagnostic team, 
which genetic testing laboratories and genetic counselors are uniquely poised to fill.  
Many participants in our study were unsure about genetic issues related to their diagnosis, 
ranging from simple questions as to whether schwannomatosis could be inherited to more 
complex questions surrounding the interpretation of their genetic testing results (Theme 
5).  Confusion about genetic terminology is common in the general public (Lea et al., 
2011), and patients with a variety of genetic disease have reported inadequate 
communication of genetic information.  For example, in a 2004 survey of European rare 
disease patients and caregivers, 25% reported that the genetic nature of their disease was 
not initially communicated adequately to them (EURORDIS, 2009) and in a 2014 survey 
of Australian adults with rare disease, 50% of patients reported not understanding all of 
the medical and genetic information given to them about their disease (Molster et al., 
2016).   
 For genetic diseases, and especially those like schwannomatosis, for which 
scientific understanding of the genetic causes of the disease are still evolving (Hulsebos 
et al., 2007; Sestini et al., 2008; Piotrowski et al., 2014), an increased focus on genetic 
counseling seems warranted.  Genetic counselors may be more likely to have the skills 
and time to adequately communicate genetic information.  For example, a survey of 
Australian rare disease patients observed the patients who saw a genetic counselor at the 
time of diagnosis were more likely to report receiving enough information about their 
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diagnosis than patients who saw only a general practitioner or specialist physician 
(Molster et al., 2016).    Mechanisms should also be in place to update patients about new 
genetic testing options as they are developed, particularly for those patients who do not 
have routine follow-up in a specialty clinic.  This is critical not only for patients’ ability 
to understand their own diagnoses, but also to enable potential diagnosis of other affected 
family members and give patients’ access to reproductive options (such as 
preimplantation genetic diagnosis) that can limit their risk of passing on the disorder to 
future children.   
Diagnostic Outcomes 
Finally, our conceptual framework encompasses both patient-level diagnostic 
outcomes and the systems-level effect of diagnostic performance on quality, safety, and 
costs of care.  At the patient-level, much of the diagnostic error literature focuses on 
direct physical harms to patients.  However, our results (in Themes 8, 10 and 11) 
emphasize that a wide array of positive and negative psychological effects (such as 
distress, stigma, reassurance, and trust) should also be considered when assessing 
diagnostic quality.  At the systems-level, a dual focus on identifying diagnostic errors and 
learning from accurate and timely diagnoses is needed to successfully improve diagnostic 
quality, safety, and cost (NAM, 2015).  Our study attempts to provide this dual focus by 
exploring not only negative diagnostic experiences, but also factors that promote care-
seeking and receipt of a timely diagnosis; communication styles that enhance patient 
understanding and coping skills; and the positive impacts receiving a diagnosis can have 
on patients.  Our findings support the need for new research paradigms that focus on 
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holistically improving diagnostic performance and efficiency, rather than simply 
correcting diagnostic error (Schiff, 2010; Newman-Toker et al., 2013). 
Study Limitations 
Our research findings should be considered with some limitations in mind.  Some 
participants discussed events happening many years in the past, leading to potential 
concerns about recall bias in our data.  Patients may not have accurately remembered the 
exact timing of events in the diagnostic process, all of the providers with whom they 
consulted, or all of the information that clinicians provided at that time.  However, even 
with imperfect recall, our qualitative analysis still validly explores how patients 
understand and derive meaning from their diagnostic experience and contextualizes the 
schwannomatosis diagnostic intervals and errors documented more precisely in Chapter 2 
of this dissertation.  Our assessment of potential diagnostic errors is limited by lack of 
corroborating clinical documentation and input from the physicians involved, and should 
not be used to ascribe fault to any individual physician.  Finally, following the principles 
of grounded thematic analysis, we attempted to create a fully inductive coding schema.  
However, we acknowledge that our a priori familiarity with our conceptual framework 
may have subtly influenced our coding choices.  We attempted to limit this bias by 
having two independent coders review each transcript. 
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Conclusions 
Despite these limitations, our study is the first to interview people with 
schwannomatosis about their care, and provides an important window into the diagnostic 
process for rare, genetic diseases.  Interviewing people with other rare, genetic diseases to 
look for common roadblocks in the diagnostic process would be especially helpful in the 
future to design larger scale interventions that can improve diagnosis across a variety of 
diseases.  Possible interventions of this type could include expanding diagnostic 
resources for patients and involving them more in the diagnostic team (McDonald et al., 
2013; Berger et al., 2017); cognitive reasoning and communication training for clinicians 
(Dwamena et al., 2012; Croskerry et al., 2013); better deployment of health information 
technology (Singh et al., 2008; Schiff and Bates, 2010); and advocacy for system-levels 
healthcare financing and organization reform (Singh et al., 2017).  Utilizing a broad, 
disease agnostic conceptual framework such as that proposed by the NAM (2015) can 
guide implementation and assessment of these interventions, with the ultimate goal of 
improving health outcomes for all patients with rare and genetic diseases. 
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CHAPTER 5: CONCLUDING REMARKS 
Research Summary 
 In the research presented in this dissertation, we examined the diagnostic process 
for the rare, genetic disease of schwannomatosis (abbreviated as SWN for brevity in this 
chapter).  Guided by the National Academy of Medicine (NAM) (2015) model of the 
diagnostic process (supplemented with components from Walter et al.’s (2012) Model of 
Pathways to Treatment), we designed three studies to determine the prevalence, causes 
and ramifications of diagnostic error in schwannomatosis.  We specifically sought to 
assess how well the diagnostic process currently functions for SWN patients; identify 
specific failures in the diagnostic process and any contributing factors to poor diagnostic 
performance; and explore the impact of the diagnostic process (and diagnostic errors) on 
patients’ lives.  To achieve these aims, we used a convergent mixed-methods design that 
combined data from the medical records of SWN patients seen at two large specialty 
clinics with analysis of interviews conducted with SWN patients from across the United 
States.  This unique approach allowed us to examine dimensions of the SWN diagnostic 
process not observable from either data source alone and triangulate our findings across 
quantitative and qualitative analyses (Creswell and Miller, 2000).   
Across all three studies, we found that the current diagnostic process for 
schwannomatosis is inadequate for a large proportion of patients (Table 5.1).  Results 
from these studies 1) emphasize a need for greater accuracy and timeliness in the SWN 
diagnostic process (Study 1); 2) highlight the range of diagnostic process failure types 
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that lead suboptimal diagnostic outcomes (Study 2); and 3) show how diagnostic process 
failures take a significant toll on patients’ lives (Study 3).   
Table 5.1 Summary of Dissertation Research 
Study 1: Assessing the Accuracy and Timeliness of the SWN Diagnostic Process 
Research Question: How well does the diagnostic process function for patients with 
probable or confirmed SWN eventually seen at specialized tertiary care clinics? 
Methods: Retrospective review of medical records for 97 SWN patients seen at 
Massachusetts General Hospital (MGH) and Johns Hopkins (JH) 
Aim 1: To quantify the 
length of each stage of the 
SWN diagnostic process 
• Median total time to diagnosis (via survival analysis) 
in all 97 patients was 11.5 years (95% CI, 8.4 – 18.9 
years) 
• Median total time to diagnosis communicated (in 60 
patients with a confirmed SWN diagnosis 
communicated) was 7.9 years  
• Median duration of initial appraisal and help-seeking 
was 91 days; median duration in primary/secondary 
care prior to NF clinic referral was 4.0 years 
Aim 2: To determine the rate 
and types of inaccurate 
diagnoses of SWN-related 
signs and symptoms 
• 36.1% of patients had at least one misdiagnosis: 
18.6% had their genetic condition misdiagnosed as 
NF1 or NF2, 16.5% had their pain etiology 
misdiagnosed, 11.3% had tumor imaging or 
pathology misinterpreted 
• 19.6% of patients had an incomplete diagnosis due to 
physician or system error (i.e. patient had multiple 
schwannomas, at least one path-proven, but received 
no workup or referral for possible underlying genetic 
disease) 
Aim 3: To assess why 
patients with probable SWN 
do not receive a confirmed 
diagnosis 
• 34.0% of patients did not have a confirmed diagnosis 
• Of these patients, 66.7% lacked IAC brain MRIs, 
42.5% lack pathological confirmation of 
schwannoma, and 6.1% lacked clear imaging 
evidence of a second schwannoma 
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Study 2: Identifying Failures in the SWN Diagnostic Process 
Research Question: What failures occur during the SWN diagnostic process and what 
affect do they have on diagnostic outcomes? 
Methods: Directed content analysis of narrative summaries of the diagnostic journey, 
created from the medical records of 52 SWN patients seen at MGH and JH 
Aim 1: To develop a unified 
taxonomy of diagnostic 
process failures based on the 
NAM model and use it to 
identify failures in the SWN 
diagnostic process 
• Taxonomy of 21 failure types across five domains is 
presented in Table 3.1 
•  94.2% of patients had at least one diagnostic process 
failure, with a median of 3 unique failures per person 
• Failures in information gathering, largely related to 
diagnostic testing and clinical history/interview, were 
observed most commonly 
Aim 2: To assess how 
diagnostic process failures 
affect the timeliness, 
accuracy and 
communication of SWN 
diagnosis 
• 67.2% of diagnostic process failures negatively 
impacted SWN diagnosis 
o 11.9% of failures led to misdiagnoses or 
inappropriate working diagnoses 
o 45.2% of failures delayed diagnostic workup (by a 
median of 11 months each) 
o 16.9% of failures led to delayed, failed, or 
inadequate communication of the diagnosis 
Aim 3: To preliminarily 
identify contributing factors 
that may promote the 
occurrence of diagnostic 
failures in SWN 
• Low symptom severity or frequency, patients’ health 
perceptions, competing priorities for patients’ time, 
and healthcare costs and inaccessibility impeded 
patient engagement in health care 
• Atypical disease presentation and patient 
comorbidities challenged clinician’s information 
interpretation 
• Poor information transfer across institutions inhibited 
information gathering 
• Lack of awareness of SWN among clinicians 
impaired information gathering, interpretation, and 
integration 
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Study 3: Understanding the Patient Experience of the SWN Diagnostic Process 
Research Question: What is the SWN diagnostic process like from patients’ 
perspective? 
Methods: Grounded thematic analysis of semi-structured interviews with 18 patients 
from the International Schwannomatosis Database 
Aim 1: To understand how 
SWN patients appraise their 
symptoms and seek health 
care 
• Patients’ first SWN symptom is often pain, which is 
difficult for both patients and clinicians to assess 
• Disease-related and personal characteristics can push 
or pull people to/from seeking medical care 
• External barriers and facilitators affect whether and 
when people receive care 
• Referrals from clinicians and patients’ own online 
research are key in connecting patients to dedicated 
NF clinics 
Aim 2: To understand how 
the diagnosis of SWN is 
communicated throughout 
the diagnostic process 
• Diagnostic communication encompasses educational/ 
informational and social/emotional components 
• Patients cope with diagnostic information differently; 
clinicians modulate how and what they communicate 
to accommodate patients’ real or perceived coping 
ability 
• Surgeons occupy a distinctive role on the SWN 
diagnostic team; their communication may reflect 
different priorities regarding diagnosis and treatment 
Aim 3: To understand the 
impact of a SWN diagnosis 
on patients’ lives, including 
the impact of diagnostic 
errors and prolonged 
diagnostic intervals 
• Receiving a diagnostic label of “schwannomatosis” 
can have positive and negative impacts on patients’ 
lives 
• Diagnostic errors can have both physical and 
psychosocial harms 
• Additionally, patients may experience stigma during 
the diagnosis and treatment of their SWN-related pain 
Table Legend: IAC –internal auditory canals; JH – Johns Hopkins; MGH – Massachusetts 
General Hospital; NF – neurofibromatoses; NF1 – neurofibromatosis type 1; NF2 – 
neurofibromatosis type 2; SWN – schwannomatosis 
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Across all three studies, we also examined contributing factors at the disease, 
patient, provider, and healthcare system level that may affect diagnostic performance.  In 
Figure 5.1, we present our conceptual framework, with a summary of the contributing 
factors we identified in quantitative or qualitative analyses as affecting the quality of the 
depicted components of the schwannomatosis diagnostic process.  
Figure 5.1 Conceptual framework of the diagnostic process with factors contributing to 
diagnostic performance in schwannomatosis 
 
We found several factors that affected patients’ symptom appraisal and help-
seeking behaviors.  At the disease level, these were symptom specificity (i.e. the degree 
to which a sign/symptom reliably indicated the underlying disease process of nerve 
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sheath tumor), symptom frequency, and symptom severity.  At the patient level, these 
were patients’ personality types, psychological coping skills, health beliefs, health 
literacy, and education.  External factors at the personal level (such as competing 
priorities for patients’ time and patients’ social support network) and more macro-level 
(such as geographical, temporal, and financial accessibility of healthcare services) also 
affected participants’ ability to engage in the healthcare system.   
We also observed factors that affected other stages of the diagnostic process. 
Problems with information transfer between institutions and time constraints on clinicians 
negatively affected clinicians’ ability to gather information.  Clinicians’ specific clinical 
knowledge about schwannomatosis and more general cognitive reasoning skills affected 
their ability to successfully interpret and integrate diagnostic information.  Information 
interpretation and integration was also more challenging for patients with atypical disease 
presentations or pain-causing comorbidities, younger patients, and patients without any 
other family members with schwannomatosis.  Finally, patients’ psychological 
characteristics and clinicians’ communication styles affected how well patients 
understood their diagnosis and how much psychological distress they experienced during 
the diagnostic process. 
   
Benefit of Mixed Methods Approach to Understanding the Diagnostic Process  
Using a mixed-methods approach that combined quantitative and qualitative 
analysis of medical record data with qualitative analysis of patient interviews allowed us 
unique insight into the schwannomatosis diagnostic process.  We used a convergent 
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mixed-methods design, in which all three studies were conducted in parallel.  This 
allowed us to integrate the data collection and analysis across studies and triangulate 
emerging findings (Creswell and Morgan, 2000; Fetters, Curry and Creswell, 2013).  For 
example, after analysis of interviews in study three revealed that some patients delayed 
seeking care when they had intermittent symptoms, we added symptom frequency to the 
data abstraction spreadsheet used in study one.  Similarly, after noticing in interviews the 
different diagnostic experiences of patients who presented with a single, peripheral 
schwannoma versus those who had multiple spinal schwannomas discovered 
simultaneously, we added the number of tumors identified on patients’ initial imaging as 
a data field for study one.  Both of these factors (presenting symptom frequency and 
initial imaging presentation) were then validated in study one as statistically significant 
predictors of patients’ total time from first symptom to communication of diagnosis. 
Information from the medical records also influenced data collection and analysis 
of patient interviews.  In a preliminary analysis of diagnostic process failures in the 
medical record (which inspired the design of study two), we saw that lack of information 
sharing between healthcare institutions was a recurring problem.  For this reason, we 
added a probe to our interview guide in study three that specifically asked if participants 
ever felt like their doctors didn’t know or didn’t have all their important medical 
information.  As explored in theme nine of study three, participants noted that inadequate 
history-taking resulted in doctors not having all the relevant information about their 
condition; this finding was replicated in study two, in which 16.3% of all identified 
diagnostic process failures were failures in information gathering during the clinical 
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history/interview.  As an additional example, we observed in study one that patients 
frequently consulted surgeons for initial care but were not always referred by these same 
surgeons to dedicated NF clinics.  This led us to take a closer look at patients’ 
interactions with surgeons in our patient interview data, which led to the development of 
theme seven in study three, regarding the distinctive role of surgeons on the diagnostic 
team and their potentially unique priorities regarding the timing and content of diagnostic 
communication. 
Using two different data sources also helped us corroborate and expand our 
findings regarding contributing factors to diagnostic performance.  For example, 
participants in study three believed that clinician’s cognitive reasoning skills (particularly 
surrounding information interpretation and integration) were key to arriving at a 
schwannomatosis diagnosis, both in connecting participants’ disparate symptoms to an 
underlying tumor and connecting participants’ multiple tumors to an underlying genetic 
predisposition syndrome.  Study two verified that failures in information integration were 
indeed a common source of negative diagnostic impact.  Studies one and two also 
extended our understanding of how cognitive reasoning skills could affect diagnosis, by 
demonstrating how expert NF clinicians reasoned to determine acceptable levels of 
diagnostic uncertainty and assess when departures from standard diagnostic assessment 
would be beneficial to patients. 
Similarly, our mixed methods research approach highlighted how and why 
contributing factors can affect multiple domains of the diagnostic process.  All three 
studies identified health insurance and the cost of health care as a potential barrier to 
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timely diagnosis of schwannomatosis, which affected patients’ initial presentation to care, 
ability to receive diagnostic testing (including MRIs and genetic testing), and treatment 
decision-making.  In particular, patient interviews in study three revealed how out of 
pocket healthcare costs affected participants’ decisions on what diagnostic workup to 
pursue (if any) and which providers to seek care with.  This suggests that at least a 
portion of the diagnostic delay seen in schwannomatosis may be ameliorated by changes 
to healthcare financing.  
Implications of Dissertations Research 
This dissertation research was performed with the aim of identifying facilitators 
and barriers to early, accurate diagnosis of schwannomatosis, so that we may assist in 
prioritizing interventions to improve future patients’ diagnostic experiences.  We also 
hoped to illuminate diagnostic problems common to other rare and genetic diseases, and 
offer comments on the utility of the NAM’s conceptual model of the diagnostic process 
in guiding empirical research.  In the remainder of this section, we reflect on how our 
findings inform each of these three goals. 
Recommendations to Improve the Schwannomatosis Diagnostic Process 
 Diagnostic error is common across diseases, but multiple features of 
schwannomatosis make diagnosis especially challenging.  For instance, the rarity (Evans 
et al., 2018) and relatively new discovery of schwannomatosis as a distinct disease entity 
(Purcell and Dixon, 1989; MacCollin et al., 1996) means that many clinicians are likely 
unaware this disorder exists (Koontz et al., 2013).   Knowledge of the clinical and genetic 
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features of schwannomatosis is rapidly evolving (Hulsebos et al., 2007; Smith et al., 
2012; Piotrowski et al., 2014; Smith, 2015), and concomitant changes have been made in 
schwannomatosis diagnostic criteria over the past two decades (Jacoby et al., 1997; 
MacCollin et al., 2005; Baser et al., 2006; Plotkin et al., 2013).  Providers may thus be 
unaware of the current standards for diagnostic ascertainment, newly available genetic 
testing options, and the full spectrum of symptoms that may indicate a person has 
schwannomatosis.  Finally, even when patients are evaluated by expert NF clinicians, 
phenotypic overlap with other neurogenetic disorders can make diagnoses uncertain 
(Kehrer-Sawatzki et al., 2018).  Given these many diagnostic complexities, a multi-
faceted approach to improving schwannomatosis diagnosis is necessary.  
Increasing Awareness of NF and Schwannomatosis 
Lack of awareness among healthcare providers about schwannomatosis 
specifically, and the differences between the three forms of NF more generally, was a 
common barrier to accurate diagnosis.  Given how rare the occurrence of multiple nerve 
sheath tumors would be in the absence of a genetic disorder, discovery of two or more 
schwannomas in a patient should serve as a trigger symptom to initiate further 
neurogenetic workup or consultation.  However, one-fifth of patients in study one had an 
incomplete diagnosis due to physician or system error, in which no diagnostic workup or 
referral for NF2/SWN was requested in a patient with a pathologically proven 
schwannoma and at least one other potential nerve sheath tumor on imaging.  While 
occasionally this could be explained by problems in information transfer between 
institutions, in at least two-thirds of cases, the error was likely due to physicians’ lack of 
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knowledge about NF2/SWN.  This knowledge gap represents a clear target for 
intervention, which has the potential to substantially reduce patients’ overall time to 
diagnosis.  For example, in study three, we estimated that interview participants had a 
median delay of 1.9 years between the time they had two or more schwannomas 
discovered (including one that was pathologically proven) and the time they received a 
diagnosis of schwannomatosis.  Interventions that encourage physicians to consider a 
diagnosis of schwannomatosis earlier in the diagnostic process (such as the electronic 
medical record interventions discussed later in this chapter) could significantly reduce 
this portion of the diagnostic interval.  
Earlier referrals for NF/SWN workup 
  Ensuring prompt investigation into underlying genetic disorders in patients with 
multiple nerve sheath tumors is particularly relevant for surgeons.  Only one 
pathologically proven schwannoma is required for a SWN diagnosis; however, many 
participants in study three were not diagnosed or referred to an NF clinic until after 
multiple schwannoma resections.  Presumably surgeons considered surgery to be 
appropriate symptom management that could be undertaken before referral for additional 
neurogenetic workup (if they considered referral at all).  However, people with 
schwannomatosis may weigh the risks and benefits of surgery differently than people 
with a single, sporadic schwannoma.  For example, schwannoma resection usually does 
not permanently eliminate pain in SWN patients (Merker et al., 2012).  Additionally, 
SWN patients have multiple tumors and may require additional surgeries in the future, 
giving them a higher cumulative lifetime risk of post-operative deficits than patients with 
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a sporadic tumor undergoing only a single surgery (Merker et al. 2012).  As such, SWN 
patients may prefer medical management or alternative pain treatments over surgery, and 
surgeons should be encouraged to refer patients with multiple nerve sheath tumors for 
neurogenetic evaluation prior to surgery to evaluate these options. 
Improving Diagnosis of Schwannomas and Hybrid Nerve Sheath Tumors 
Targeted education for neuropathologists about nerve sheath tumors may also 
help improve SWN diagnosis.  Six patients (6.2%) in study one had a schwannoma or 
hybrid nerve sheath tumor that was misdiagnosed as a neurofibroma (based on 
subsequent re-review of pathology); an additional four patients (4.1%) had pathology 
reported as neurofibroma that was not re-reviewed, but was likely also misdiagnosed 
given that subsequent surgical specimens from these patients were all schwannomas.  
Hybrid nerve sheath tumors, which display features of both neurofibroma and 
schwannoma, are common in schwannomatosis (Harder et al., 2012).  While these tumors 
were initially described in the late 1990s, they have only recently received more 
widespread recognition, suggesting that increased education about this tumor type may 
still be needed (Feany, Anthony and Fletcher, 1998; Rodriguez et al., 2012).  Further 
attention to the subtypes of schwannoma most likely to be misdiagnosed (such as 
schwannomas with myxoid change and cellular schwannomas) may also help improve 
diagnostic accuracy (Kurtkaya-Yapicier, Scheithauer, and Woodruff, 2003).  Clinically, 
careful re-review of pathology is likely indicated in patients who have prior pathology 
reports of both neurofibromas and schwannoma (to appropriately classify them as NF1 
spectrum or NF2/SWN spectrum), and in patients diagnosed with NF1 based on 
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neurofibroma pathology but no other clinical features of NF1 (since these patients may 
actually have NF2 or SWN). 
Facilitating Ordering of Appropriate Diagnostic Imaging 
Our first study showed that failure to confirm a diagnosis of schwannomatosis in 
patients with probable disease is a common occurrence, with 34% of SWN patients seen 
at the MGH and JH NF clinics over the past decade not officially meeting current 
diagnostic criteria.  For just over half of these patients, not having a brain MRI with thin 
cuts through the internal auditory canals (IAC brain MRI) was the sole barrier to 
diagnostic confirmation.  IAC brain MRIs are required by SWN diagnostic criteria to 
most sensitively exclude bilateral vestibular schwannomas, which if present, would 
suggest an alternative diagnosis of NF2.  However, many brain MRIs ordered for patients 
in whom NF2/SWN should be high on the differential diagnosis do not include this key 
sequence – almost two-thirds of patients lacking an IAC brain MRI in study one had a 
standard brain MRI ordered specifically for evaluation of multiple neurogenic tumors 
discovered elsewhere in the body.  To improve rates of ordering IAC brain MRIs, 
encouraging proactive consultation with radiologists to determine appropriate scans 
and/or electronic prompts in computerized image ordering systems may be helpful.  
Furthermore, failures in ordering diagnostic testing were a common problem in study two 
(representing 10% of all observed failures), suggesting that increased involvement of 
radiologists on the diagnostic team could improve other facets of the SWN diagnostic 
process as well (Harolds, 2016; Graber et al., 2017). 
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Integrating the Schwannomatosis Diagnostic Team 
As highlighted in the prior three subsections, surgeons, pathologists, and 
radiologists sit at pivotal junctions of the schwannomatosis diagnostic process.  These 
three types of specialists diagnose and treat schwannomas, the primary clinical 
manifestation of schwannomatosis.  Surgeons, radiologists and pathologists are thus best 
positioned to recognize that a patient has multiple nerve sheath tumors (via review of the 
patient’s clinical history, imaging, or tissue samples, respectively).  However, given the 
fluid nature of diagnostic teams, the expertise of these specialists may not always be 
appropriately utilized.  In order to more effectively integrate these specialists into the 
diagnostic team, enhanced opportunities for bidirectional communication and knowledge 
sharing across all diagnostic team members are needed.  In addition, clear referral 
pathways should be established for when surgeons, radiologists, or pathologists identify 
patients who potentially have schwannomatosis.  Engaging these specialists as equal 
members of the traditionally neurology- or genetics-led diagnostic team could thus lead 
to faster, more accurate schwannomatosis diagnoses. 
Improving Access to Specialty NF Clinics 
Finally, improving access to specialty NF clinics may improve diagnostic 
communication and diagnostic outcomes in schwannomatosis.  While specialists outside 
of dedicated NF clinics may diagnose patients with SWN, study three showed that many 
interview participants valued the expertise and support of expert clinicians practicing at 
NF clinics.  However, access to this type of specialized care may be a problem for SWN 
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patients.  As of 2015, there were only eight U.S. clinics within the Children’s Tumor 
Foundation NF Clinic Network with high NF2/SWN patient volume, and researchers 
estimated that SWN patients would have to drive a median of 311 miles to reach one of 
these clinics (Merker et al., 2018).  Given that studies two and three identified geographic 
accessibility as an important factor contributing to diagnostic performance, the need to 
travel long distances may prevent patients from initially accessing or receiving 
recommended follow-up at specialty NF clinics.  Follow-up is a key issue in 
schwannomatosis; in study two, delays or failures in follow-up were the most common 
failure within the domain of information integration and establishing a diagnosis, and in 
study one, one quarter of patients with probable SWN did not get the diagnostic testing 
required to confirm their diagnosis before being lost to follow-up at NF clinics.  
Expanded use of telehealth at NF clinics may help patients overcome these geographic 
barriers and receive continuing specialty care (Agnihotri and Koralnik, 2015; Augustine, 
Dorsey, and Saltonstall, 2017). 
Diagnostic Challenges in Rare, Genetic Diseases  
The research presented in this dissertation can also inform how we understand 
diagnostic error in rare, genetic diseases more generally, particularly regarding diagnostic 
accuracy and the quality of diagnostic communication. 
Diagnostic Accuracy and Incomplete Diagnoses 
As highlighted in our introduction chapter, the NAM committee (2015) 
conception of diagnostic accuracy requires that a diagnosis be both a true and complete 
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representation of the nature of a patient’s health problem.  The issue of a ‘complete’ 
diagnosis is a key issue in genetic diseases, in which patients may receive accurate 
diagnoses of individual health problems (e.g. that a schwannoma is causing their pain) 
without receiving the correct underlying diagnosis linking each health problem together 
(e.g. that their multiple schwannomas are caused by schwannomatosis).   Diagnosis of the 
underlying genetic disorder may not immediately change patients’ clinical management 
strategies (because perhaps like schwannomatosis, no disease-specific treatments 
currently exist for the genetic disorder in question).  However, diagnosis of the 
underlying genetic disease is still important to ensure that patients and their family 
members receive appropriate genetic and reproductive counseling. 
 Unfortunately, incomplete diagnosis due to physician or system error is likely 
common in rare, genetic disease; roughly 20% of schwannomatosis patients in study one 
had clear evidence of this type of error occurring.  Providers may not consider a rare, 
genetic diseases because they have not sufficiently integrated diagnostic information (a 
deficit in cognitive reasoning) or because they are unaware of the disorder that links the 
patients’ symptoms (a deficit in clinical knowledge).  Both factors were at play in 
schwannomatosis, with study two revealing that failures to consider the correct diagnosis 
and suboptimal weighting of medical information both negatively impacted diagnostic 
accuracy, and study three highlighting that clinicians’ ability to ‘connect the dots’ and see 
the big picture was a key facilitator for making a schwannomatosis diagnosis.  For this 
reason, educational efforts and cognitive debiasing interventions may need to be 
implemented in tandem to truly improve diagnosis of rare, genetic diseases, so that 
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clinicians both think to look for an underlying cause to patients’ symptoms and can 
correctly ascertain what that underlying cause is. 
Diagnostic Communication for Rare, Genetic Diseases 
 Once a diagnosis is ascertained, it must also be adequately communicated to the 
patient, such that the patient understands the full implications of the diagnosis for their 
health.  Given the low rate of genetic health literacy in the general population, 
communication of genetic diagnoses may be especially difficult (Lea et al., 2011), and 
communication needs will only become more prevalent with increasing rates of clinical 
genetic testing (particularly via whole genome or exome testing panels).  Patient 
interviews in study three revealed that many people wanted additional information about 
their disorder (particularly regarding genetic issues), and that having good rapport with 
the provider delivering this information helped patients cope with a potentially 
distressing diagnosis.  These results highlight the need for clear, understandable 
diagnostic information about genetic disorders that is delivered in a compassionate 
manner, recapitulating similar findings previously published in patients with NF2 (Carillo 
et al., 2012). 
Genetic counselors may be uniquely poised to help fill this communication gap, 
given that their training is focused on both adequately educating and counseling patients.  
Indeed, a survey of Australian rare disease patients observed the patients who saw a 
genetic counselor at the time of diagnosis were more likely to report receiving enough 
information about their diagnosis than patients who saw only a general practitioner or 
specialist physician (Molster et al., 2016).  Rare disease patient advocacy organizations 
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may also be able to assist in efforts to communicate better with patients by providing 
educational materials online.  Multiple interview participants in study three mentioned 
that online research was key to understanding their diagnosis and connecting with 
specialty clinics, so wider availability of information targeted to lay audiences may assist 
patients with other rare, genetic diseases in understanding their diagnosis and receiving 
appropriate care. 
Considerations Regarding Our Conceptual Framework  
The research presented in this dissertation also has implications for researchers’ 
understanding of various aspects of the NAM model of the diagnostic process, 
particularly diagnostic uncertainty and diagnostic delay.  
Diagnostic Uncertainty  
A key step in the process of gathering, interpreting and integrating diagnostic 
information is knowing when sufficient information has been collected to adequately 
explain the patient’s health problem and enable optimal treatment decision-making.  
Sufficient information may or may not include definitive proof that a patient has a 
particular diagnosis, since it is not always possible or preferable to obtain additional 
diagnostic information, particularly when acquiring that information carries risk of 
clinical harm (as in the case of invasive procedures like tissue biopsies).  Ideally all 
members of the diagnostic team, including the patient, would agree on how much 
diagnostic information is sufficient, reflecting shared agreement as to the acceptable level 
of diagnostic uncertainty.  However, our research revealed that providers may disagree 
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with published diagnostic criteria, with each other, or with their patients as to what level 
of clinical evidence is required to make a sufficiently certain diagnosis. 
  Diagnostic criteria offer a set standard with which to judge whether a patient has 
sufficient evidence of a diagnosis, making such criteria particularly attractive for non-
expert physicians (who may not have the clinical experience necessary to accurately 
judge how much evidence is sufficient to favor one diagnosis over another) and for 
researchers (who value replicability in assigning patients to disease groups).  However, 
diagnostic criteria are not always perfect classifiers, and many have not been tested as to 
their sensitivity and specificity.  Often this is because there is no gold standard against 
which to compare clinical criteria to, although with genetic diseases, genetic testing 
confirming the presence or absence of a pathogenic mutation could perhaps be used in 
this way.  The fact that diagnostic criteria are not perfect classifiers of disease status is 
demonstrated by how criteria change over time with advances in scientific knowledge (as 
was the case with schwannomatosis, when the criteria issued by Plotkin et al. (2013) 
amended previous criteria from Baser et al. (2006) to allow for the presence of 
meningiomas and unilateral vestibular schwannomas). 
In real-life clinical situations, physicians may desire more or less evidence than 
diagnostic criteria require.  For example, in study one there were 64 patients with a 
confirmed SWN diagnosis by diagnostic criteria.  Four (6%) of these patients did not 
have sufficient evidence by expert clinical judgment to warrant communication of a 
confirmed diagnosis, and seven (11%) had sufficient evidence of the diagnosis by clinical 
opinion prior to actually meeting diagnostic criteria (and as such, had a diagnosis 
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communicated earlier in the diagnostic process).  Additionally, 42% (14/33) of patients 
with probable SWN by diagnostic criteria already had sufficient evidence of the diagnosis 
by expert clinical judgement, as evidenced by the clinicians’ recommendation not to 
pursue further diagnostic testing (i.e., IAC brain MRIs or tissue biopsy).  Studies one and 
two revealed that these differences between clinical judgement and diagnostic criteria 
occurred when patients had additional clinical features potentially suggestive of alternate 
diseases, when the pre-test probability of a diagnostic test being positive was extremely 
low, when there were physical risks to additional diagnostic testing, and when refining 
the working diagnosis would not lead to an immediate change in clinical management.  
These data suggest that physician disagreement with published clinical criteria 
can be quite high, although we also observed clinician judgement can be fallible.  Study 
two demonstrated that patients sometimes had misdiagnoses that stemmed from a 
clinician’s inexpert judgement (via failures in information interpretation or suboptimal 
weighting and prioritization of diagnostic information) that was then later corrected by 
another clinician.  And clinicians may not always agree with each other or with their 
patients as to whether a patient has sufficient evidence of a particular diagnosis.   
  In study one, 15% (5/33) of patients with probable schwannomatosis declined to 
have further diagnostic testing recommended by their clinician, and study two revealed 
that this could reflect patients’ own beliefs about the clinical benefits and risks of further 
diagnostic workup.  Patients’ understanding of diagnostic uncertainty and the value of 
diagnostic testing was further explored in study three, which revealed that patients 
evaluate diagnostic certainty not only in terms of physical risk/benefits, but also in terms 
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of the psychological risk/benefits of knowing one’s true diagnosis and the costs in time 
and money of pursuing additional diagnostic testing.  Overall, this tension between 
published clinical criteria, expert clinical judgement, and patient preferences illuminates 
that diagnostic certainty is complex construct that fluctuates across diagnostic teams.  
Researchers should be wary of automatically assuming that clinician or patient deviations 
from published diagnostic criteria represent diagnostic errors, and must consider the 
unique personal context of each patient’s clinical presentation and preferences. 
Diagnostic Delay  
 Diagnostic delay represents an important dimension of diagnostic error, but is 
perhaps the hardest to define in rare, genetic diseases based on observation of diagnostic 
outcomes alone (rather than also observing diagnostic processes).  The NAM committee 
recognized that delay is contextual, i.e. that the length of time that is considered a ‘delay’ 
for any particular patient will depend on the severity and urgency of that patient’s health 
problem.  But while it is clear than an acute stroke needs to be diagnosed faster than a 
rare, genetic disease like schwannomatosis, it is unclear at what cut-off point, if any, a 
schwannomatosis diagnosis can unilaterally be considered meaningful delayed.  Knowing 
only the total length of time between a patient’s first symptom and communication of 
their diagnosis, can researchers say that the patient did or did not experience a delayed 
diagnosis?   Or does judgement of diagnostic delay rely on knowledge of the patient’s 
unique clinical presentation and specific diagnostic activities undertaken?  
 Defining diagnostic delay in rare, genetic disease could take one of at least three 
approaches, based on assessment of diagnostic intervals, timing of diagnostic processes, 
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or patient health outcomes.  If we define diagnostic delay based on length of the 
diagnostic interval, a panel of patients and healthcare providers could be convened to 
determine via expert consensus methods (such as a Delphi panel) a single cut-point that 
represents an unacceptably long diagnostic interval (for example, 5 years).  However, this 
one-size fits all approach does not accommodate that some patients may have more 
pressing needs to be diagnosed than others – for example, patients actively trying to 
conceive a child who would select alternate reproductive strategies if diagnosed with a 
genetic disorder.  This approach also gives no insight into whether the delay was 
preventable – for example, did the patient have multiple schwannomas discovered 
initially and yet went undiagnosed with SWN for 5 years, or did they only begin to have 
symptoms of a second schwannoma five years after their first tumor was treated? 
 Defining diagnostic delay based on the timing of diagnostic activities would at 
least address the latter of these two issues.  Using guidelines issued by healthcare 
institutions, medical professional societies and healthcare accrediting bodies, we could 
assess whether each diagnostic activity was undertaken in a reasonable timeframe (e.g. 
was a new patient given an appointment within 2 weeks, was an incidental imaging 
finding followed-up within 30 days, etc.), and declare the diagnosis delayed if any 
subcomponent was delayed.  This would clearly identify the portions of the diagnostic 
process needing improvement, but risks confusing diagnostic process failures with 
diagnostic errors, in that small problems (say of following up imaging results in 31 days 
instead of 30) that do not meaningfully delay the patient’s overall diagnosis would be 
misjudged as diagnostic error.   
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 To address this issue, diagnostic delay could instead be judged solely on patient 
health outcomes.  If the lack of diagnosis has not changed their treatment making 
decisions or negatively affected their physical and psychological health, then we could 
say that the diagnostic interval, no matter what the length, was not meaningfully delayed 
and no diagnostic error occurred.  This type of framework is appealing in that it 
accommodates individuals’ unique needs for diagnostic information and preferences for 
diagnostic certainty.  However, a definition based on a counterfactual is somewhat 
problematic (while researchers could ask patients and their care teams whether they 
would have recommended a different treatment strategy or felt differently if they had 
known the patients’ true diagnoses earlier, researchers could never unequivocally prove 
that an earlier diagnosis would have led to different health outcomes).  This type of 
outcome-based definition can also only be applied retrospectively, after the patient harm 
has occurred (as opposed to other definitions of delay, in which certain time goals can be 
prospectively set to ensure no error occurs). 
 Since all three types of definitions have drawbacks, perhaps the ultimate solution 
for grappling with diagnostic delay in rare, genetic conditions is to choose a definition 
based on the specific goals of the clinical or research project.  For example, to assess the 
efficacy of diagnostic quality improvement projects, simply measuring patients’ 
diagnostic intervals and seeking to reduce the median time to diagnosis under a certain 
benchmark may be sufficient.  In research projects that require individual-level 
assessments of diagnostic error, more holistic assessments of delay that consider both 
process and outcome might be needed, ideally undertaken by both patients and clinicians 
  
199 
familiar with the disease in question.  Additional research aimed at reaching consensus on 
how best to define diagnostic delay in these varied contexts would be beneficial, 
particularly for diseases which lack disease-specific treatment (like the majority of rare, 
genetic diseases) and thus lack traditional markers for indicating delay (i.e. delay in 
diagnosis that leads to delay in treatment and impaired health outcomes). 
Future Research Directions 
The results of this dissertation suggest multiple avenues of future research aimed 
at better understanding and addressing the needs of patients with rare, genetic diseases 
like schwannomatosis.  In this section, we discuss two overarching approaches that could 
achieve this aim: implementing electronic interventions to improve the diagnostic process 
and using large patient surveys to identify common areas of diagnostic need. 
Electronic Interventions to Improve Diagnosis of Schwannomatosis and Other Rare 
Diseases 
Future research in schwannomatosis should prioritize pilot testing and eventual 
large-scale deployment of interventions to address the diagnostic challenges identified 
throughout this dissertation.  While educational efforts designed to increase knowledge 
about schwannomatosis among healthcare professionals (particularly those in specialties 
most likely to encounter SWN patients such as surgeons and neurologists) could be 
helpful, they are unlikely to significantly improve SWN diagnosis on their own.  For 
example, most rare diseases would benefit from increased awareness, but creating 
educational campaigns that expect already overburdened clinicians to remember the key 
features of the over 6,800 rare disease seems an unrealistic strategy.  For this reason, 
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interventions focused on leveraging health IT to assist clinicians in performing diagnostic 
activities may provide more value than educational interventions, both in 
schwannomatosis and other rare diseases.  Technology-focused interventions could 
include redesign of electronic medical records (EMR) to facilitate identification and 
appropriate diagnostic workup of rare disease patients and the expansion of health 
information exchanges and/or personal health records to enable information transfer 
across healthcare settings. 
To depict the potential of thoughtfully designed electronic medical records to 
improve diagnosis of schwannomatosis and other rare diseases, imagine the following 
scenario.  A primary care provider (PCP) orders a spine MRI in a patient with back pain.  
The radiologist observes multiple possible nerve sheath tumors, and flags her report as 
having clinically significant findings, which automatically adds it to the PCP’s queue of 
pending results requiring review.  Natural language processing algorithms embedded in 
the electronic medical record (EMR) detect the mention of multiple potential nerve 
sheath tumors in the radiology report.  The EMR searches medical reference sources for 
diseases associated with multiple nerve sheath tumors, and checks to see if the patient 
already has an ICD-10 diagnosis code for one of these disorders noted in their chart.  
Finding none, the EMR displays potential underlying diagnoses in a small reference 
window when the PCP opens the radiology report.   
The PCP, seeing schwannomatosis listed as a possible diagnosis, clicks on this 
diagnosis and is automatically taken to the Neurology Up-to-Date reference article on the 
disorder.  Realizing the patient may have the disorder, the physician uses the EMR to 
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connect to the state health information exchange, which allows her to instantly view 
pathology reports and other records from outside hospitals participating in the exchange.  
Finding that the patient had a schwannoma resected at another hospital many years ago, 
the PCP decides to further work-up the patient for SWN by ordering a brain MRI.  When 
‘schwannomatosis’ is entered as the reason for exam, the order template auto-generates 
instructions to include 3mm thin cuts through the internal auditory canals (as per 
requirements of the diagnostic criteria).  
The patient has the brain MRI, which confirms their SWN diagnosis, and returns 
to see their PCP.  Upon entering the new diagnosis code for SWN in the encounter note, a 
referral list is generated of any physicians in the healthcare network who have self-
identified as specializing in schwannomatosis.  Finding a physician at an NF clinic in the 
academic medical center associated with the PCP’s community hospital, the PCP clicks 
on their name and completes a brief referral form that is automatically sent directly to the 
intake nurse at the NF clinic.  When the intake nurse schedules the patient for an 
appointment at the NF clinic, this patient’s name is automatically removed from the 
PCP’s list of pending referrals.  Additionally, an easy-to-understand information sheet 
about schwannomatosis (created by patient advocacy organizations and curated by the 
NF clinic) is automatically sent to the patient via the EMR’s patient portal.  Through 
these many modifications to existing EMR features, the patient receives a timely, 
accurate diagnosis of schwannomatosis and is quickly connected to specialty care for 
appropriate treatment and genetic counseling. 
While the whole-sale overhaul of EMR to enable all of the features in this 
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vignette may seem idealistic, testing of many of the individual components mentioned is 
already underway with promising preliminary results in other disease contexts (Graber, 
Byrne and Johnston, 2017; El-Kareh, Hasan and Schiff, 2013).  For example, electronic 
triggers (e-triggers) that automatically search EMR data to identify patients with potential 
adverse events (such as diagnostic delays, adverse drug reactions, and surgical 
complications) have already been implemented in a wide variety of settings (Murphy, 
Meyer, Sittig et al., 2018).  Regarding e-triggers for diagnosis, algorithms have been 
developed to evaluate delays in follow-up after abnormal lung CT and mammography 
findings (Murphy, Thomas et al. 2015; Murphy, Meyer, Vaghani et al. 2018) and a 
randomized controlled trial of an e-trigger based intervention demonstrated reduced 
diagnostic delay in colorectal and prostate cancer (Murphy, Wu et al. 2005).  And while 
most e-triggers are currently based on structured data fields, e-triggers have been 
developed based on identification of key terms in unstructured text (Kane-Gill et al., 
2016), and advances in natural language processing could extend e-trigger capabilities 
into parsing more complex free text fields (Divita et al., 2016; James et al., 2017).  Thus, 
it would be technically feasible to develop an e-trigger for SWN that identifies patients 
with multiple pathology reports of schwannoma and/or radiology reports mentioning 
multiple potential nerve sheath tumors, and flag these patients as potentially in need of 
diagnostic workup for neurogenetic syndrome.  Future research could thus focus on 
developing and validating this type of electronic trigger according to best practice 
evaluation methods, such as the Safer Dx e-trigger tool framework (Murphy, Meyer, 
Sittig et al., 2018).    
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Similarly, developing real-time, diagnostic decision support with easy access to 
appropriate medical reference materials within EMRs could facilitate diagnosis, 
particularly in rare diseases (Bates and Gawande, 2003; Graber et al., 2012).  Multiple 
programs for computer-assisted differential diagnosis are already commercially available, 
and applications specifically for rare diseases have been proposed (Bond et al., 2012; 
Riches et al., 2016; Alves et al., 2016).   While diagnostic performance varied across 
programs, meta-analysis showed an accurate diagnosis rate of 89% in one of the most 
common tools (ISABEL), which has been also been shown in simulated diagnostic 
situations to reduce errors of omission (i.e. when the correct diagnosis is not considered) 
and improve ordering of diagnostic tests (Ramnarayan et al., 2006; Riches et al., 2016).  
Further development of these programs, with attention to improving technical ease of use 
and integration into clinicians’ workflow, could thus be helpful in improving non-
specialists’ rates of diagnosing rare diseases like schwannomatosis (Porat, Delaney, and 
Kostopoulou, 2017). 
Inter-operable health IT systems and health information exchanges that allow for 
more streamlined sharing of records across institutions (Kaelber and Bates, 2007; Hersh 
et al., 2015) may also be particularly beneficial for patients with rare diseases, since 
large, international surveys have shown that rare disease patients often consult with many 
(8+) physicians before reaching a diagnosis and thus may be more likely to have records 
at multiple institutions (Shire Human Genetic Therapies, 2013; EURORDIS, 2009).  In 
addition, granting patients easier access to their own medical record data through direct 
access initiatives (such as OpenNotes) or development of personal health records could 
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allow patients to assist in transferring their own information across institutions (Delbanco 
et al., 2010; Roehrs et al., 2017; Roehrs et al., 2018).  This approach could have added 
benefits, such as increasing patient engagement as members of the diagnostic team, 
enhancing patients’ understanding of their conditions, and improving patient-physician 
communication (Nazi et al., 2015; Esch et al., 2016; Goldzweig, 2017). 
Understanding Common Needs Across Rare Diseases 
Many of the electronic interventions suggested above are primarily targeted at 
facilitating clinicians’ diagnostic activities.  Recognizing that patients and their family 
members are also key members of the diagnostic team, additional efforts will be needed 
to understand patient needs and facilitate patient engagement in the diagnostic process.  
Patient interviews in study three identified several barriers patients face in attempting to 
accurately appraise symptoms, promptly access health care and understand their 
diagnoses.  However, it is unknown how common these barriers are and to what degree 
these concerns are shared by patients with other rare, genetic diseases.   
Thus, launching a national survey of patients with a variety of rare, genetic 
diseases would be beneficial to validate our qualitative findings in a larger sample of 
patients and identify cross-cutting factors affecting rare disease diagnostic quality.  This 
type of survey could be modeled off the two surveys fielded by the European 
Organization for Rare Disease (EURORDIS) from 2003 to 2008 to investigate diagnostic 
delay and access to medical and social services for rare disease patients. These surveys 
each had approximately 6,000 respondents, due in part to the organizations’ outreach to 
disease-specific rare disease advocacy organizations.  Members of these disease-specific 
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organizations gave feedback on an earlier pilot survey and helped recruit patients, which 
helped EURORDIS create useful, comprehensible survey questions and reach a diverse 
group of participants (EURORDIS, 2009).   
A similar model could be followed here in the United States by partnering with 
the National Organization of Rare Diseases, a nonprofit umbrella organization connected 
to 280 individual rare disease organizations.  By holding pilot focus groups with patients 
from multiple rare disease organizations, we could add to the list of concerns generated 
during our analysis of schwannomatosis patients’ experiences and ensure a 
comprehensive assessment of rare disease diagnostic experiences.  While the final list of 
survey topics would be dependent on such focus groups, the survey would likely include 
issues identified in this dissertation such as access to care, educational and social support 
needs, and stigma and psychological distress.  For example, the survey could be used to 
identify the educational materials and social support services utilized by patients during 
the diagnostic process, assess patient satisfaction with these materials/services, and solicit 
suggestions for improvement.  Then, after the survey design was finalized, we could 
leverage the existing contact lists and media outreach capabilities of NORD partner rare 
disease organizations to reach as wide a participant sample as possible, allowing us to 
make more precise statements as to the burden of rare disease diagnostic process failures 
in the Unites States. 
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APPENDIX A: Additional Materials for Chapter 2 
Appendix A1: Diagnostic Criteria for Schwannomatosis 
To be considered as having “confirmed” schwannomatosis in our study, a patient had to 
meet the consensus clinical diagnostic criteria for schwannomatosis published by Plotkin 
et al. (2013).   
 
To meet Plotkin et al. (2013) criteria, patients had to meet one of the following criteria: 
 
1. Two or more non-intradermal schwannomas, one with pathologic confirmation 
AND no bilateral vestibular schwannomas by high-quality MRI (detailed study of 
internal auditory canals (IACs) with slices no more than 3mm thick). 
2. One pathologically confirmed schwannoma or intracranial meningioma AND 
affected first degree relative 
3. One pathologically proved schwannoma or meningioma AND germline 
SMARCB1 pathogenic mutation 
4. Two or more pathologically proved schwannomas or meningioma AND genetic 
studies of at least two tumors with loss of heterozygosity for chromosome 22 and 
two different NF2 mutations 
And they could not meet any of the following criteria: 
 
A. Germline pathogenic NF2 mutation 
B. Fulfill diagnostic criteria for NF2 
C. First-degree relative with NF2 
D. Schwannomas in previous field of radiation therapy only 
 
 
Regarding inclusion criterion 1: we interpreted “2 or more non-intradermal 
schwannomas” as two schwannomas, that if not already pathologically sampled, were 
apparent on appropriate clinical imaging such as MRI and consistent with nerve sheath 
tumor.  If a mass had not been imaged (e.g. it was palpable lesion felt on physical exam) 
or there was disagreement as to whether the radiologic features of the mass were 
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compatible with a schwannoma, we did not consider the mass to be eligible to fulfill this 
criterion. 
 
Regarding inclusion criterion 1: to satisfy the requirement of “high-quality MRI (detailed 
study of IAC with slices no more than 3mm thick”, we required that either 1) personal 
review of MRI images by our research team confirmed thin cuts through the IAC were 
present; 2) official radiology report of the images specified that a dedicated IAC 
sequence was obtained; or 3) a clinician reviewing the MRI images specifically wrote in 
their encounter note that the brain MRI had thin cuts through the IACs.  
 
Regarding exclusion criterion A: we did not require that NF2 genetic testing be 
performed.  However, if NF2 germline testing had been performed, it must not have 
shown a pathogenic NF2 mutation. 
 
Regarding exclusion criterion B: we did not exclude patients who fulfilled the 
Manchester criteria for NF2 (Evans et al. 1992) due to the presence of multiple non-
vestibular schwannomas plus either a unilateral vestibular schwannoma or multiple 
meningioma because the explanatory text for the clinical diagnosis guidelines in Plotkin 
et al. (2013) explicitly state that “some schwannomatosis patients have been reported to 
have unilateral vestibular schwannomas or multiple meningiomas.” 
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We also assessed if patients met earlier published diagnostic criteria for definite 
schwannomatosis (MacCollin et al., 2005; Baser et al., 2006). 
 
To meet MacCollin et al. (2005) criteria for definite schwannomatosis, patients had to 
meet one of the following criteria: 
 
1. Age >30 years AND two or more non-intradermal schwannomas, at least one with 
histologic confirmation AND no evidence of vestibular tumor on high-quality 
MRI scans AND no known constitutional NF2 mutation 
2. One pathologically confirmed non-vestibular schwannoma plus a first degree 
relative who meets above criteria 
 
Regarding criterion 1:  we interpreted “Age >30 years” to require that patients were 30 
years of age or older at the time that their high-quality MRI scan was performed to 
exclude vestibular tumor.  We did not consider it sufficient for a patient to simply be 
evaluated in clinic after the age of 30, if their only high-quality MRI scan was performed 
prior to age 30. 
 
Regarding criterion 1:  we interpreted “high quality MRI scan” according to the 
definition of Plotkin et al. (2013), as an MRI with thin slices (of 3mm or less) through the 
entire IACs.   
 
To meet Baser et al. (2006) criteria for definite schwannomatosis, patients had to meet 
one of the criterion listed by MacCollin et al. (2005) and could not meet any of the 
following criteria: 
 
A. Fulfill any of the existing sets of diagnostic criteria for NF2 
B.  Evidence of vestibular schwannoma on high quality MRI scan 
C. First-degree relative with NF2 
D. Known constitutional NF2 mutation 
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Regarding exclusion criterion B:  we interpreted “high quality MRI scan” according to 
the definition later formalized in Plotkin et al. (2013), as an MRI with thin slices (of 3mm 
or less) through the entire IACs.   
 
Regarding exclusion criterion D:  we interpreted this criterion as not requiring that NF2 
genetic testing be performed.  However, if NF2 germline testing was performed, it must 
not have shown a pathogenic germline mutation. 
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Appendix A2: Protocol for Date Estimation 
If a date range is given (e.g. 4 to 6 weeks ago), use the midpoint of the range.  
Example: In a note dated August 31st, 2018, a physician writes that the patient began 
experiencing symptoms 2 to 3 weeks ago.  Symptom onset would be estimated as August 
14, 2018. 
If event is dated by a patient’s age (e.g. “Patient started experiencing pain at age 
16”), use the midpoint of the year the patient was that age.  Example: If a person is born 
on April 1st, 1980 and reports that their pain started when they were 16, symptom onset 
would be estimated as September 30th, 1996. 
If date is given as a month (e.g. January), use the midpoint (e.g. the 15th) of that 
month. If date is given as an approximate part of the month (e.g. early/mid/late [Month]), 
use the following estimates: early month is the 5th, mid-month is the 15th, and late month 
is the 25th. 
 If date is given as a season, use the following as estimates: Winter – January 15th, 
Spring – April 15th, Summer - July 15th, Autumn – October 15th. 
 If date is given as a year, use midpoint of year (i.e. July 1st).  However, if the 
context of the medical record data indicates that event happened before another date in 
the year, then use the midpoint between beginning of year and the date in question. 
Example: At a doctor appointment on October 1, 2010, patient says his or her pain began 
sometime in 2009 and he or she first went to their doctor sometime in 2010.  Estimated 
date of symptom onset would be July 1, 2009 and estimated date of first engagement in 
the healthcare system would be May 17, 2010.  
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Appendix A3: Hierarchy of Sources for Medical Record Data 
When adjudicating between conflicting data in the medical record, we used the following 
information, in decreasing order of priority: 
1. Relevant primary source document (e.g. clinician encounter note, pathology report, 
MRI report, operative note.)   Applies to primary data only – for example, in a 
clinician encounter note, the date of an appointment and the physician’s diagnostic 
assessment are primary data, but information on the patient’s prior medical 
history/appointments with other physicians is secondary data. 
2. Direct information from patient (e.g. patient emails or self-report questionnaire that 
were copied into electronic medical record), except in cases of tumor pathology.  
For questions regarding the pathology classification of a tumor, any clinician 
encounter notes trump patient self-report. 
3. Clinician encounter notes from the clinician most local to event in question (e.g. For 
information on a patient’s first symptom, use the descriptions recorded by the first 
clinician the patient consulted.) 
4. Clinician encounter notes from specialty clinicians reviewing information pertinent to 
their specialty (e.g. If notes from the neurosurgeon who performed a surgery are 
unavailable, use data provided by the next neurosurgeon a patient consulted.) 
5. Clinician encounter notes from an NF specialty clinician.   
6. Any other clinical information available in the medical record. 
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APPENDIX B: Additional Materials for Chapter 3 
Appendix B1: Guide to Creating Narrative Summaries 
Step 1: Determine if medical record note (from a clinician encounter) describes the 
diagnosis of or evaluation/treatment of a sign/symptom related to schwannomatosis.  If 
yes, record the following: 
1. Patient history and present symptomology (regarding each of the signs/symptoms 
related to schwannomatosis).  If history refers to other clinician encounters, record 
all possible details (enumerated in this list) about that encounter separately just as 
you are recording primary note information, but with a comment – titled 
“SOURCE” - listing the source of the secondhand information.  
2. Reason for patient presentation to care (e.g. worsening pain), and person 
referring patient for care (including self-referral). 
3. Date and location of care 
4. Clinician providing care.  [Note:  Physicians, mid-level providers (such as nurse 
practitioners and physician assistants) and ancillary healthcare professionals (such 
as audiologists, genetic counselors, and physical therapists) are all relevant 
clinicians.  If a resident or fellow sees a patient with an attending physician and/or 
writes a portion of the note, we will record the attending physician as the provider.] 
5.  Diagnostic examinations ordered/performed/reviewed.  [Note: This includes 
imaging, ophthalmology and audiology exams, and genetic testing.  Does not need 
to include physical exam, unless reviewer thinks it’s particularly relevant.] 
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6. Referrals made.  Document name, specialty, and practice location of any 
providers the patient is referred to for the diagnosis/evaluation/treatment of 
schwannomatosis-related symptoms/signs. 
7. Clinician’s diagnostic assessment.  [Note: This is often located at the end of the 
note under “Assessment”, “Plan”, or similar section.] At reviewer’s discretion, 
directly quote the provider’s reasoning in the summary.  Quotes are particularly 
desirable if the clinician uses “I” statements, or otherwise illuminates their personal 
reasoning/beliefs about the case. In particular, note any descriptions around cause of 
tumors, including as a sporadic issue, as possible cancer, or as NF1, NF2, or 
schwannomatosis. 
8. Treatment.  Note any plans for or administration of a treatment that results in 
feedback of diagnostic information (such as a tumor biopsy/resection leading to 
pathology results). 
 
If any of the above information is missing, write a comment – titled “DATA QUALITY” 
– to certify reviewer could not find the information in the medical chart.  Use this 
comment also to highlight instances where there is missing data about a patient’s early 
symptoms/medical care (for example, if there is no documentation on specific early 
medical visits, just general information that patient has sought care before.) 
 
Repeat Step 1 for all notes up to the time of the patient’s formal diagnosis of 
schwannomatosis or last visit to a dedicated NF specialty clinic (if no formal 
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confirmation of diagnosis is obtained) as of January 31, 2016 (the date data collection 
was closed).  For patients diagnosed prior to visiting an NF specialty clinic, summaries 
will be extended to cover the first visit to the NF clinic.  
*Note: “Formal diagnosis” is the later of A. the date when the patient meets 
diagnostic criteria as we have interpreted them and B. the date when the patient’s 
clinician communicates to them that they meet diagnostic criteria.   If there are 
conflicting representations of diagnosis communication (for example, when one 
physician notes that the patient has probable schwannomatosis and another notes they 
have definite schwannomatosis, or when a physician communicates the final diagnosis 
but then appears to copy/paste incorrect documentation saying the patient still has 
probable schwannomatosis in future notes), the summary may conclude when the first 
specialist correctly identifies the patient as having definite schwannomatosis.  In this 
case, any documentation regarding diagnosis status should be summarized and included 
at the end of the summary (ranging until all clinicians note the patient has definite 
schwannomatosis, or until the last follow-up in the study period, whichever comes first). 
 
If a patient repeatedly sees the same clinician for standard follow-up (where there are no 
new schwannomatosis symptoms/diagnostic tests/treatment, reviewer may summarize 
follow-up visits together.  For example, “Patient saw Dr. X for standard post-surgical 
follow-up on dates 1, 2, and 3 with no complications.” Or “Patient saw Dr. Y on dates 1, 
2, and 3 with yearly brain MRIs (done on dates A, B, and C at Hospital X) to monitor 
tumor growth with findings of no significant growth.” 
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Step 2:  Examine supporting documentation (i.e. imaging reports, operative notes, 
pathology reports, scanned communications between patient and clinicians, etc.) for 
events that contributed to the diagnosis/evaluation/treatment of a sign/symptom related to 
schwannomatosis. 
1. For imaging: date of exam, date radiology report was issued (if available), name 
of imaging facility, ordering provider, stated reason for exam, exam findings.   
2. For operative notes/pathology reports: date of surgery, date of final pathology 
report (if available), hospital surgery was performed at, name of surgeon, path 
diagnosis. 
3. For miscellaneous documentations: any of above criteria from Step 1 or Step 2 
reviewer deems applicable. 
 
Step 3.  Arrange events into chronological order, as experienced by patients (as opposed 
to the dates in which clinicians wrote about them.)  If exact date of event is unknown, 
estimate using criteria followed in quantitative chart review (Appendix A2) and write a 
comment – titled “DATE ESTIMATION” – about what data was used to estimated date 
from.  If there is conflicting information, follow the hierarchy of sources used in 
quantitative chart review for the primary narrative (Appendix A3 below), and write a 
comment – titled “AUDIT” – noting the conflicting information.  For context, note the 
patient’s age at beginning of diagnostic journey and, if applicable, the date they met 
published diagnostic criteria (following diagnostic criteria interpretations in Appendix 
A1). 
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Step 4.  Ensure narrative is a limited dataset.  Things that may be in dataset: names of 
physicians and hospitals, full dates for medical encounters/procedures, patient age.  
Things that must be redacted: name of patient and family members, other HIPAA 
identifiers not mentioned above. 
 
Step 5. Record the number of primary medical notes that were used to create the 
summary in each of the following categories – Clinician Encounter Notes, Imaging 
Reports, Pathology Reports, Operative/Procedure notes, and Other (which includes but is 
not limited to documentation of phone conversations, patient questionnaires, referral or 
triage notes, and discharge notes from inpatient stays.)  This is needed per SPQR 
guidelines.  
 
Audit Trail Comment Types 
DATA QUALITY:  specify any pertinent missing data.  This comment certifies that 
reviewer tried to find a certain piece of information in above guide, but could not find it.  
E.g.: Narrative text reads “Patient had an MRI prior to appointment with Dr. Jones” and 
comment reads “Date of MRI not found in EMR”. 
 
AUDIT: In cases of conflicting information, explain why the reviewer picked the account 
they did.  In cases of unclear source information, explain why reviewer interpreted 
account as they did. Sample comment: “Grammar of Dr. Jones’s note was unclear – Dr. 
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Jones wrote that “he” referred the patient to Dr. Smith.  We will assume that “he” is the 
orthopedic surgeon who saw the patient immediately prior to the visit with Dr. Smith.” 
 
SOURCE: specify from what source information about secondarily-reported events came 
from. E.g.: comment reads “From Dr. Jones’ note on 10/5/2010”.  This comment is not 
needed for clinician’s observations/assessment taking place at time of note, as these are 
already expressly dated and sourced in the narrative text. 
 
DATE ESTIMATION:  explain on what basis a date was estimate.  E.g. Narrative text 
reads “Patient was in car accident in November 2013” and comment reads “Dr. Jones 
noted that car accident was approximately one year ago in his 11/4/2004 note.” 
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Appendix B2. Final Codebook for Directed Content Analysis with Examples 
Conceptual 
Framework 
Domain 
Nature of 
Diagnostic Process 
Failure 
Description of Diagnostic Process Failure Examples from Schwannomatosis 
(SWN) Narrative Summaries  
Failure to Engage in the Healthcare System or in the Diagnostic Process 
Patient 
Experiences a 
Health Problem 
Failure/Delay in 
patient presenting  
Patient does not appreciate a relevant health 
problem, realize that he/she should seek 
care for a given symptom, or realize that 
he/she should seek care in a more urgent 
manner.) 
Patient does not seek medical treatment 
for pain because they attribute it to non-
illness causes (ex: getting older, over-
exertion)  
Patient Engages 
with Healthcare 
System  
Failure/Delay in 
patient accessing 
care 
 
Patient is prevented or delayed from 
seeking care for a recognized health 
problem.   
Patient attempts to seek care with 
specialist, but there are excessive wait 
times for an appointment  
Failure in Information Gathering 
Clinical History 
and Interview 
Failure/delay to 
elicit key history 
finding 
Failure/delay to elicit key history finding, 
including: 
- failure of patient (or healthcare proxy) to 
provide accurate medical history 
- failure of clinician to obtain, record or 
update pertinent history/interview data 
- failure to transmit, obtain or review 
previous medical documentation  
Prior history of schwannoma is not 
elicited during treatment for a new 
schwannoma 
Physical Exam Failure/delay to 
elicit key physical 
exam finding 
Failure/delay to elicit key physical exam 
finding (i.e. physical exam is absent or 
inadequate) 
None observed in dataset. 
(Hypothetical example: Patient has a 
palpable mass, but physician fails to 
perform a physical exam and does not 
appreciate it.) 
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Diagnostic 
Testing 
Failure/delay to 
order needed tests 
Failure or delay in selecting and ordering 
appropriate diagnostic test (i.e. no 
diagnostic test is ordered, the wrong test or 
a duplicate test is ordered, or the wrong 
sequence of tests is ordered.) 
Patient being worked up for multiple 
schwannomas does not have brain MRI 
ordered with thin cuts through the 
internal auditory canal 
Failure/delay in 
performing 
ordered tests 
Patient is unwilling or unable to complete 
ordered test or services are not available to 
provide test (e.g.  no earlier appointment is 
available) 
Patient does not receive ordered MRI 
(for e.g. because they forgot about 
appointment, no longer wish to receive 
it, or cannot afford the cost.) 
Technical errors in 
the handling, 
labeling, or 
processing of tests 
Sample mix-up; test is performed or 
processed incorrectly 
Brain MRI is ordered to have thin cuts 
through internal auditory canal, but due 
to error at MRI facility, this sequence is 
not performed 
Failure/delay in 
transmission, 
receipt, review or 
documentation of 
test results 
Failure or delay in transmitting test result to 
ordering clinician; or review of test result 
and documentation of findings by ordering 
provider is not completed or is significantly 
delayed. 
Patient has an MRI performed, but the 
images and/or report are not transmitted 
to ordering provider or abnormal results 
are not reviewed in a timely fashion 
Referral and 
Consultation 
Appropriate 
consult/referral to 
specialists is not 
made or delayed 
Failure or delay in making appropriate 
referral, including: 
- clinician did not believe referral was 
required; 
- referral was made to the wrong specialist; 
- no appropriate specialist was identified. 
Patient is diagnosed with multiple 
schwannomas, but surgeon does not 
refer patient to neurologist, oncologist, 
geneticist or another provider 
specializing in NF care  
Consult/referral to 
specialist is not 
adequately 
managed 
Failure to obtain, understand, or follow-up 
on specialist recommendations 
None observed in dataset. 
(Hypothetical example: PCP refers 
patient to neurologist for workup but 
does not receive neurologist’s 
assessment that patient might have 
SWN.)  
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Treatment Failure/delay in 
monitoring 
response to 
treatment  
Failure to monitor treatment response, delay 
in re-assessing treatment response, or 
failure to adjust diagnosis in light of 
treatment response inconsistent with 
original diagnosis  
None observed in dataset. 
(Hypothetical example: Patient is 
prescribed physical therapy to treat 
suspected musculoskeletal pain; after 6 
months with no clinical benefit, patient 
is not reassessed for alternate causes of 
pain.) 
Failure in Information Interpretation 
Information 
Interpretation 
Inaccurate or 
failed 
interpretation of 
medical data by 
treating provider 
Treating clinician misinterprets or does not 
realize the significance of a piece of 
medical information (i.e. history data, 
physical exam findings, test results, or 
referral/consult recommendations).  
Provider thinks that pathology of 
neurofibroma is suggestive of diagnosis 
of NF2 or schwannomatosis. 
Inaccurate or 
failed 
interpretation of 
medical data by 
interpreting 
provider 
Radiologist, pathologists, or laboratory 
professionals gives inaccurate interpretation 
of imaging or biological specimens.  
Patient’s tumor sample is originally 
diagnosed as a neurofibroma, but when 
re-reviewed by an expert at another 
institution, it is classified as a 
schwannoma. 
 
Failures in Information Integration and Establishing an Explanation 
Information 
Integration 
Failure/Delay in 
considering 
correct diagnosis 
Failure to consider correct diagnosis in a 
timely fashion (i.e. failure in hypothesis 
generation)  
Patient is known to have multiple 
schwannoma, and provider does not 
mention possibility of NF2/SWN in 
their note 
Suboptimal 
weighting and 
prioritization  
Suboptimal weighting or prioritizing of 
medical information (history data, physical 
exam finding, diagnostic test, or referral 
opinions) including 
 - putting too much weight on a lower 
probability diagnosis;  
Patient has no clinical signs or 
symptoms of NF1 (e.g. no café au lait 
spots, skinfold freckling, cutaneous 
neurofibromas), but clinician interprets 
MRI findings of multiple nerve sheath 
tumor as indicative of 
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- giving too little consideration for higher 
probability or higher priority diagnosis; 
- putting too much weight on a competing 
or coexisting diagnosis. 
neurofibromas/NF1 instead of possible 
schwannomas and NF2/SWN 
Failure to 
recognize or 
weight urgency 
Failure to appreciate the urgency/acuity of 
illness and act appropriately 
None observed in dataset. 
(Hypothetical example: Patient has 
symptoms of cauda equina syndrome, 
and action is not taken to urgently 
evaluate for spinal tumors.) 
Working 
Diagnosis 
Failure/Delay to 
follow up 
Failure to follow up until accurate diagnosis 
is reached, including: 
- failure to create or implement an 
appropriate follow-up plan;  
- selecting too much time for follow-up;   
- failure of patient to attend scheduled 
follow-up 
Patient is being worked up for potential 
schwannomatosis but elects not to 
return to NF clinic or continue 
diagnostic workup 
Scientific 
knowledge 
limitations  
Signs and symptoms have not been 
recognized as a specific disease 
Patient has unilateral vestibular 
schwannoma or meningioma and is 
diagnosed with NF2 (prior to the 
recognition that these tumors could also 
be related to SWN). 
Failure to Communicate the Explanation to the Patient 
Communication 
of the Diagnosis 
Failure/Delay in 
Patient 
Notification  
Diagnosis has been established by a HCP, 
but explanation is not communicated to 
patient or is not is not communicated in a 
timely fashion 
Patient receives brain MRI confirming 
diagnosis of schwannomatosis, but the 
patient never returns to clinic to receive 
the result and no phone/email contact is 
documented. 
Incomplete 
explanation  
 
Incomplete diagnosis is made, such that the 
totality of the patient’s health problem is 
not communicated to them 
Patient is told they have 
schwannomatosis, but they are not told 
about genetic implications of this 
diagnosis  
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Patient does not 
understand 
explanation 
Patient did not understand explanation of 
health problem, possibly because 
communication was not aligned to patient’s 
health literacy level, cognitive ability, or 
language preference 
Patient is left a voicemail notifying her 
that they observed suspected tumors on 
her MRI; patient calls PCP and says she 
did not understand voicemail and is 
worried she has cancer. 
 
Abbreviations:  NF – neurofibromatoses; NF1 – neurofibromatosis type 1; NF2 – neurofibromatosis type 2; SWN – 
schwannomatosis; PCP – primary care provider; MRI – magnetic resonance images
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APPENDIX C: Additional Materials for Chapter 4 
Appendix C1: Semi-Structured Interview Guide 
1.  Could you tell me about the first time you experienced something related to 
schwannomatosis? 
 A. What were you thinking when this happened? 
            B. What happened next? 
C. What led you to choose that course of action? 
 D. Why did you go to (Provider or Institution Name)? 
 E. What did (Provider Name) tell you about your symptom/condition? 
  
2. Could you describe the events that led up to you going to the NF clinic at (Institution)? 
 
3.  What was it like finding out you had schwannomatosis?  
A. When did you first hear about neurofibromatosis or schwannomatosis?   
B. When did you find out that you had schwannomatosis? 
C. Who told you that you had schwannomatosis? 
D. How did you feel about getting your diagnosis? 
E. Do you think your life changed once you knew you had schwannomatosis?  
 
4. Was there anyone or anything that was helpful to you during the process of getting a 
diagnosis?  How were they/it helpful? 
 
5. Was there anyone or anything that made it harder to get a diagnosis? 
A. Was there anything that made it harder to see a doctor or get a test when you 
wanted to?  
B. Was there anything that made you not want to see a doctor or get a test? 
C. Did you ever feel like your doctors didn’t know or have all of the important 
information about you? 
 
6. Were your family, friends, or any other non-medical people involved in the process of 
getting a diagnosis?  How so? 
 
7. Were you ever told that you had a different condition, before you were told that you 
had schwannomatosis? Can you tell me more about that?  How did that impact you? 
 
8. Looking back on your experience getting a diagnosis of schwannomatosis, is there 
anything about your care that you wish had happened differently?  
 
9.  Is there anything else you think I should know to understand what it’s like for people 
to be diagnosed with schwannomatosis? 
 
  
224 
 
Additional Information about the Interview Guide 
 The interview guide begins with an open-ended question and probes designed to 
elicit the participant’s diagnostic story in their own words.   The vague wording of 
“something related to schwannomatosis” was intentionally chosen rather than “symptom” 
in consideration of our conceptual framework regarding the appraisal interval.  As noted 
by Walter et al. (2012) in their description of the Model of Pathways to Treatment, the 
appraisal interval begins when a person detects a bodily change, and part of the appraisal 
interval is the person’s assessment of that bodily change as an abnormal symptom of 
disease.  Probes for this question focused on drawing out the participant’s story and 
establishing a timeline of important diagnostic events. 
 In accordance with our specific aims, Questions 1, 2, 5a, and 5b were designed to 
elicit information about symptom appraisal and help seeking; question 3a-c were 
designed to elicit information about diagnosis communication; and questions 3d, 3e, and 
7 were designed to elicit information about the impact of a diagnosis on people’s lives.   
 We additionally wanted to explore facilitators and barriers to timely and accurate 
diagnosis (questions 4 and 5).  The question about facilitators was intentionally placed 
first to avoid biasing the interview towards negative experiences.  The probe regarding 
not wanting to see a doctor or get a test was created because of experiences related by a 
pilot interviewee of being overwhelmed by seeing multiple doctors and choosing not seek 
care for a year.  The probe regarding feeling like doctors didn’t know or have all of the 
important information was created based on emerging patterns of impaired information 
flow between different medical institutions, observed during our medical record review 
  
225 
and discussed in chapter three of this dissertation.  
 During the conduct of the study, one additional question (question #6) was added 
to the interview guide, regarding the potential involvement of family, friends, or any 
other non-medical personnel in the diagnostic process.  This was added in response to 
repeated discussion of this topic in early interviews and in consideration of the 
importance of patients’ non-medical associates to our conceptual framework.    
 Finally, the interview guide concluded with an open-ended question of “Is there 
anything else you think I should know to understand what it’s like for people to be 
diagnosed with schwannomatosis?”  We felt it was important to ask participants if there 
were any important topics or insights that we may have missed, given that the primary 
purpose of the study was to understand patients’ perspective of the diagnostic process. 
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Appendix C2: Final Interview Codebook 
In the table below, shaded gray rows list overarching coding categories, with 
individual code names in the left column and short definitions for each code in the right 
column.  (Long definitions of codes are available upon request from the author.) 
Abbreviations: SWN = schwannomatosis; Pt. = participant; HCP = healthcare 
professional. 
Patient Experiences a Health Problem 
Early Symptoms First signs or symptoms of SWN that pt. recalls experiencing 
Additional Symptoms  Signs/symptoms of SWN that occur after "Early Symptoms" 
Downplaying of 
Symptoms 
Someone expresses idea that symptoms are not that important 
Impact of symptoms Pt. discusses impact of SWN symptoms on their life 
Patient Engages with the Healthcare System 
Entry into Health care First time pt. sees an HCP for SWN symptoms 
Impetus to Seek Care 
Pt. seeks medical care for SWN sign/symptom, may describe 
specific "push" factor 
Delay in Seeking Care 
Pt. does not immediately seek medical care for SWN 
sign/symptom, may describe specific barrier 
Facilitating Factors to 
Receive Care 
Helpful factor to receive health care (as pt. is actively seeking 
care) 
Impeding Factors to  
Receive Care 
Factor that makes it harder to receive health care or delays 
patient's receipt of health care (as pt. is actively seeking care) 
NF Clinic Patient seeks or receives care at a specialty NF clinic 
Information Gathering/Interpretation/Integration 
Diagnostic Workup 
Diagnostic activities performed to investigate SWN 
signs/symptoms 
Monitoring and Follow-
up 
Medical activities performed to monitor SWN signs/symptoms 
after they have been diagnosed 
Information Integration 
HCP connects (or fails to connect) information from multiple 
sources or about multiple symptoms to inform diagnostic 
reasoning 
Diagnosis 
Diagnosis 
Communication 
What Pt. is told by HCPs about SWN and SWN-related 
symptoms, including misdiagnoses and comments on a lack of 
adequate communication 
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Alternate Explanation 
of Symptoms 
Someone attributes a sign/symptom of SWN to another cause 
Impact of Diagnosis 
Impact of getting a diagnosis label on the Pt.’s life or on their 
family 
Treatment 
Treatment 
Treatment decision-making and subsequent receipt or non-
receipt of treatments for SWN signs/symptoms 
Impact of Treatment Impact of treatment for SWN symptoms on patient's life 
Outcomes 
Things Going Wrong 
Delays, errors, and other events that negatively affected the 
SWN diagnostic process 
Things Going Well 
Events or factors that positively impacted the SWN diagnostic 
process 
Blame for delays/errors 
Pt. discusses blame for delays or errors in their care, either by 
assigning blame (to themselves/another person/"the system") or 
saying that someone/thing was not to blame 
Impact of delay/errors 
Impact of delays or errors in the diagnostic process on patient's 
health, life, and family 
Psychological Distress 
Emotional or psychological distress engendered by diagnostic 
process 
Patient Wisdom 
What patient has learned from their diagnostic experience and 
advice they have for others 
Diagnostic Team 
Patient/provider 
interactions 
Descriptions of interactions with HCP, including positive and 
negative aspects of these interactions 
Physician 
Conversations 
Specific conversations (often in quotes) between pt. and their 
HCPs 
Physician Referral When and why one HCP refers Pt. to another HCP 
Patient Factors 
Taking control 
Pt. demonstrates particular agency in decision-making about 
their health/health care, or comments on their failure to do so 
Support from others Pt. gets tangible or emotional support from non-HCPs 
Family History Pt. describes family members with SWN-like symptoms 
Provider Factors 
Physician 
uncertainty/lack of 
knowledge 
HCP expresses uncertainty about Pt. diagnosis, appropriate 
diagnostic workup, or treatment options 
Going above and 
beyond 
Pt. evaluations of HCPs as going (or not going) above and 
beyond their normal expected effort 
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Other 
Doing research 
Someone does research to understand SWN or its 
signs/symptoms 
Value of information Value (in time or money) of medical information 
Comparison to others Pt. compares themselves to other people or patient groups 
Time Period Any mention of timing of events or intervals between events 
Patient Background General background information about Pt.’s life 
Golden Nugget Great quotes that illustrate other codes or larger themes 
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